

## 2023 HRS/EHRA/APHRS/LAHRs expert consensus statement on practical management of the remote device clinic

Aileen M. Ferrick, PhD, ACNP, RN, FHRs (Co-Chair),<sup>1,\*</sup>  
 Satish R. Raj, MD, MSCI, FHRs (Co-Chair),<sup>2,\*</sup>  
 Thomas Deneke, MD, PhD, FHRs (EHRA Vice-Chair),<sup>3,†</sup>  
 Pipin Kojodjojo, MBBS, PhD, FHRs (APHRS Vice-Chair),<sup>4,‡</sup>  
 Nestor Lopez-Cabanillas, MD (LAHRs Vice-Chair),<sup>5,§</sup> Haruhiko Abe, MD, PhD,<sup>6,‡</sup>  
 Serge Boveda, MD, PhD, FEHRA, FESC,<sup>7,†</sup> Derek S. Chew, MD, MSc, FHRs,<sup>2,\*</sup>  
 Jong-Il Choi, MD, PhD, MHS,<sup>8,‡</sup> Nikolaos Dagnes, MD,<sup>9,†</sup>  
 Aarti S. Dalal, DO, FACC, FHRs, CEPS-P,<sup>10,¶</sup> Brynn E. Dechert, APN, FHRs, CCDS,<sup>11,¶</sup>  
 Camille G. Frazier-Mills, MD, MHS, CCDS,<sup>12,\*</sup> Olivia Gilbert, MD, MSc, FACC,<sup>13,#</sup>  
 Janet K. Han, MD, FACC, FHRs,<sup>14,\*\*</sup> Sherri Hewit, PharmD,<sup>††</sup>  
 Christine Kneeland, BSN,<sup>15,\*</sup> Starr DeEllen Mirza,<sup>††</sup> Suneet Mittal, MD, FHRs,<sup>16,\*</sup>  
 Renato Pietro Ricci, MD,<sup>17,†</sup> Mary Runte, PhD,<sup>18,††</sup> Susan Sinclair, NZCS, PGDHSc,<sup>19,‡</sup>  
 Ricardo Alkmim-Teixeira, MD, PhD,<sup>20,§</sup> Bert Vandenberk, MD, PhD,<sup>2,21,†</sup>  
 Niraj Varma, MA, MD, PhD<sup>22,‡‡</sup>

**Document Reviewers:** Elizabeth Davenport, MSN, CNML, Vicki Freedomberg, PhD, RN, MSN, Taya V. Glotzer, MD, Jin-Long Huang, MD, PhD, Takanori Ikeda, MD, PhD, FACC, FESC, FJCS, Daniel B. Kramer, MD, FACC, David Lin, MD, FHRs, FACC, Ulises Rojel-Martínez, MD, FHRs, Markus Stühlinger, MD, FACC, FEHRA, Paul D. Varosy, MD

From the <sup>1</sup>White Plains Hospital, White Plains, New York, <sup>2</sup>University of Calgary, Calgary, Alberta, Canada, <sup>3</sup>Heart Center Bad Neustadt, Bad Neustadt, Germany, <sup>4</sup>Asian Heart & Vascular Centre, Singapore, <sup>5</sup>Adventist Cardiovascular Institute, Buenos Aires, Argentina, <sup>6</sup>University of Occupational and Environmental Health Hospital, Kitakyushu, Japan, <sup>7</sup>Clinique Pasteur, Toulouse, France, <sup>8</sup>Korea University Medical Center, Seoul, Korea, <sup>9</sup>Heart Center Leipzig at the University of Leipzig, Leipzig, Germany, <sup>10</sup>Vanderbilt University Medical Center, Nashville, Tennessee, <sup>11</sup>C.S. Mott Children's Hospital, Ann Arbor, Michigan, <sup>12</sup>Duke University Medical Center, Durham, North Carolina, <sup>13</sup>Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, <sup>14</sup>VA Greater Los Angeles Healthcare System, Los Angeles, California, <sup>15</sup>Mayo Clinic, Rochester, Minnesota, <sup>16</sup>The Valley Hospital, Ridgewood, New Jersey, <sup>17</sup>Cardio Arrhythmology Center, Rome, Italy, <sup>18</sup>University of Lethbridge, Lethbridge, Alberta, Canada, <sup>19</sup>Auckland City Hospital, Auckland, New Zealand, <sup>20</sup>Hospital Renascentista, Pouso Alegre, Minas Gerais, Brazil, <sup>21</sup>Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium, and <sup>22</sup>Cleveland Clinic, Cleveland, Ohio.

\*Representative of the Heart Rhythm Society (HRS)

†Representative of the European Heart Rhythm Association (EHRA)

‡Representative of the Asia Pacific Heart Rhythm Society (APHRS)

§Representative of the Latin American Heart Rhythm Society (LAHRs)

¶Representative of the Pediatric and Congenital Electrophysiology Society (PACES)

#Representative of the American College of Cardiology (ACC)

\*\*Representative of the American Heart Association (AHA)

††Patient Partner

‡‡Representative of the International Society for Holter and Noninvasive Electrocardiology (ISHNE)

**ABSTRACT**

Remote monitoring is beneficial for the management of patients with cardiovascular implantable electronic devices by impacting morbidity and mortality. With increasing numbers of patients using remote monitoring, keeping up with higher volume of remote monitoring transmissions creates challenges for device clinic staff. This international multidisciplinary document is intended to guide cardiac electrophysiologists, allied professionals, and hospital administrators in managing remote monitoring clinics.

This includes guidance for remote monitoring clinic staffing, appropriate clinic workflows, patient education, and alert management. This expert consensus statement also addresses other topics such as communication of transmission results, use of third-party resources, manufacturer responsibilities, and programming concerns. The goal is to provide evidence-based recommendations impacting all aspects of remote monitoring services. Gaps in current knowledge and guidance for future research directions are also identified.

**TABLE OF CONTENTS**

Take-home messages .....	3	4.2. Staff credentialing and qualifications for remote monitoring .....	15
Section 1 Introduction .....	3	Section 5 Technical considerations in remote monitoring .....	15
1.1. Preamble .....	3	5.1. Devices with noncontinuous remote monitoring .....	16
1.2. Document scope and rationale .....	4	5.2. Site-based remote monitoring .....	17
1.3. Editorial independence .....	4	Section 6 Alert-based remote monitoring .....	18
1.4. Organization of the writing committee .....	4	Section 7 Programming considerations for optimal remote monitoring .....	19
1.5. Evidence review and formulation of recommendations .....	5	7.1. Manufacturer and device-specific knowledge .....	20
1.6. Class of recommendation and level of evidence .....	5	7.2. Programming for clinical indications with different types of cardiovascular implantable electronic devices .....	22
1.7. Document review and approval .....	5	7.3. Special programming considerations for implantable loop recorders .....	24
1.8. Document updates .....	5	Section 8 Managing alerts .....	25
1.9. Relevant clinical practice documents .....	5	8.1. Defining high-priority alerts .....	25
Section 2 General concepts .....	7	8.2. Programming considerations to minimize inappropriate alerts .....	27
2.1. Definitions .....	7	8.3. Timeline recommendations for alert management .....	28
2.2. Remote monitoring considerations .....	8	Section 9 Remote monitoring reporting .....	29
2.3. Remote monitoring payment/reimbursement models .....	9	9.1. Communication of the remote monitoring report to patients .....	29
Section 3 Administrative and nonclinical staff .....	10	9.2. Components of a comprehensive report .....	29
3.1. Patient enrollment techniques .....	10		
3.2. Managing and updating manufacturer websites .....	11		
3.3. Techniques to optimize patient connectivity .....	11		
Section 4 Staffing of remote monitoring clinics .....	12		
4.1. Recommended staffing requirements for remote monitoring .....	12		

**KEYWORDS** Alerts; Cardiovascular implantable electronic device; CIED; Connectivity; Device clinic; Programming; Remote monitoring

**ABBREVIATIONS** **AF** = atrial fibrillation; **AHP** = allied health professional; **AI** = artificial intelligence; **ATP** = anti-tachycardia pacing; **CIED** = cardiovascular implantable electronic device; **COR** = class of recommendation; **CRT** = cardiac resynchronization therapy; **CRT-D** = cardiac resynchronization therapy defibrillator; **CRT-P** = cardiac resynchronization therapy pacemaker; **EHR** = electronic health record; **HF** = heart failure; **ICD** = implantable cardioverter-defibrillator; **IEGM** = intracardiac electrogram; **ILR** = implantable loop recorder; **LOE** = level of evidence; **LV** = left ventricular; **MRI** = magnetic resonance imaging; **PM** = pacemaker; **RM** = remote monitoring; **RV** = right ventricular; **RWI** = relationships with industry; **VF** = ventricular fibrillation; **VT** = ventricular tachycardia (Heart Rhythm 2023;■:1–46)

(APHRS), and the Latin American Heart Rhythm Society (LAHRS), and in collaboration with and endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the International Society for Holter and Noninvasive Electrocardiology (ISHNE), and the Pediatric and Congenital Electrophysiology Society (PACES). Endorsed by the EHRA, the APHRS, the LAHRS, the ISHNE, and the PACES. For copies of this document, please contact the Elsevier Inc. Reprint Department ([reprints@elsevier.com](mailto:reprints@elsevier.com)). This article has been co-published with permission in *EP Europace*, *Journal of Arrhythmia*, and *Heart Rhythm*. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Any citation can be used when citing this article. **Correspondence:** Heart Rhythm Society, 1325 G St NW, Suite 500, Washington, DC 20005. E-mail address: [clinicaldocs@hrsonline.org](mailto:clinicaldocs@hrsonline.org).

Developed in partnership with and endorsed by the European Heart Rhythm Association (EHRA), the Asia Pacific Heart Rhythm Society

9.3. Techniques for incorporating reports into electronic health records .....	30
Section 10 Patient education for remote monitoring	31
10.1. Patient education for participation and compliance .....	32
10.2. Patient education of clinic-specific policies	33
Section 11 Manufacturer responsibilities with remote monitoring .....	33
11.1. Manufacturers' role to optimize individual patient care .....	34
11.2. Manufacturers' role in the management of patient safety advisories via remote monitoring .....	35
11.3. Support surrounding implantation from manufacturers .....	36
Section 12 Third-party resources for remote monitoring .....	36
12.1. Use of third-party resources in remote monitoring .....	37
Section 13 Pediatric considerations with remote monitoring .....	38
Section 14 Geographic differences with remote monitoring practices .....	38
14.1. Availability of remote monitoring .....	38
Section 15 Knowledge gaps and future needs .....	39
15.1. Remote monitoring can "shorten" large geographic distances .....	39
15.2. Remote programming .....	39
15.3. Inequitable access to cardiovascular implantable electronic device remote monitoring .....	39
15.4. Reimbursement reform for remote monitoring .....	40
15.5. Better information, not more information	40
15.6. Direct patient access to device information	40
15.7. Summary: Further research about remote monitoring .....	40
15.8. Summary: Past, present, and future .....	41
References .....	43
Appendix 1 .....	48
Appendix 2 .....	53

## Take-home messages

1. For patients with cardiovascular implantable electronic devices (CIED), remote monitoring (RM) is the standard of care.
2. Prompt patient enrollment and maintenance of regular connectivity with long-term adherence to RM accomplished by individualized patient and caregiver education is essential to an effective RM program.

3. Adequate staffing using both clinical and nonclinical personnel with appropriate patient-to-staff ratios and dedicated time to perform defined roles and responsibilities are essential for managing RM clinic workflows.
4. Clinical staff in the RM clinic should be appropriately educated and/or certified and participate in ongoing quality assurance and improvement programs.
5. Programming alerts specific to device type and indication with established mechanisms for promptly dealing with high-priority alerts can moderate increasing data volume and workload for RM programs.
6. Communicating RM device results with patients, their health care providers, and the patient electronic medical record in a secure and confidential manner should be accomplished according to individual device clinic workflows.
7. A relationship between RM clinics and device manufacturers for bidirectional exchange of ideas for staff training, patient education, patient care services, and management of safety advisories and recalls is imperative.
8. Use of third-party resources may offer financial and practical benefits for dealing with increased device clinic volume.
9. Pediatric patients with CIEDs on RM require scheduling similar to that for RM of adult patients but may have special needs requiring additional considerations.
10. Implantable loop recorders require immediate connectivity to RM with special programming needs based on the patient's clinical indication for the implantable loop recorder.
11. Alert-based RM that relies on continuous connectivity allowing for extended time intervals between in-office device interrogations.

## Section 1 Introduction

### 1.1. Preamble

The Heart Rhythm Society (HRS) has developed scientific and clinical documents that have guided clinical care in the management of cardiac arrhythmias since 1996. This HRS-led expert consensus statement was developed in partnership with the European Heart Rhythm Association (EHRA), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS), and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the Pediatric and Congenital Electrophysiology Society (PACES), and the International Society for Holter and Noninvasive Electrocardiology (ISHNE). This international expert consensus statement is intended to provide comprehensive guidance to cardiac electrophysiologists, allied professionals, and other supportive health care technicians and administrative professionals who participate in the management of cardiovascular implantable electronic device (CIED) remote monitoring (RM) programs.

## 1.2. Document scope and rationale

The years since the publication of *2015 HRS Expert Consensus Statement on Remote Interrogation and Monitoring of Cardiovascular Implantable Electronic Devices* (2015 HRS Expert Consensus Statement on RM)<sup>1</sup> have seen several key factors that have had direct and lasting impact on RM and RM management. The number of CIEDs implanted on an annual basis has grown to approximately 1.7 million worldwide.<sup>2</sup> The number of patients followed remotely has increased significantly. Possible drivers of this increase in RM have been the class 1 recommendation in the 2015 HRS Expert Consensus Statement on RM to use RM for CIED patients as standard of care and the use of RM for staff safety during the COVID-19 pandemic. Also, implantable loop recorders (ILRs), which are designed for alert-based management, have added significantly to the daily volume of data generated for RM clinic workflow.<sup>3</sup>

The overarching goal of this document is to provide evidence-based and expert consensus recommendations on how to effectively operate an RM clinic, whether hospital or nonhospital based. This takes a joint effort from RM clinic staff—which includes clinical and nonclinical personnel—hospital and health system administrators, payers, manufacturers, and regulators. Many topics considered for this document were identified through a survey of RM device clinic staff. RM is an international issue, but different jurisdictions face very different challenges related to RM availability and reimbursement.

Although RM is beneficial, its increased use can place an extra strain on already limited device clinic resources. This additional workload magnifies preexisting challenges associated with CIED RM. Some of the issues identified by RM clinic stakeholders include managing differences unique to each CIED manufacturer (eg, monitoring hardware, connectivity, programmability, nomenclature, accessibility, and web-based platforms) as well as the dynamic evolution and complexity of new devices and technology. There are other issues specific to the needs of individual RM clinics, which include the coordination of patient enrollment, scheduling, reporting, billing, and interfacing with electronic medical records. Adequate staffing with both clinical and nonclinical personnel is required for an effective and efficient RM program. Appropriate staffing roles, ratios, and credentialing are discussed. Third-party services have emerged that allow for outsourcing some or all RM services. Some of the advantages, challenges, and costs that can come with these third-party services are presented. While RM is available around the world, some regions and jurisdictions face challenges in RM availability, uptake, and reimbursement. The barriers that lead to this disparity in RM use are explained.

Patients and their caregivers are central to the RM process. Education is key to maintaining patient adherence and connectivity. Concepts related to patient and caregiver engagement are suggested for guiding RM clinics in maintaining their interest and understanding the value of the benefits of RM. The pediatric section reviews specific needs of

the pediatric patient with a CIED as it relates to RM. Although the pediatric RM recommendations are similar to the adult recommendations, it is recognized that the needs of pediatric patients may be different in specific circumstances. Industry partnership is essential for updating key stakeholders to maintain quality initiatives related to ever-emerging new technology and the potential need to coordinate safety notifications and advisories. Some ideas presented in this document may be a “wish list” of ideas with the hope that manufacturers can provide the means to accomplish certain goals as a collaborative team inclusive of patients and their caregivers.

The document finishes with a discussion of future research and goals for improving RM. Knowledge gaps are evident, and it is only through the ongoing process of acquiring evidence through research that these gaps in knowledge can be addressed.

## 1.3. Editorial independence

This expert consensus statement is sponsored by the HRS and was developed without commercial support. All writing committee members volunteered their time to the writing and review efforts.

## 1.4. Organization of the writing committee

The writing committee consisted of internationally recognized experts from 11 countries in the fields of clinical electrophysiology, cardiology, pediatric cardiology, and heart failure (HF) nominated by the partnering and collaborating organizations. HRS strives to ensure that the writing committee contains both requisite expertise and diverse representation from the broader medical community. This is achieved by selecting participants from a wide range of backgrounds representing different geographic regions, genders, races, ethnicities, intellectual perspectives, and scopes of clinical practice and by inviting organizations and professional societies with related interests and expertise to participate as partners or collaborators. In addition, three patient partners were included in the writing committee to ensure a focus on delivering optimal patient care that is in alignment with patients' wants, needs, and preferences.

HRS has rigorous policies and methods to ensure that documents are developed without bias or improper influence. The HRS policy on relationships with industry (RWI) and other entities can be found in the [HRS Code of Ethics and Professionalism: Appendix C](#) and in the [HRS Clinical Document Development Methodology Manual and Policies](#). A majority of the writing committee was free of relevant RWI throughout the development of the document and sections with recommendations were written by the writing committee members who were free of relevant RWI. For full transparency, [Appendix 1](#) is a comprehensive list of RWI (both relevant and nonrelevant to the document topic) disclosed by the writing committee members. [Appendix 2](#) is a comprehensive list of RWI disclosed by the peer reviewers.

### 1.5. Evidence review and formulation of recommendations

This expert consensus statement was developed in accordance with the clinical practice methodology processes detailed in the *HRS Clinical Document Development Methodology Manual and Policies: Executive Summary*,<sup>4</sup> and with the standards issued in 2011 by the Institute of Medicine (now National Academy of Medicine).<sup>5</sup>

The writing committee reviewed evidence gathered by electronic literature searches (MEDLINE, PubMed, Embase, Cochrane Library, Ovid). No specific year was chosen for the oldest literature. The asterisk (\*) was used for truncation to search for all forms of a word, the plus (+) symbol was used to search for plural and singular forms of a word, and the pound symbol (#) was used as a wildcard to search for variant spellings or hyphenation of a word. Search terms included but were not limited to the following: *3rd party, action\*, active transm\*, adher\*, agree\*, AICD\*, alert, alert#burden, alert#driven, allied professional, arrhythmi\*, artifact\*, artificial, cardiac, cardiac implantable electronic device\*, cardiac resyn\* therap\*, cardiovert\*, care utilization, child\*, CIED, clinic\*, clinical outcomes, communic\*, complian\*, comply\*, connecti\*, consistent, continu\*, contract\*, cost effective\*, CRT-device\*, customiz\*, defibrillator\*, devic\*, disparit\*, economic impact, economic model, economic outcomes, educat\*, efficient\*, EHR, electronic health record\*, electronic#device\*, enrol\*, event\*, geograph\*, heart failure, HF, home monitor\*, ICD, implant\*, implantable loop recorder, in#office visit, in#person, inclus\*, industry, inform\*, initiati\*, insertable cardia monitor, instruct\*, interrog\*, leadless, letter\*, loop record\*, manage\*, manufactur\*, mode\*, monitor\*, noise\*, nurse, optimiz\*, organization\*, organizational model, outsource\*, pacemaker\*, passive transm\*, patient compli\*, patient educat\*, patient monitor\*, patient portal, patient#driven, pediatri\*, personnel, physiologic\* monitoring, program\*, randomized controlled trial, RCT, reimburs\*, remote monitor\*, remote\*, report, reportable results, resource, responsibility\*, routine results, schedul\*, socio#econom\*, staff\*, subcutaneous cardiac monitor, surveil\*, task\*, techn\*, technical overview, telehealth, telemetry, telemonitor\*, third-party, tim\*, transm\*, utility analysis, utilization, variabil\*, website, work#flow\*, workforce, workload.* Literature searches focused whenever possible on randomized controlled trials, but systematic reviews, nonrandomized and registry studies, cohort studies, and case series were included. Case reports were not used to support recommendations. Evidence tables are included in [Appendix 3](#) and summarize the evidence used by the writing committee to formulate recommendations. References are representative of the totality of data and are not meant to be all-inclusive. Limitations of the evidence base are discussed in individual sections.

To assess consensus after discussions, the writing committee members participated in surveys. A predefined threshold of 70% approval for each recommendation was required,

with a minimum quorum of two-thirds of the writing committee. An initial failure to reach consensus was resolved by subsequent discussions, revisions as needed, and re-voting. Writing committee members with RWI did not vote on recommendations concerning relevant topics. The final mean consensus over all recommendations was 98.9%, with 46 of 59 recommendations reaching 100% consensus.

### 1.6. Class of recommendation and level of evidence

Recommendations in this expert consensus statement are designated with both a class of recommendation (COR) and a level of evidence (LOE). The COR denotes the strength of the recommendation based on the assessment of the magnitude and certainty of the benefits in proportion to the risks. The LOE reflects the quality of the evidence that supports the recommendation based on type, quantity, and consistency of data from clinical trials and other sources ([Table 1](#)).<sup>6</sup>

For clarity and usefulness, each recommendation is linked to the supportive evidence through the specific references from the literature used to justify the LOE rating, which are also summarized in their evidence tables ([Appendix 3](#)). Each recommendation is accompanied by explanatory text. Flow diagrams and appropriate tables provide a summary of the recommendations, intended to assist clinicians at the point of care.

### 1.7. Document review and approval

The HRS invites public and stakeholder involvement in document development. In addition to patient representation in the writing committee, draft recommendations were posted for public comment, and contribution was solicited from regulatory agencies and patient organizations.

This expert consensus statement was approved by the writing committee and underwent internal review by the HRS Scientific and Clinical Documents Committee. The document underwent external peer review by reviewers appointed by HRS and each of the collaborating societies, and revisions were made by the chairs. A record of writing committee response to reviewer comments and rationale is maintained by the HRS.

### 1.8. Document updates

The HRS Scientific and Clinical Documents Committee reviews each clinical practice document for currency at least every 5 years, or earlier in the event of newly published data. The literature is routinely monitored to evaluate the continued validity of recommendations.

### 1.9. Relevant clinical practice documents

[Table 2](#) lists pertinent guidelines and expert consensus statements that the writing committee considered for this document. The included documents contain relevant information for the practical management of the remote device clinic.

**Table 1 ACC/AHA recommendation system: Applying class of recommendation and level of evidence to clinical strategies, interventions, treatments, and diagnostic testing in patient care (updated May 2019)\***

CLASS (STRENGTH) OF RECOMMENDATION	LEVEL (QUALITY) OF EVIDENCE†‡
<b>CLASS 1 (STRONG)</b> <span style="float: right;"><b>Benefit &gt;&gt;&gt; Risk</b></span> <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>• Is recommended</li> <li>• Is indicated/useful/effective/beneficial</li> <li>• Should be performed/administered/other</li> <li>• Comparative-Effectiveness Phrases†:               <ul style="list-style-type: none"> <li>– Treatment/strategy A is recommended/indicated in preference to treatment B</li> <li>– Treatment A should be chosen over treatment B</li> </ul> </li> </ul>	<b>LEVEL A</b> <ul style="list-style-type: none"> <li>• High-quality evidence‡ from more than 1 RCT</li> <li>• Meta-analyses of high-quality RCTs</li> <li>• One or more RCTs corroborated by high-quality registry studies</li> </ul>
<b>CLASS 2a (MODERATE)</b> <span style="float: right;"><b>Benefit &gt;&gt; Risk</b></span> <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>• Is reasonable</li> <li>• Can be useful/effective/beneficial</li> <li>• Comparative-Effectiveness Phrases†:               <ul style="list-style-type: none"> <li>– Treatment/strategy A is probably recommended/indicated in preference to treatment B</li> <li>– It is reasonable to choose treatment A over treatment B</li> </ul> </li> </ul>	<b>LEVEL B-R</b> <span style="float: right;"><b>(Randomized)</b></span> <ul style="list-style-type: none"> <li>• Moderate-quality evidence‡ from 1 or more RCTs</li> <li>• Meta-analyses of moderate-quality RCTs</li> </ul>
<b>CLASS 2b (WEAK)</b> <span style="float: right;"><b>Benefit ≥ Risk</b></span> <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>• May/might be reasonable</li> <li>• May/might be considered</li> <li>• Usefulness/effectiveness is unknown/unclear/uncertain or not well-established</li> </ul>	<b>LEVEL B-NR</b> <span style="float: right;"><b>(Nonrandomized)</b></span> <ul style="list-style-type: none"> <li>• Moderate-quality evidence‡ from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies</li> <li>• Meta-analyses of such studies</li> </ul>
<b>CLASS 3: No Benefit (MODERATE)</b> <span style="float: right;"><b>Benefit = Risk</b></span> <b>(Generally, LOE A or B use only)</b> <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>• Is not recommended</li> <li>• Is not indicated/useful/effective/beneficial</li> <li>• Should not be performed/administered/other</li> </ul>	<b>LEVEL C-LD</b> <span style="float: right;"><b>(Limited Data)</b></span> <ul style="list-style-type: none"> <li>• Randomized or nonrandomized observational or registry studies with limitations of design or execution</li> <li>• Meta-analyses of such studies</li> <li>• Physiological or mechanistic studies in human subjects</li> </ul>
<b>CLASS 3: Harm (STRONG)</b> <span style="float: right;"><b>Risk &gt; Benefit</b></span> <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>• Potentially harmful</li> <li>• Causes harm</li> <li>• Associated with excess morbidity/mortality</li> <li>• Should not be performed/administered/other</li> </ul>	<b>LEVEL C-EO</b> <span style="float: right;"><b>(Expert Opinion)</b></span> <ul style="list-style-type: none"> <li>• Consensus of expert opinion based on clinical experience</li> </ul>

COR and LOE are determined independently (any COR may be paired with any LOE).

A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

\* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).

† For comparative-effectiveness recommendations (COR 1 and 2a; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

‡ The method of assessing quality is evolving, including the application of standardized, widely-used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.

COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.

Adapted with permission from the American College of Cardiology (ACC) and the American Heart Association (AHA).

**Table 2 Relevant clinical practice documents**

Title	Publication Year
2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals <sup>7</sup>	2021
2021 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy <sup>8</sup>	2021
2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients <sup>9</sup>	2021
Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology <sup>10</sup>	2020

**Table 2** (Continued)

Title	Publication Year
HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic <sup>11</sup>	2020
EHRA/HRS/APHRS/LAHRS Expert Consensus on Risk Assessment in Cardiac Arrhythmias: Use the Right Tool for the Right Outcome, in the Right Population <sup>12</sup>	2020
HRS White Paper on Interoperability of Data From Cardiac Implantable Electronic Devices <sup>13</sup>	2019
Transparent Sharing of Digital Health Data: A Call to Action <sup>14</sup>	2019
HRS Expert Consensus Statement on Remote Interrogation and Monitoring for Cardiovascular Implantable Electronic Devices <sup>1</sup>	2015
ISHNE/EHRA Expert Consensus on Remote Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs) <sup>15</sup>	2012
HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations <sup>16</sup>	2008
Recommendations from the Heart Rhythm Society Task Force on Device Performance Policies and Guidelines endorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) and the International Coalition of Pacing and Electrophysiology Organizations (COPE) <sup>17</sup>	2006

## Section 2 General concepts

Studies since 2015 have continued to show the value of RM and its potential positive effects on morbidity and mortality, cementing RM as an essential part of CIED patient care.<sup>18-23</sup> This has led to a deluge of patients on RM,<sup>24</sup> resulting in large amounts of RM data and an increase in RM-related workload.<sup>25-28</sup> While the 2015 HRS Expert Consensus Statement on RM<sup>1</sup> provides recommendations on the benefits of RM and the importance of integrating RM into CIED patient care, it does not account for the challenges related to RM that have been realized in the intervening years. These include the need for organizational RM infrastructure, staffing, and workflow to handle RM data and RM-related work. It also includes ensuring that pa-

tients with CIEDs on RM remain connected and at the center of RM programs. There is also a need for developing an improved RM reimbursement structure. The RM device clinic includes a multidisciplinary team involved with the monitoring of CIEDs. The increasing number of CIEDs implanted as well as unexpected challenges such as the COVID-19 pandemic have resulted in high demands on in-person services and a shift toward virtual outpatient clinics.<sup>11,29</sup>

### 2.1. Definitions

To standardize the terminology used in the description of RM, terms used in this expert consensus statement are defined in [Table 3](#).

**Table 3** Definitions

Term	Definition
<b>Programmer</b>	A manufacturer-specific device designed to receive and transmit information from CIEDs and allow temporary and permanent programming of CIEDs.
<b>Device interrogation</b>	Data transmission from the CIED to the programmer, including device settings and data stored in the CIED memory. The data can be viewed and stored directly on the programmer or transformed to a report that can be exported to a computer, dedicated CIED follow-up software, and internet servers.
<b>Device programming</b>	Bidirectional telemetry allowing the programmer operator to assess CIED function, select CIED settings, and optimize system performance tailored to the individual patient's condition in a noninvasive and reversible manner.
<b>Home monitor</b>	Remote telemetry device, either a strategically positioned device in the proximity of the patient or a smartphone-based application, able to communicate with the CIED, which serves as a substation to transmit the encrypted data to dedicated servers.
<b>Remote monitoring (RM)</b>	Automated remote transmissions of predefined alerts related to clinical events (eg, ICD therapies) or related to device functioning (eg, lead integrity alerts).
<ul style="list-style-type: none"> <li>• <b>Individual-based RM</b></li> <li>• <b>Site-based RM</b></li> </ul>	<p>RM where the manufacturer-specific transmitter is assigned to an individual patient at enrollment.</p> <p>RM where the manufacturer-specific transmitter is assigned to a specific site and could be used to collect device data for many individual patients (even if they are not individually enrolled).</p>

(Continued)

**Table 3** (Continued)

Term	Definition
<b>RM platform</b>	Manufacturer-specific remote web-based communication system allowing access to the encrypted data transmission from the home monitor to individual clinic and/or third-party resources.
<b>Third-party resources</b>	External services available using manufacturer-specific RM systems to collect and communicate patient data. This could be software based, which collates data, or personnel based, which can outsource some of the clinics' work.
<b>Scheduled transmission</b>	Programmable scheduled transmissions during which routine CIED parameters are collected remotely from the RM platform by members of the remote device clinic team in a format like that obtained during a routine in-person clinic visit.
<b>Nonscheduled transmission</b>	
• <b>Patient-initiated interrogation</b>	Nonscheduled data transmission initiated by the patient due to experiencing real or perceived clinical events, for which the patient is seeking expert evaluation.
• <b>Alert-initiated Interrogation</b>	Nonscheduled data transmission initiated by predefined programmed parameters for alerting the clinic of a potentially actionable event.
<b>Actionable event</b>	Device-related or clinical event that requires intervention prior to the next scheduled in-person clinic visit.
<b>Continuous connectivity</b>	Continuous data collection within the device with automatic transmission using manufacturer-specific transmission frequency, which often occurs once daily. While the data collection is continuous, the transmissions and monitoring are not continuous.
<b>Noncontinuous monitoring</b>	Noncontinuous data collection requiring manual transmission using manufacturer-specific transmission either scheduled by the clinic or initiated by the patient.

CIED = cardiovascular implantable electrical device; ICD = implantable cardioverter-defibrillator; RM = remote monitoring.

## 2.2. Remote monitoring considerations

Since the 2015 HRS Expert Consensus Statement on RM<sup>1</sup>, more recent studies have strengthened the evidence for the organizational benefits of RM and have offered new insights into the impact of RM on patient outcome, particularly in those with HF. RM as first-line strategy

for CIED follow-up has been established by the 2020 HRS/EHRA/APHS/LAHS/ACC/AHA *Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic*<sup>11</sup> and in 2021 ESC *Guidelines on Cardiac Pacing and Resynchronization Therapy*.<sup>8</sup>

### Recommendations for RM considerations

COR	LOE	Recommendations	References
1	A	1. In patients with CIEDs, RM is recommended as part of the standard of care.	1,11,30-38
1	B-R	2. In patients with CIEDs on RM, routine surveillance of lead function and battery status is recommended to ensure device integrity.	30,39,40
1	C-EO	3. In patients with CIEDs on RM with a device capable of continuous connectivity, connectivity should be maintained.	

### Synopsis

In patients with CIEDs, RM is recommended as standard of care in the 2015 HRS Expert Consensus Statement on RM.<sup>1</sup> Several large, randomized studies as well as large registries and observational studies consistently demonstrated major organizational benefits, such as follow-up optimization, and clinical benefits, with improved patient management and clinical outcome associated with RM.

### Recommendation-specific supportive text

1. RM reduces the number of health care visits and increases follow-up adherence and patient retention. It provides earlier detection of actionable events such as atrial and ventricular

arrhythmias without compromising safety.<sup>30-38</sup> It has been demonstrated to be useful in reducing inappropriate implantable cardioverter-defibrillator (ICD) shocks by early detection of atrial fibrillation (AF) with rapid ventricular response rates,<sup>41</sup> T-wave oversensing, electromagnetic interference, and device malfunction. No study to date has shown a reduction in appropriate ICD shocks with RM. RM can facilitate early detection and quantification of AF episodes and arrhythmia burden that may prompt clinical reaction, preventing adverse events such as stroke, shock therapy, and HF. Continuous connectivity allows individualized patient treatment and continuous updating of therapeutic strategy. Observational studies,<sup>42-44</sup> subanalysis of



randomized trials,<sup>37</sup> and metaanalysis<sup>20</sup> suggest potential benefits of RM in preventing stroke; these findings have yet to be confirmed by randomized studies.<sup>45</sup>

The ability of RM to prevent disease progression and improve outcomes with HF is still controversial. Modern implantable devices continuously provide diagnostic information to monitor for HF decompensation, creating opportunities for early intervention prior to deterioration and hospitalization. Some trials demonstrated significant benefits of RM<sup>46</sup> in reducing hospitalizations and mortality,<sup>47,48</sup> as corroborated by real-world large registries.<sup>49</sup> Continuous connectivity<sup>50,51</sup> and prompt and structured reaction to alerts<sup>23,52,53</sup> may be key to improving patient outcomes. Automatic multiparameter monitoring<sup>53-55</sup> seems promising in prevention of HF exacerbation. Analysis of mega-cohorts<sup>22,56</sup> showed improved survival in patients followed by RM, with high connectivity being the greatest benefit. This is consistent with the pooled analysis of 3 trials<sup>50</sup> in which RM reduced all-cause mortality and the composite endpoint of all-cause mortality or worsening HF hospitalization. The similar magnitudes of absolute risk reductions for worsening HF and cardiovascular endpoints suggest that the benefit of RM is driven by the prevention of HF exacerbation.

RM is generally regarded as cost-effective, depending on the health care model and items assessed,<sup>57</sup> as it results in reduction of in-hospital scheduled and emergency visits, reduction of diagnostic test burden, and reduction of follow-up duration and physician and nurse time.<sup>58-60</sup> RM also reduces patient costs for travel to in-person visits, time off from work, and interruption of daily activities of patients and accompanying persons.<sup>61</sup>

Conflicting results do exist regarding the impact of RM on patient acceptance and quality of life. Several studies have reported a high rate of patient satisfaction for diverse aspects such as the patient's perceived relationship with their health care providers, ease of use, psychological impact, and the ability to maintain follow-up compliance.<sup>35,62-65</sup> Other studies observed neutral effects.<sup>66-68</sup>

2. RM allows effective and safe surveillance of device functioning with alerts for battery depletion, circuit disruption, and lead failure, ensuring device function and integrity. Early detection of malfunctions when the patient is still asymptomatic may prevent catastrophic consequences, particularly in cases of lead or device advisory.<sup>21,39,69-71</sup> RM also allows for continuous connectivity of pacing thresholds, allowing optimization of battery longevity.<sup>72-74</sup>
3. For patients with continuous connectivity, consistent connectivity depends on appropriate functioning of the RM home device as well as on telecommunication system availability and patient adherence to the follow-up plan. Many manufacturers currently provide mobile smartphone applications<sup>75</sup> that can facilitate CIED RM transmission and alert patients to the status of RM connectivity, encouraging patient engagement and partnership vital to maintaining RM.<sup>76-78</sup> Consistent connectivity is critical to maximize RM benefits by early detection of actionable events, allowing for early intervention for arrhythmias and HF decompensation, with potential to improve overall patient outcomes.<sup>19,21,22,56,69-72</sup> Timely reaction to implanted system technical failure as well as to changes in clinical status may impact patient outcomes.<sup>73-75</sup>

### 2.3. Remote monitoring payment/reimbursement models

#### Recommendations for RM payment/reimbursement models

COR	LOE	Recommendations	References
1	B-NR	1. For the care of patients with CIEDs on RM, it is recommended that health care payers adopt adequate reimbursement for RM that is tailored to regional health system care patterns and facilitates sustainable and cost-effective CIED follow-up care.	35,57-60,62,66,79-89

#### Synopsis

There are an increasing number of economic studies that report the cost-effectiveness<sup>58</sup> (ie, increased clinical benefits for additional costs that fall within country-specific, societally accepted thresholds for health care value) or cost savings of RM compared to conventional in-clinic visits.<sup>57,59,60,62,66,79-85,87,90,91</sup> Possible mechanisms of economic benefit include fewer clinic visits without clinically actionable events,<sup>92</sup> reduction in hospitalizations or emergency department visits due to earlier detec-

tion of clinical deterioration,<sup>35,93</sup> or a reduction in patient- and caregiver-borne costs related to travel and missed work.<sup>59</sup> It is important to note that these prior studies describe the economic outcomes associated with the RM of ICDs, cardiac resynchronization therapy (CRT) devices, and pacemakers (PMs), but not ILRs, for which the evidence of clinical benefit is less certain. Lack of reimbursement is frequently cited as a barrier to widespread adoption of RM<sup>86,94</sup> that varies widely by country,<sup>15</sup> and within country by health jurisdiction.<sup>95</sup>

### Recommendation-specific supportive text

1. Given the fundamental differences in the health care financing across health systems, a single prototypic reimbursement model is likely unsuitable for all settings. More generally, however, implementation or reform of existing reimbursement should consider several cost categories: (a) costs associated with the RM system itself, such as hardware, software, and industry service reimbursement; (b) physician fees for RM data interpretation; and (c) hospital- and nonhospital-based clinic overhead costs including those for allied health professionals (AHPs) and administrative and nonclinical personnel. In particular, reimbursement models should account for the effort required to coordinate care (for instance, between device clinics and HF clinics) and the added indirect workload when managing an RM clinic that is not reflected by in-clinic patient evaluations. This additional work may include triaging and reviewing frequent remote transmissions, and timely management of alerts.<sup>3</sup> Reimbursement will also need to be adaptable to the potentially evolving landscape of industry charges and ongoing expenses for RM infrastructure, data servers, and technical support personnel. Ideally, reimbursement models should be aligned with the broader goals of the health care system, which may include access, sustainability, quality,

and equity. RM could decrease health care costs by reducing and shortening hospital stays if implemented properly.<sup>83</sup> Innovative models may be required to facilitate the goals of access and equity, particularly among patients without cell phone coverage or internet access.<sup>96</sup> Without focused policy efforts, there is a risk of exacerbating care disparities and excluding vulnerable patients from the potential benefits of RM.

### Section 3 Administrative and nonclinical staff

As device clinics are burdened with the increased volume of remote transmissions sent from patient with CIEDs on RM, there is an opportunity to review responsibilities that could be completed by administrative and nonclinical staff to assist in optimizing prompt patient enrollment, patient follow-up, and workflow efficiencies. This could include but is not limited to tasks such as assisting with patient enrollment, handling missed appointment notices, managing patient connectivity, ordering monitors, handling patient transfer requests, scheduling, and maintaining patient information on manufacturer web-based platforms. It is important to define the scope of practice when evaluating appropriate duties for administrative and nonclinical staff.

### 3.1. Patient enrollment techniques

Recommendations for patient enrollment techniques			
COR	LOE	Recommendations	References
1	C-EO	1. In patients with an ILR, enrollment in an RM program is recommended prior to discharge given the daily availability of diagnostic data.	
2a	B-NR	2. In patients with a CIED, it can be beneficial to initiate RM prior to discharge or within 2 weeks of CIED implantation.	97,98

### Synopsis

The concept of RM should be discussed as part of patient education before CIED implantation, allowing assessment of the preferred connection method that may affect device selection in certain circumstances. For ILRs, diagnostic data might be available very soon after discharge. It is important that RM enrollment occurs prior to discharge from the hospital or clinic. For non-ILR CIEDs, there is significant variability in practice regarding the timing of patient enrollment in RM. Ideally, patients would be enrolled prior to discharge, with chosen RM equipment. For same-day discharge, this would assure additional safety by providing immediate remote surveillance, replacing what was previously hospital-based surveillance. There are challenges and limitations to this model. Patients may need time to process the life change a CIED implementation could represent. Technical limitations (eg, lack of hardware availability) and patient characteristics (eg, absence of primary caregivers) could also limit the opportunity to initiate RM prior to discharge. In these circum-

stances, patients should be enrolled virtually or at the first post-implantation in-office visit. Both enrollment options have been used in clinical trials without direct comparison for any clinical outcome. As up to 50% of patients fail to activate their RM receiver,<sup>22,99</sup> the use and confirmation of a successful “handshake transmission” can minimize the proportion of patients who fail to activate RM. In-office setup with pairing of the CIED and the RM receiver has been shown to be feasible and to increase the proportion of patients with a successful first RM transmission after discharge.<sup>100</sup>

### Recommendation-specific supportive text

1. ILRs have daily diagnostic data available, and their entire *raison d'être* is to provide diagnostic information. Important diagnostic information could occur in the days immediately following ILR implantation. To avoid missing this information, it is important that RM be initiated prior to discharge. In this way, symptom-rhythm correlation will not be lost when the patient is no longer monitored in the hospital.<sup>101</sup>

2. It can be beneficial to enroll patients with a CIED in an RM program within 2 weeks of CIED implantation, and ideally prior to discharge if feasible. In a randomized trial comparing RM with conventional follow-up, enrollment in RM before discharge was associated with earlier detection of actionable events

without increasing unnecessary in-patient evaluations.<sup>98</sup> RM enrollment within 3 months of implant was associated with improved survival in all CIED types, but the survival benefit was greatest in patients with cardiac resynchronization therapy defibrillators (CRT-Ds).<sup>97</sup>

### 3.2. Managing and updating manufacturer websites

#### Recommendations for managing and updating manufacturer websites

COR	LOE	Recommendations	References
1	C-EO	1. For the care of patients with CIEDs on RM who undergo device change or upgrade, have a change in vital status, or request clinic transfer, it is recommended that there is a process to update patient information on the manufacturer web-based platform in a timely manner to avoid gaps in RM.v	

#### Synopsis

In patients with CIEDs on RM, timely updates of the device manufacturer's web-based platform are needed to avoid gaps when a patient undergoes device change or upgrade, dies, or requests clinic transfer, or when there are other equipment changes. For continuous optimal care of patients with CIEDs on RM with these circumstances, updating baseline device/demographic information on the manufacturer web-based platform is essential to avoid clinical or demographical gaps with ongoing use of RM. This information-updating process also contributes to maintaining a more accurate roster of patients being followed by device clinic staff, thus improving workflow efficiency.

#### Recommendation-specific supportive text

1. RM staff in clinic- or hospital-based programs need to update patient information on the manufacturer web-based platform for those who undergo device change or upgrade before discharge to ensure ongoing monitoring and compatibility of new device with existing RM equipment. These updates on the manufacturer website are also required in the case of a change in vital status (such as patient death), a change in patient's contact information (telephone number or address), or a patient transfer from or to another clinic. Workflows should be established to address whether administrative or clinical staff should address these updates.

### 3.3. Techniques to optimize patient connectivity

#### Recommendations for techniques to optimize patient connectivity

COR	LOE	Recommendations	References
1	C-EO	1. For the care of patients with CIEDs on RM who lose connectivity, it is recommended that clinics have an established process that includes dedicated clinic staff to facilitate reconnection.	

#### Synopsis

Established processes for overcoming challenges with connectivity increase efficiency, thereby reducing response time necessary to address patients' concerns as well as minimizing time that patients remain disconnected.

#### Recommendation-specific supportive text

1. Patient connectivity to RM is critical for the success of an RM program and most importantly for the patient to realize the known benefits of RM (see **Section 2.2**). Rapid management of disconnected patients is

imperative. This responsibility falls on the patient and the device clinic. It is important that every reasonable effort be made by the clinic to reach the disconnected patient. Manufacturers as collaborative partners can assist by providing a notification directly to the patient about a disconnection and can provide technical support if needed. This time-intensive process that includes contacting the patient and troubleshooting the issue(s) can be accomplished by adequately trained nonclinical or clinical staff with adequate time budgeted for this important task.

## Section 4 Staffing of remote monitoring clinics

The 2015 HRS Expert Consensus Statement on RM identified the roles and responsibilities of the RM team members.<sup>1</sup> The document identified the following as members of the team: physician, advanced practice provider, allied professional, and ancillary staff. In addition, the original document clearly stipulated that an event detected by RM can trigger a full interrogation, office visit, or even an emergency department evaluation, each of which would be associated with the appropriate communication with the patient's additional health care providers. Inherent to RM is the work effort needed

to consistently operate and maintain an effective and efficient RM clinic. Furthermore, several important developments have transpired since the 2015 HRS Expert Consensus Statement on RM was published. These include an increase in the number of patients on RM, the availability of ILRs that transmit data daily for years at a time, the continued absence of a national coverage determination that provides a uniform reimbursement model for RM, and the proliferation of multiple operational models to conduct an RM program. These developments require us to reconsider the appropriate staffing requirements for RM clinics.

### 4.1. Recommended staffing requirements for remote monitoring


Recommendations for staffing requirements for RM			
COR	LOE	Recommendations	References
1	B-NR	1. For the care of patients with CIEDs on RM, a team-based organizational model with formal policies, procedures, and clear definitions of the roles and responsibilities of qualified staff is recommended to optimize all related RM tasks.	1,25,28,29,53,90,102-109
1	B-NR	2. For the care of patients with CIEDs on RM, it is recommended that there is adequate dedicated time to perform all RM tasks, including scheduled and nonscheduled transmissions, patient follow-up, and administrative tasks.	25,28,57,104,106,110
1	B-NR	3. For the care of patients with CIEDs on RM, it is recommended that the staff-to-patient ratios in RM clinics reflect the increasing unscheduled transmission workload.	3,28,59,111,112
2a	C-LD	4. For the care of patients with CIEDs on RM, it is reasonable for clinics to have a minimum of 3.0 full-time equivalents per 1000 patients on RM, comprising both clinical and administrative staff.	27

### Synopsis

The 2015 HRS Expert Consensus Statement on RM assigned a class 1 recommendation to RM in all CIED patients.<sup>1</sup> The adoption of RM was further facilitated by the COVID-19 pandemic, which prompted adoption of digital and virtual technologies to provide safe, uninterrupted monitoring and care for CIED patients.<sup>10,11,24,113</sup> However, staffing challenges are multifaceted, interrelated, and continue to persist (Figure 1). The value of RM and its benefits may not be widely known or accepted, which can affect resourcing, reimbursement, and ultimately allocation of staffing for RM monitoring within an institution.<sup>28,95,114</sup> CIED RM work hours are incorporated into a “virtual” space; while the patient may not be physically in the clinic, the work burden related to managing CIED RM patients still exists on multiple levels.<sup>28</sup> The success of CIED RM programs is directly related to the ability to absorb and complete this workload in an efficient manner. This requires organizational models and infrastructure, with policies and procedures to govern operations and workflow and dedicated time, space, and equipment.<sup>25,28,29,90,102-104,108</sup> Critical to this organizational model is a team of CIED RM personnel with clearly defined roles—physicians and advanced allied professionals, nurses and/or cardiac physiologists, technicians, and administrative support staff.<sup>1,25,28,29,102,103,107</sup>

### Recommendation-specific supportive text

1. The continued uptake of RM has led to a deluge of data from scheduled and unscheduled RM transmissions. Some institutions report receiving >100,000 transmissions annually.<sup>3,103</sup> Although RM transmission volume can be extremely high, RM transmission review can be highly efficient, as long as staff, workflow, and decision trees are in place.<sup>29,103,107,111</sup> The Italian HomeGuide Registry structured organizational model of a primary nurse and physician team to review RM transmissions and manage RM patients was found to be highly effective, safe, and efficient.<sup>29,107</sup> Subsequent observational studies have corroborated the use of structured organizational models with dedicated staff, workflows, and decision trees, showing improvements in patient management, timely detection of actionable events, and gains in clinic efficiencies.<sup>90,103,108,109</sup> Structured workflow with dedicated RM staff (a central monitoring unit) and duties (RM transmission review with forwarding of events to clinical teams) may have contributed to improved outcomes in patients on RM in the implant-based multiparameter telemonitoring of patients with HF randomized controlled trial (IN-TIME).<sup>53</sup> These data led to a position paper from the Italian Association of Arrhythmology and Cardiac Pacing calling for RM



**Figure 1** Staffing challenges with remote monitoring. AI = artificial intelligence; EHR = electronic health record; RM = remote monitoring.

organizational model standardization and formally recommending the use of dedicated, trained teams to manage RM transmissions in CIED patients.<sup>102</sup>

2. The growth of RM and RM transmissions has been accompanied by an exponential increase in workload.<sup>3,25,28,103</sup> In addition to reviewing RM transmissions, other RM-related tasks must be completed to appropriately manage CIED patients on RM.<sup>28,57,103,105,106,110,112</sup> While review of RM transmissions is rapid, the total RM-related work burden is high.<sup>110,112</sup> The EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients) trial showed that total staff time required to manage home monitoring “on” vs home monitoring “off” groups was similar (176 vs 178 min, P = NS).<sup>57</sup> In 2021, an international study of RM time-motion workflow<sup>28</sup> found that for each RM transmission, at least 15 tasks needed completion, including transmission review and diagnosis, patient communication and clinical action, and electronic charting and billing. Furthermore, there were 17 additional tasks, including triage and scheduling, technology and connectivity troubleshooting, and telephone work, to completely manage a CIED patient on RM.<sup>28</sup> Without investment in infrastructure and personnel with dedicated time for RM, the benefits of RM on clinic efficiencies, on patient adherence, satisfaction, and quality of life, and, most importantly, on patient morbidity and

mortality cannot be realized, and systems become overwhelmed.<sup>3,25,28,90,95,104-106</sup> Lack of formalized policies to perform the “invisible work” of RM prevents personnel from performing at the top of their license, especially if also tasked with other non-RM responsibilities. This leads to job dissatisfaction, burnout, and high staff turnover in under-resourced teams.<sup>3,25,28,90,95,104-106</sup>


3. Clinical trials have highlighted the efficiencies and time saved by an RM scheduled follow-up vs an in-clinic follow-up.<sup>107,112</sup> However, many patients will have unscheduled transmissions in addition to their scheduled follow-ups and each of these requires triage, data review, and documentation with an associated time cost.<sup>3</sup> Unscheduled remote transmissions comprise 27-40% of clinic workload, and as such, sufficient staff resources will need to be provided to review this data.<sup>111</sup> Additionally unscheduled transmissions have more actionable events that require longer time for clinical management; this also needs to be taken into consideration when calculating the number of staff required.<sup>28,92</sup> When integrating this evidence into clinical practice, the actual remote clinic workload may be underestimated, and thus staffing has become an important issue for many clinics as the number of patients followed by RM continues to increase.

4. CIED RM comprises multiple tasks; these include patient education and enrollment, connectivity and troubleshooting,

data triage and review, alert management, and final sign-off, which includes documentation, communication, and billing. Figure 2 shows task-based responsibilities and implications for staffing as compared to prior guidelines that were personnel based. Requirements for documentation and communication vary extensively from region to region. Each of these tasks is best performed by a different member of the RM team, which includes physicians, advanced practice providers, registered nurses, physiologists, device technicians, and ancillary staff. It is important to understand how many staff members are required to manage RM, keeping in mind that RM does not exist in a vacuum, but rather adds to the non-RM workload inherent to ongoing in-person device evaluations. Future research is needed to establish specific models balancing in-office vs RM roles.

A recent analysis attempted to quantify the mean cumulative staff time required per remote transmission and in-person clinic visit, in a population of clinics using guideline-recommended RM in combination with in-person device follow-up for their patients.<sup>28</sup> The analysis determined the average staff time required to review these transmissions, both scheduled and unscheduled, stratifying data for device type (PM, ICD, CRT, and ILR) and location (United States vs Europe). The combined workload of RM transmission review and in-person device follow-up varied based on device

type, ranging in the United States from 2.1 hours per patient per year with a PM to 9.3 hours per patient per year with an ILR. Another analysis of a large multicenter cohort of patients undergoing RM and using proprietary patient management software reported the following breakdown of devices: 46.7% PMs, 18.8% non-CRT ICDs, 18.7% CRT-Ds, and 15.7% ILRs.<sup>3</sup> Based on these two data sets, assuming a 40-hour work week, an estimated 53.5 hours a week (equivalent to 1.34 full-time equivalent [FTEs]) in Europe and 64.2 hours a week (equivalent to 1.61 FTEs) in the United States are required to manage 1000 CIED patients followed via a combination of RM and in-clinic visits. As the proportion of patients with ILRs monitored remotely increases, the associated workload increases in a disproportionate manner.<sup>3,25</sup> Modeling the aforementioned data with an increase in proportion of ILRs to 30% increases the staffing needs to 2.3 FTEs.<sup>115</sup> This also did not account for the workload from additional RM-related tasks shown in Figure 2. Furthermore, institutions need to account for time away from the office and the potential need to monitor on weekends. Thus, we estimated that 3.0 FTEs are required to support the care of 1000 CIED patients managed with a combination RM and in-clinic visits with varying proportions of the type of personnel (clinical vs nonclinical) depending on individual clinic workflows and mix of devices being followed. This staffing ratio will differ in practices using third-party staffing resources and may also vary based on other local circumstances.



**Figure 2** 2015 HRS Expert Consensus Statement on RM<sup>1</sup> vs 2023 HRS Expert Consensus Statement. APP = advanced practice provider; CIED = cardiovascular implantable electronic device; EHR = electronic health record; HRS = Heart Rhythm Society; NP = nurse practitioner; PA = physician assistant; RN = registered nurse; Tech = technician.

## 4.2. Staff credentialing and qualifications for remote monitoring

### Recommendations for staff credentialing and qualifications for RM

COR	LOE	Recommendations	References
1	C-EO	1. For the care of patients with CIEDs on RM, it is recommended that clinical providers who independently prescribe, interpret, and document RM possess appropriate education and/or certification.	
1	C-EO	2. For the care of patients with CIEDs on RM, it is recommended that clinics regularly conduct quality improvement reviews to support current evidence-based standards.	

### Synopsis

Similar to the 2015 HRS Expert Consensus Statement on RM, this document upholds the recommendation that providers who oversee or independently review, manage, or document and bill for CIED RM demonstrate specific expertise in CIED management by holding appropriate education and/or certification.<sup>1,9</sup> Certification and education should be supported by the institute/center of employment. Quality improvement review is essential for maintaining high-quality care. All members of the RM team should receive training and continuing education specific to RM. All staff/personnel involved with CIED RM should engage in quality improvement review to support current evidence-based standards. All related complications should be reviewed at these meetings, and a process should be in place for reporting outcomes and complications with a goal of continuous improvement.

### Recommendation-specific supportive text

1. The International Board of Heart Rhythm Examiners (IBHRE), Certified Cardiac Device Specialist (CCDS) or Cardiac Device Remote Monitoring Specialist (CDRMS), or American Board of Internal Medicine (ABIM), are currently recognized options for certification of CIED clinic personnel.<sup>1,9</sup> For AHPs performing initial review and/or triage of RM who do not possess appropriate certification, final remote interpretation should be completed by an appropriately trained professional with such certification. AHPs are eligible for the IBHRE CCDS certification, which focuses on comprehensive clinical knowledge pertinent to CIED management, or CDRMS certification, which focuses specifically on RM technology and interpretation of remote CIED transmissions. Additional details and eligibility requirements for these examinations are listed on the IBHRE website ([www.ibhre.org](http://www.ibhre.org)). The 2021 HRS Educational Framework for Clinical Cardiac Electrophysiology recommends continuing education for both physicians and AHPs who provide clinical care for heart rhythm patients.<sup>116</sup> It provides a topical framework for education for all professionals delivering heart rhythm care and can be used to structure existing or new education through the HRS. The IBHRE supports continuing education through IBHRE-C3—a program providing up-to-date accredited continuing education (ACE) options for maintenance of certification. Additional options for RM continuing education

are available through various entities such as the HRS's online learning platform, HRS 365 ([heartrhythm365.org](http://heartrhythm365.org)), or the annual Heart Rhythm conference.

2. Quality improvement is an important part of health care delivery and has been the focus of many international and multidisciplinary collaborations such as the IMPACT registry (Improving Pediatric and Adult Congenital Treatments)<sup>117</sup> and Pediatric Cardiac Critical Care Consortium (PC<sup>4</sup>).<sup>118</sup> These registries support the review and transparency of internal data, which then can be compared to other similar programs with the goal of improving care. The International Accreditation Commission (IAC) accredits facilities meeting high standards of process and now has accreditation for the CIED clinic that focuses on postprocedural onsite and longitudinal RM of implantable cardiac devices. IAC accreditation requires programs to perform regular quality improvement review.<sup>119</sup>

## Section 5 Technical considerations in remote monitoring

RM technology differs widely by manufacturer. Some RM technologies offer continuous connectivity capabilities, and others offer noncontinuous monitoring capabilities. Continuous connectivity involves continuous data collection within the device with automatic transmission using manufacturer-specific transmission frequency, which often occurs once daily. This assures ongoing surveillance of device and lead parameters with the potential of rapid communication when there is a problem. These monitors are not transmitting on a minute-by-minute, or even hourly, basis. This transmission frequency should be communicated to patients, their caregivers, and their other health care providers. They are not substitutes for an emergency medical system. Noncontinuous monitoring involves noncontinuous data collection and requires manual efforts for transmission to occur. This can be either scheduled by the clinic or initiated by the patient.

Whereas continuous connectivity may be preferred as it expedites transmission of actionable events, intermittent monitoring should at least meet the recommended frequency of in-person device interrogation. Some centers may be without on-site device interrogation capabilities but still have a need for acute device surveillance. In these instances, site-based RM and an established workflow to connect with device experts may help to reduce time to getting diagnostic information from the device.

5.1. Devices with noncontinuous remote monitoring

Recommendations for devices with noncontinuous RM			
COR	LOE	Recommendations	References
1	C-E0	1. In patients with CIEDs on RM in the absence of continuous connectivity, remote transmissions are recommended at least every 3-12 months for PMs and every 3-6 months for ICDs.	
1	C-E0	2. In patients with CIEDs on RM in the absence of continuous connectivity, as the device approaches elective replacement, the frequency of remote transmissions should be increased to every 1-3 months.	

Synopsis

Remote device management may consist of multiple types of transmissions. The first, full remote device interrogation at scheduled intervals, mimics in-office visits. The second, automatic unscheduled RM transmission, consists of continuous connectivity with ongoing, real-time assessment of device function following predefined alert events. In the final type, patients can initiate a remote transmission when they experience an event (Figure 3).<sup>8</sup> Evidence regarding the frequency of remote follow-up interrogations and transmissions is lacking. In general, transmissions for ICDs should be more frequent than for PMs due to the increased complexity of their function as well as the in general, sicker population. There will be some circumstances (eg, if a patient is PM dependent) where the transmission frequency for PMs may match or exceed that for some ICDs. In most cases, a CRT-D could be treated like an ICD and a cardiac resynchronization therapy pacemaker (CRT-P) could be treated like a PM for RM follow-up.

be based on the recommendations for in-office visits of devices that are not monitored remotely. This approach uses a remote platform to mimic traditional in-office visits and does not offer ongoing monitoring and timely communication of any potential problem between visits. We have not altered the previously recommended interval between visits for these patients based on the prior guidelines and expert consensus statements.<sup>1,8,15,16</sup> Patients may need to be evaluated more frequently in specific circumstances. These circumstances could include patients who are PM dependent, those whose device is under safety advisory, or those who have other medical conditions that warrant closer assessment.

Recommendation-specific supportive text

1. In patients without continuous connectivity, the frequency of routine remote device transmissions should

2. The 1-3 month frequency of transmissions for devices on RM that approach elective replacement due to battery depletion, and that do not have continuous connectivity, match the indicated frequency of follow-up of cardiac devices without RM.<sup>1,8,16</sup> As the CIED approaches end of life and the battery depletes, more frequent monitoring is needed due to the unpredictable risk of rapid falls in battery voltage. As the device gets closer to its elective




Figure 3 Example of a timeline for patients with cardiovascular implantable electronic devices on remote monitoring. CIED = cardiovascular implantable electronic device; ERI = elective replacement indicator.



replacement indicator, or beyond it, monthly monitoring will likely be needed, as the expected operational longevity of the device is only 90 days from that point.

This recommendation is not substantively different than those from prior guidelines and expert consensus statements.<sup>1,8,16</sup>

## 5.2. Site-based remote monitoring

### Recommendations for site-based RM

COR	LOE	Recommendations	References
2a	C-E0	1. For patients with CIEDs in centers without onsite device interrogation capability, it is reasonable to use site-based remote interrogation technology to facilitate access to care.	
2a	C-E0	2. For patients with CIEDs in centers with onsite device interrogation capability, it is reasonable to use site-based remote interrogation technology to provide expedited care.	


### Synopsis

CIED patients frequently encounter situations whereby an immediate, unscheduled device interrogation is clinically necessary. The most common settings for these encounters are the emergency department or perioperative areas where the patient may have presented with cardiac or CIED-related symptoms such as perceived shocks, or unrelated conditions, for urgent surgical interventions, magnetic resonance imaging (MRI) scans, or unplanned hospitalizations. In the past, a device physician, a trained AHP, or a manufacturer representative would be notified. The person notified would then travel to perform the interrogation and discuss the findings with the attending clinician or implanting electrophysiologist. This arrangement is costly, time-consuming, and associated with significant delays to clinical decision-making. A more recent alternative is site-based RM. In this type of RM, a special manufacturer-specific transmitter is pro-

vided to a clinical site and can be used to interrogate CIEDs belonging to the associated manufacturer, even if the patient is not individually enrolled in RM. Figure 4 depicts the difference between traditional and site-based RM. These transmitters have no ability to reprogram the device. This tool can be used to expedite CIED device interrogation and patient care when onsite CIED interrogation is not immediately available.


### Recommendation-specific supportive text

1. To leverage the capabilities of RM, most device manufacturers have developed site-based (rather than individual-based) remote transmission systems. These can be placed in clinical areas with the largest need for unscheduled interrogations, including from patients not enrolled in an RM system.<sup>120,121</sup> This could include hospital and urgent care centers without on-site device interrogation capabilities. These transmitters can perform manual download



**Figure 4** Traditional personal 1:1 vs site-based remote monitoring. With traditional personal 1:1 remote monitoring (RM), each patient is individually enrolled into the RM program and the RM data is routed to both the facility and the patient's device clinic. With site-based RM, multiple patients can use the system, even if they are not individually enrolled into the RM program, and the RM data is shared with that facility's clinic in addition to the patient's home clinic.

of device data onto the manufacturers' proprietary web portal. They can be downloaded by trained technical staff through a CIED clinic or a third-party monitoring service for review and interpretation by an expert device clinician.



**Figure 5** Illustrative example of unscheduled cardiovascular implantable electronic device interrogation using a site-based remote monitoring transmitter. CIED = cardiovascular implantable electronic device.

(Figure 5.) These systems could be used to extend the reach of RM into rural, isolated, inaccessible, or other underserved areas. Device reprogramming is not possible using these monitoring devices.

- Using the Medtronic CareLink Express system to handle 7044 transmissions from the emergency department and operating room, time to device interrogation/interpretation was reduced by 78% to a mean of  $22 \pm 14$  minutes, compared to calling for the local device representative to physically attend the patient's location.<sup>120</sup> Only 9.1% of interrogations were clinically actionable. In the overwhelming majority of cases, the device was functioning normally, no device or arrhythmia concerns were found after an expert technical review of the transmitted data, and the attending clinician could be notified and provided with a report of the interrogation. In the minority of cases where there are concerns about device function or reprogramming is required, an in-person evaluation by trained electrophysiology staff with a programmer can be arranged immediately or nonurgently when the clinic reopens. Similarly, using a Boston Scientific LATITUDE Consult installed in 42 hospital facilities to evaluate 509 discreet unscheduled transmissions, device evaluation was completed in less than 15 minutes for 89% of cases and only 10% of transmissions were classified as urgent.<sup>121</sup> These site-based RM workflows provide a time-efficient and cost-effective strategy to manage unscheduled device interrogations, even when there are on-site device interrogation capabilities.

## Section 6 Alert-based remote monitoring

The follow-up and management of increasing numbers of patients with CIEDs is generating larger workloads for clinical staff. Advances in telecommunication technologies can minimize this burden by monitoring chronic conditions during ambulatory care, thus creating more efficient health care systems. In the 2015 HRS Expert Consensus Statement on RM, the recommendation was to interrogate CIEDs every 3 months, either in-person or remotely. In clinical practice, this regimen requires significant effort from both patients and clinic staff. These scheduled visits miss interim events until the next scheduled visit, delaying treatment of actionable alerts. RM systems are evolving to continuous connectivity, where device and disease-related alerts are generated as and when they occur and transmitted often within 1 day.<sup>122</sup> Continuous connectivity may facilitate the implementation of alert-based RM, which is a combination of continuous connectivity with clinic visits that are prompted only by the detection of actionable events.

Recommendations for alert-based RM			
COR	LOE	Recommendations	References
1	B-R	1. In patients with CIEDs and a component with a safety advisory, it is recommended that continuous connectivity be added to scheduled remote or in-person interrogation to enable early detection of actionable events.	18,29,31,32,35,39,42,123,124
2a	B-R	2. In patients with PMs on RM with consistent and continuous connectivity, and in the absence of recent alerts or other cardiac comorbidity, it is reasonable to schedule in-person visits every 24 months.	37,125,126
2a	B-R	3. In patients with ICDs on RM with consistent and continuous connectivity, and in the absence of recent alerts or other cardiac comorbidity, it is reasonable to schedule in-person visits every 24 months.	31,35,57,92,98

## Synopsis

The implementation of continuous connectivity extends remote patient management beyond periodic calendar-based follow-up (see [Figure 3](#), Continuous).<sup>122</sup> In randomized clinical trials, RM was associated with a reduction of hospital use and staff workload and a shorter time to clinical decisions.<sup>31,32,35,92,125,126</sup> “Alert-based RM” was increasingly used during the COVID-19 pandemic out of necessity.<sup>11</sup> The practice was effective and yielded a positive experience. This form of remote management has the potential to replace structured intermittent device follow-up (whether in-person or remote).<sup>92</sup> This could minimize low-value effort, optimize clinic visits for actionable events, and decrease health care costs.<sup>89</sup> For alert-based RM to be effective, there must be near-perfect connectivity, robust systems to assure connectivity from the manufacturers, and excellent patient compliance.

## Recommendation-specific supportive text

1. During the last few decades, the number of safety advisories for CIED components has increased due to the increasing complexity of the technology.<sup>127,128</sup> Monitoring compromised CIED system integrity is challenging due to the unpredictability of CIED malfunction and the need for immediate action. The addition of continuous connectivity to regularly scheduled remote or in-person follow-up has been shown to allow for more rapid detection of and response to actionable events, including system malfunction.<sup>18,29,31,32,35,39,40,42,71,123,124,128</sup>
2. In randomized trials, alert-based RM in patients with a PMs was safe, cost-effective, and an efficient substitute for conventional follow-up, reducing hospital visits and staff workload and facilitating early detection of actionable events. If, however, continuous connectivity is not present, the connectivity is inconsistent for any reason, there have been CIED alerts, or there are concomitant comorbidities, then more frequent in-person visits might be necessary.<sup>37,125,126</sup> If shorter follow-up intervals are necessary due to cardiac comorbidities, the most recent RM data may be referenced and an in-person device check may not be necessary.
3. Randomized trials comparing alert-based RM with conventional follow-up in patients with ICDs on continuous connectivity have shown reduced in-person visits, lower staff

workload, almost immediate detection of actionable events, and also improved patient retention, follow-up, and quality of life.<sup>31-33,35,57,92,98</sup> If there are inconsistent and noncontinuous connectivity issues, recent CIED alerts, or concomitant cardiac comorbidities, more frequent in-person visits may be necessary.<sup>31,35,57,92,98</sup> If shorter follow-up intervals are necessary due to cardiac comorbidities, the most recent RM data may be referenced and an in-person device check may not be necessary.

## Section 7 Programming considerations for optimal remote monitoring

RM of CIEDs has facilitated effective surveillance of device function as well as follow-up for arrhythmic events that require clinical intervention, regardless of CIED type.<sup>1</sup> RM significantly reduces the volume of in-person evaluations and can decrease the delay from arrhythmia onset to clinical decision, without undermining safety concerns.<sup>31,32,35,46</sup> To optimize the efficient use of RM, both optimal device programming and an infrastructure of trained clinicians, who can interpret massive information derived from RM, are required. Although the programming details might vary by platform, preferred programming strategies are those that enable the most accurate detection of arrhythmia or problems, enable earlier detection of arrhythmia or problems, and facilitate subsequent therapeutic measures. All types of CIEDs should be programmed to alert for intrinsic changes of device function that need attention. CIEDs that are capable of monitoring atrial arrhythmia should be programmed to improve detection rate of sustained atrial arrhythmia and its burden. Since CIEDs are utilized by different patient populations with distinct cardiovascular needs, RM should be programmed and stratified according to the indications for the CIED. Patients with ICD or CRT often have underlying HF, which necessitates specific monitoring for signs of HF decompensation. In contrast, monitoring for right ventricular (RV) pacing burden may be of interest in patients without CRT pacing. Programming can reduce nonactionable alerts (see [Section 8.2](#)) for patients that have known clinical conditions, such as sinus tachycardia especially during exercise (especially in younger

patients), chronic AF, or complete heart block with 100% RV pacing. CIEDs that are indicated for diagnostic purpose rather than therapeutic indication (such as ILRs)

should be programmed to optimize diagnostic accuracy and reduce false-positive events caused by undersensing or oversensing.

## 7.1. Manufacturer and device-specific knowledge

### Recommendations for manufacturer and device-specific knowledge

COR	LOE	Recommendations	References
1	C-EO	1. For the care of patients with CIEDs on RM, it is recommended that clinic staff are knowledgeable about the specific differences between, and within, manufacturers' devices and their RM platforms to optimize patient care.	

### Synopsis

Proper management of patients with CIEDs on RM essentially depends on specific knowledge of the system in use. This knowledge includes the differences in layout and presentation of the various information displayed, but, more importantly, relates to the programmability of parameters and alerts. It is essential that the team that will remotely monitor the patient has a full understanding about the specific system that will be used. This should be considered even before implanting the device, since specific device-related differences may make one CIED/RM system preferable to another system for a particular patient. Manufacturers' support for training staff about their systems is imperative.

### Recommendation-specific supportive text

1. Although the different RM systems share common principles, they differ significantly in philosophy and practical application, the type and number of programmable alerts, and some proprietary algorithms. The programming and information display screen itself differs considerably among different manufacturers.<sup>129</sup> The capabilities and limitations of the different RM systems should be understood when considering the best CIED system for an individual patient. Some examples of these differences between manufacturers are outlined in [Table 4](#).

**Table 4 Remote monitoring system differences between manufacturers**

Manufacturer	Abbott	Biotronik	Boston Scientific	Medtronic	MicroPort
RM system	Merlin.net	Home Monitoring	LATITUDE	CareLink	SmartView
Home monitor	Merlin@home	CardioMessenger II CardioMessenger II-S CardioMessenger Smart	LATITUDE NXT Remote Patient Management System	MyCareLink Relay home communicator MyCareLink monitor	SmartView Connect (Bluetooth-enabled CIED)
Smartphone-based RM applications	myMerlinPulse mobile app (ICD and CRT-D) myMerlin mobile app (ILR)	No	No	MyCareLink Heart mobile app (Bluetooth ILR, IPG, CRT-P, ICD, CRT-D) MyCareLink Smart (IPG, including leadless IPG)	Yes; limited to a dedicated smartphone delivered to the patient
Patient smartphone applications without RM	No	Biotronik patient app (Biomonitor III or IIIm)	MyLATITUDE Patient App	No	No
Transmitter	Stationary or mobile	Stationary or mobile	Stationary	Stationary or mobile	Stationary or mobile
Connectivity	Bluetooth; mobile network; Wi-Fi; analog phoneline; RF; inductive telemetry	Mobile network; analog phoneline	Mobile network; Wi-Fi; ethernet; analog phoneline	Bluetooth; mobile network; Wi-Fi; analog phoneline	Bluetooth; mobile network
Frequency of transmissions	Scheduled FU; daily FU; alert events	Scheduled FU; daily FU; alert events	Scheduled FU; daily FU; alert events	Scheduled FU; daily FU; alert events	Scheduled FU; daily FU; alert events

**Table 4** (Continued)

Manufacturer	Abbott	Biotronik	Boston Scientific	Medtronic	MicroPort
Programmability of frequency of transmissions	Yes	No	Yes	Yes	Yes
Programmability of alerts and parameters	Alerts fully configurable online (settings, such as alert notifications, report settings, and data export settings can be done online; adjustments to the patient's device settings must be done in person).	Alerts can be customized by users into high, medium, and low priorities according to their preferences. Some alerts and parameters can be programmed online. Certain life-threatening alerts cannot be changed as a safety feature.	RM alerts and parameters can be programmed online through the LATITUDE website.	BlueSync devices: parameters and alerts are configurable via in-clinic programming; notifications for alerts are remotely configurable. BlueSync device (LINQ II only): parameters, alerts, and notifications are configurable remotely. Conexus devices: parameters and alerts are configurable via in-clinic programming; notifications for alerts are configurable remotely; alerts may be manually reset remotely (awaiting approval).	Alerts can be programmed.
Patient-initiated transmission	Yes	No	Yes	Yes	Yes
Recommended distance from transmitter	<2 meters	<2 meters	<3 meters	<3 meters	<2 meters
Real-time IEGM at remote follow-up	30 seconds	30 seconds	10 seconds	10 seconds	7 seconds
IEGM of arrhythmic episodes	All memorized	All memorized	All memorized	All memorized	All memorized
Provider communication method	E-mail, SMS, fax	E-mail, SMS, fax	E-mail, SMS, fax	E-mail, SMS, website	E-mail, SMS, pager, voicemail, mobile app
FDA and CE Mark approved	Yes	Yes	Yes	Yes	Yes
Additional features	Electronic health record export compatibility; patient callback feature; CorVue fluid status alert; integrated heart failure website for patients with both CardioMEMS (pulmonary artery pressures) and Abbott CIED.	Electronic health record export compatibility; patient callback feature; HeartInsight heart failure monitoring.	Electronic health record export compatibility; HeartLogic heart failure monitoring; optional Bluetooth weight scales and blood pressure cuffs; configurable data transmission to associated caregivers.	Electronic health record export compatibility; OptiVol thoracic impedance alert; Cardiac Compass HF report; TriageHF integrated HF risk assessment tool.	Electronic health record export compatibility.

This is current as of the publication date of this document and is subject to change over time. App = application; CE = Conformité Européene; CIED = cardiovascular implantable electronic device; CRT = cardiac resynchronization therapy; CRT-D = cardiac resynchronization therapy defibrillator; CRT-P = cardiac resynchronization therapy pacemaker; FDA = Food and Drug Administration; FU = follow-up; ICD = implantable cardioverter-defibrillator; IEGM = intracardiac electrogram; ILR = implantable loop recorder; IPG = implantable pulse generator; PM = pacemaker; RF = radio frequency; RM = remote monitoring; SMS = Short Message Service.

## 7.2. Programming for clinical indications with different types of cardiovascular implantable electronic devices

### Recommendations for programming for clinical indications with different types of CIEDs

COR	LOE	Recommendations	References
1	B-R	1. In patients with CIEDs on RM, it is recommended that alert parameters be customized to clinical indications.	48,92,108,111,130
1	C-LD	2. In patients with ICDs on RM, it is recommended that the ICD be programmed to alert the clinic for all ventricular shock therapies.	35,36,39,48,92,131
2a	B-R	3. In patients with CIEDs on RM, it is reasonable to remotely monitor HF diagnostics to detect incident HF and/or progression.	19,23,46-55,72,74,88,132-134
2a	C-LD	4. In patients with CIEDs on RM with CRT, it is reasonable that the CIED be programmed to alert the clinic when there is a low percentage of biventricular pacing.	48,131
2a	C-LD	5. In patients with CIEDs on RM with atrial arrhythmia monitoring capabilities, it is reasonable that the CIED be programmed to alert the clinic of the first episode, a prolonged episode, or a high burden of atrial arrhythmia.	31,45,123,131
2a	C-LD	6. In patients with ICDs on RM, it is reasonable that the CIED be programmed to alert the clinic for all ventricular anti-tachycardia pacing therapies.	131
2a	C-E0	7. For the care of patients with CIEDs on RM, it is reasonable that the CIED be programmed to alert the clinic for excessive percentage of RV pacing.	

### Synopsis

The programming of the devices that will be remotely monitored must be customized based on the capabilities of the system and according to the type of device itself, the clinical characteristics of each patient, and the expectation of the occurrence of clinically relevant outcomes. Some information is important regardless of device type, such as lead integrity, battery longevity, and AF occurrence. In contrast, diagnostics related to HF, risk of life-threatening ventricular arrhythmias triggering shock or anti-tachycardia pacing (ATP) therapies, and percentage of ventricular or biventricular pacing are parameters that will not be relevant for all patients. (Figure 6.)

### Recommendation-specific supportive text

1. RM alerts should be programmed at a minimum to monitor battery/lead status, lead integrity, and arrhythmic events in virtually all scenarios. Beyond those basic parameters, the patient's clinical profile and needs will drive a customized pool of programming. Examples include the use of LV/biventricular pacing in a patient with a CRT device.
2. The clinic needs to quickly know about significant CIED events that may indicate the necessity of reprogramming or system revision (eg, battery status; increasing pacing threshold; AF and ventricular tachycardia [VT]/ventricular fibrillation [VF] detection and shock therapy). Shock therapy is usually related to a high-risk event, or a device sensing problem, and the cause of the shock discharge should be checked and appropriately managed. Hemodynamically destabilizing rhythms (VT/VF), unnecessary therapy (nonsustained ventricular tachycardia), inappropriate therapy (AF, oversensing, sinus tachycardia), and noise interference (lead failure) all can result in harm to the pa-


tient. Likewise, electrical storm and repeat device discharges can result in adverse physical and psychological effect, in addition to draining the battery.

3. CIEDs are currently able to monitor several parameters such as heart rate and rhythm, daily activity, and transthoracic impedance for estimating fluid status that can help to identify the patient's clinical status. RM-based risk stratification of HF patients can indicate the possibility of clinical decompensation. A recent meta-analysis of three randomized controlled trials (TRUST [Lumos-T Safely Reduces Routine Office Device Follow-Up], ECOST [Effectiveness and Cost of ICD Follow-up Schedule With Telecardiology], and IN-TIME [Influence of Home Monitoring on the Clinical Status of Heart Failure Patients]) demonstrated improved survival and a reduced composite endpoint of all-cause mortality or HF hospitalizations with RM.<sup>50</sup>
4. One important reason for CRT nonresponse is inadequate biventricular pacing. A direct correlation between CRT response and maintenance of high percentage of biventricular pacing (CRT%) has been well proven. The relation between optimal CRT% and clinical outcomes has been studied on different cut-off values (from >80% to >98.47%). RM seems to be the best tool for early identification of those patients at risk for CRT% loss and the cut-off >95% should be the target. Using alert-based RM strategy for CRT% makes it possible to restore optimal biventricular pacing as quickly as possible.<sup>48,56,135,136</sup>
5. Early detection of AF may help to reduce clinical complications, such as preventing inappropriate ICD therapies (the ECOST trial showed a 74% reduction in the number of inappropriate shocks related to supraventricular tachycardia in the RM arm compared with standard follow-up).<sup>137</sup> AF may trigger hemodynamic instability and worsen

- congestive HF, both directly and via the loss of adequate CRT%. The IN-TIME study showed more favorable outcomes and survival in patients with HF and RM of their ICD ([1] patients with a history of AF benefited more from RM than did the patients without AF, and [2] AF was the RM alert that most often led to patient contact).<sup>137</sup> Early detection of AF may lead to initiation of anticoagulation therapy after appropriate risk stratification. A large proportion of AF episodes are asymptomatic, and RM shortens the time to its detection (1 to 5 months earlier). Furthermore, an electrogram of an AF episode that has been initially stored in the device, but not yet transmitted, may be absent from the ICD records if overwritten by more recent episodes.<sup>29,35,39</sup> If the patient is known to have a high burden of AF where additional transmissions documenting atrial arrhythmias will not alter management, then these alerts can be turned off (see **Section 8.2**).
6. Nonshocked ventricular therapy episode alerts allow reduction in time to medical evaluation for VT and VF events, as shown in the TRUST trial.<sup>31</sup> Such episodes may relate to supraventricular tachycardia, P/R/T-wave oversensing, noise oversensing, or lead dysfunction. RM systems that generate alerts following ATP delivery could reduce emergency presentations for ICD shock by 24%.<sup>138</sup> Asymptomatic cancelled shock therapy (whether for actual VT or noise) may reduce battery longevity. Their early identification provides an opportu-

nity for prevention of therapy and battery preservation. Early RM notification of ventricular arrhythmia episodes enables preemptive action to avoid further inappropriate shock therapy and/or aborted shocks.<sup>73,129,138,130,139</sup>

7. Conventional pacing from the right ventricle results in altered electromechanical ventricular activation that can have detrimental effects on myocardial perfusion and metabolism.<sup>140</sup> This can lead to progressive ventricular remodeling, function deterioration, and HF (pacing-induced cardiomyopathy).<sup>141</sup> Even though only a subset of patients with RV pacing develop cardiomyopathy (9- 19.5%),<sup>142-145</sup> the MOST (Dual-Chamber and VVI Implantable Defibrillator) and DAVID (Mode Selection Trial in Sinus-Node Dysfunction) trials suggested a threshold of RV pacing of more than 40% for the development of pacing-induced cardiomyopathy.<sup>146</sup> Another study identified a RV pacing burden >33% as a risk factor.<sup>147</sup> Early knowledge of high RV pacing burdens could lead to mitigation strategies that could lower the rate of RV pacing.<sup>147</sup> Conduction system pacing (His area or left bundle branch area), with its advantage of minimizing or eliminating electromechanical dyssynchrony, is emerging as an attractive alternative and this concern may not apply.<sup>148</sup> If the clinic is aware that the patient is chronically paced in the right ventricle 100% of the time, then this alert is not required.



**Figure 6** Alert recommendations by device type. Color corresponds to the class of recommendation (COR) in **Table 1**. ATP = anti-tachycardia pacing; CRT = cardiac resynchronization therapy; HF = heart failure; ICD = implantable cardioverter defibrillator; PM = pacemaker; RV = right ventricular.

### 7.3. Special programming considerations for implantable loop recorders

Recommendations for special programming considerations for ILRs			
COR	LOE	Recommendations	References
1	B-NR	1. In patients with ILRs on RM, it is recommended that clinic staff confirm an actionable event transmission by reviewing the electrograms to exclude misdiagnoses.	3,25,149,150
1	B-NR	2. In patients with ILRs on RM, it is recommended that programmed alerts be tailored to the clinical indication.	3,25,149
1	B-NR	3. In patients with ILRs on RM and frequent undersensing and/or oversensing, reprogramming is recommended.	3,25,149,150
1	B-NR	4. In patients with ILRs on RM for unexplained syncope, it is recommended to emphasize to the patient the need to perform a symptom marking or manual transmission immediately following syncope to obtain a symptom-rhythm correlation.	25,149
2a	B-NR	5. In patients with ILRs on RM for cryptogenic stroke, it is reasonable to adjust the sensitivity to improve detection of AF.	25,149
3: No benefit	C-EO	6. In patients with ILRs on RM with consistent connectivity, in-office visits are not indicated for routine patient care.	

#### Synopsis

ILRs can have some unique challenges when implementing RM. These include a high burden of transmissions, frequent misdiagnoses, and the need for a symptom-rhythm correlation in some cases. Due to the relatively high false-positive rate for both AF and sinus pauses with ILRs,<sup>25,149,150</sup> clinical staff must confirm putative dysrhythmias by manually reviewing electrograms of individual events to exclude misdiagnosis.<sup>3</sup> The sensitivity of detection of atrial arrhythmias could be increased in patients with cryptogenic stroke, to improve detection of symptomatic or asymptomatic AF. Conversely, this might not be desired when the ILR is implanted for unexplained syncope. In this group, educating the patient about the importance of a manual activation at the time of syncope is critical to obtain a symptom-rhythm correlation.

#### Recommendation-specific supportive text

1. In 2021, Geneva Remote Technicians archived 20% of all ILR transmissions due to oversensing or undersensing. The most common cause of an archived false alert was misidentification of AF (54%), followed by Pause (33%).<sup>151</sup> This analysis demonstrates the burden of false arrhythmic events in remote ILR data management and suggests the need for improved arrhythmia detection algorithms and greater attention to ILR programming of sensitivity and blanking periods. Factors for false-positives of bradycardic episodes in ILRs may include undersensing of small R-wave amplitude, variable signal amplitude, nonphysiologic flatline from loss of electrode contact, and/or saturated sense amplifiers. The incidence of false-positive detections of AF during RM has been reported in 46-86% patients,<sup>149</sup> although this might

improve with newer devices and newer algorithms.<sup>150</sup>

When monitoring for tachycardia episodes, low detection and false-positives from undersensing and oversensing due to noise may cause frequent false-positives. To avoid misdiagnosis and potential errors in clinical management, device clinic staff need to confirm an actionable event transmission by reviewing the electrograms.<sup>3,25,149</sup>

2. Programming of alert setting on RM should be optimized for different clinical indications.<sup>3,149</sup> In unexplained syncope patients, alert transmission is essential for the patient's symptom-rhythm correlation. In patients with symptomatic AF, programmed alert transmission should be set based on rate, frequency, duration, or AF burden. In cryptogenic stroke patients, it important to detect correctly for symptomatic or asymptomatic AF. Careful and tailored programming will help maximize the diagnostic benefit of ILRs.<sup>25,149</sup>
3. Primary causes of false-positives in ILR transmissions are signal dropout, undersensing, and atrial and ventricular ectopy.<sup>3,149</sup> More recent ILR algorithms use a combination of R-R variability, beat variation, ventricular scatter, heart rate density index, P-wave morphology, artificial intelligence (AI), and filters that evaluate QRS morphology, noise discrimination, and/or pattern detection to aid in rejecting false-positives.<sup>150</sup> This advancement of technologies may reduce the false-positive transmissions with ILRs and may help to avoid misdiagnosis. Clinical staff still need to confirm each transmission by reviewing the electrogram for accuracy. If the presence of a false-positive transmission is confirmed after review, reprogramming the ILR could help to minimize future false-positive transmissions.<sup>149</sup>



4. The purpose of an ILR in the setting of unexplained syncope is to determine if the syncope is due to an arrhythmia. Many patients can have an arrhythmia that is incidental to their syncope. A symptom-rhythm correlation is critical to establish that the arrhythmia is truly causing syncope. The patient needs to be instructed to initiate a symptom marking or manual transmission directly following the event to communicate the symptoms to the clinic.<sup>3,25</sup>
5. ILRs allow clinics to alter their sensitivity to make it more likely, or less likely, to detect AF. For patients in whom the ILR was implanted for cryptogenic stroke, it is of paramount importance that diagnostic episodes of AF are not missed.<sup>149</sup> In these patients, the sensitivity of the ILR for AF should be maximized, even if this is at the cost of reduced specificity.<sup>25</sup> Device clinic staff need to confirm the AF transmission by reviewing the electrograms and clinically determining if anticoagulation is appropriate.<sup>25,49,99</sup>
6. After ILR insertion, if ILR alerts are appropriately programmed for device indication, a wound check has been satisfactorily completed in a timely manner, and continuous RM connectivity is confirmed, future routine in-office visits are not indicated until battery depletion.

## Section 8 Managing alerts

RM of CIEDs allows both scheduled remote follow-up and automatic unscheduled transmission of data for predefined alerts. There is clear evidence of a significant reduction in the time to diagnosis and clinical decision-making for unscheduled actionable events, compared to in-clinic follow-up alone.<sup>31,35</sup> Early notification of actionable events is associated with improved outcomes and reductions in hospitalizations and health care costs.<sup>36,59,87,138</sup> A significant reduction in all-cause mortality for systems with daily RM has been reported in systematic reviews and meta-analyses.<sup>50,51</sup>

Unscheduled transmissions generate a significant workload for clinics, since all transmissions require triage, review, and documentation.<sup>3</sup> The number of alert transmissions received by clinics will vary depending on the programming practices of each individual clinic, device indication, and patient engagement.<sup>28</sup> Some manufacturers provide auditory or vibratory alerts to the patient directly, and the use of RM of these alerts can allow the clinics to advise the patients as to the nature of the alert. Given that there are fundamental differences between manufacturers in the number and type of programmable alerts, and how and when these are communicated, this introduces further complexity for clinics in RM alert management.<sup>129,152,153</sup> Remote clinics will require robust organizational models and processes in place to safely manage alerts and workload.<sup>29,90,108</sup>

### 8.1. Defining high-priority alerts

#### Recommendations for defining high-priority alerts

COR	LOE	Recommendations	References
1	B-R	1. In patients with CIEDs on RM, it is recommended that for concerns related to critical device or lead function, high-priority alerts be programmed to promptly notify the clinic.	31,40,48,108,139

#### Synopsis

The definition of high-priority alerts, and of the response to them, is crucial for organization of care pathways, prioritization of review of alerts, and definition of acceptable response timelines. A significant percentage, if not the majority, of alerts transmitted from remotely monitored CIED are nonactionable alerts (such as detection of known AF)<sup>3,27</sup> and concern events that do not require immediate action. In contrast, and as demonstrated in randomized studies, reaction to alerts concerning battery capacity, lead integrity, and therapies delivered by ICDs for ventricular tachyarrhythmias has been shown to reduce adverse outcomes.<sup>39,138,139</sup> Arrhythmic events such as shock therapies or ATP therapies delivered by the ICD not only indicate an increased risk for subsequent therapies, but


may also indicate lead integrity issues.<sup>154</sup> Reaction to these alerts may reduce adverse clinical events.

#### Recommendation-specific supportive text

1. Alerts related to lead impedance or pacing threshold may indicate lead failure leading to adverse clinical events, similar to alerts related to battery capacity, as shown in randomized trials.<sup>39,48</sup> These alerts should be considered high-priority alerts. "Red alerts" are "critical alerts" that could potentially leave the patient without device therapy, whereas "yellow alerts" are important alerts that do not rise to the level of a critical alert but do warrant review or investigation. [Figure 7](#) indicates what constitutes CIED red and

		RED (CRITICAL) ALERTS	YELLOW ALERTS
ICD ALERTS	Device Integrity Alerts	<p><b>Device</b></p> <ul style="list-style-type: none"> <li>• VF detection/therapy off</li> <li>• End of service/low battery voltage</li> <li>• Device reset/safety mode</li> <li>• Long charge time</li> </ul> <p><b>Lead</b></p> <ul style="list-style-type: none"> <li>• Shock impedance out of range</li> <li>• RV pacing impedance out of range</li> <li>• Noise episode</li> </ul>	<p><b>Device</b></p> <ul style="list-style-type: none"> <li>• Recommended replacement</li> <li>• MRI mode</li> </ul> <p><b>Lead</b></p> <ul style="list-style-type: none"> <li>• RA/RV/LV <ul style="list-style-type: none"> <li>• Pacing impedance out of range</li> <li>• Pacing threshold out of range</li> </ul> </li> </ul>
	Clinical Alerts	<p><b>Therapy</b></p> <ul style="list-style-type: none"> <li>• Multiple Shocks (<math>\geq 2</math>) delivered<sup>a</sup></li> </ul>	<p><b>Therapy</b></p> <ul style="list-style-type: none"> <li>• Single shock delivered</li> <li>• ATP delivered</li> </ul> <p><b>Arrhythmias</b></p> <ul style="list-style-type: none"> <li>• Atrial Fib burden &gt; programmed value</li> <li>• Ventricular rate in atrial arrhythmia &gt; programmed value</li> <li>• NSVT in select patients</li> </ul> <p><b>Pacing</b></p> <ul style="list-style-type: none"> <li>• RV pacing &gt; programmed value</li> <li>• CRT pacing &lt; programmed value</li> </ul>
PACEMAKER ALERTS	Device Integrity Alerts	<p><b>Device</b></p> <ul style="list-style-type: none"> <li>• In PM-dependent patients: <ul style="list-style-type: none"> <li>• Low battery voltage</li> <li>• Device reset or in safety mode</li> </ul> </li> </ul> <p><b>Lead</b></p> <ul style="list-style-type: none"> <li>• In PM-dependent patients <ul style="list-style-type: none"> <li>• RV pacing impedance out of range</li> <li>• Noise episode</li> </ul> </li> </ul>	<p><b>Device</b></p> <ul style="list-style-type: none"> <li>• Recommended replacement</li> <li>• MRI mode</li> <li>• In non-PM-dependent patients: <ul style="list-style-type: none"> <li>• Low battery voltage</li> <li>• Device reset or in safety mode</li> </ul> </li> </ul> <p><b>Lead</b></p> <ul style="list-style-type: none"> <li>• RA/RV/LV pacing <ul style="list-style-type: none"> <li>• Pacing impedance out of range</li> <li>• Pacing threshold out of range</li> </ul> </li> <li>• Noise episode (non-PM-dependent)</li> </ul>
	Clinical Alerts	<p><b>None</b></p>	<p><b>Arrhythmias</b></p> <ul style="list-style-type: none"> <li>• Atrial fibrillation burden &gt; programmed value</li> <li>• Ventricular rate in atrial arrhythmia &gt; programmed value</li> <li>• NSVT in select patients</li> </ul> <p><b>Pacing</b></p> <ul style="list-style-type: none"> <li>• RV pacing &gt; programmed value</li> <li>• CRT pacing &lt; programmed value</li> </ul>
ILR ALERTS	Device Integrity Alerts	<p><b>None</b></p>	<ul style="list-style-type: none"> <li>• Battery depletion or reset</li> </ul>
	Clinical Alerts	<p><b>Bradycardia</b></p> <ul style="list-style-type: none"> <li>• HR <math>\leq</math> 30bpm (with complete heart block)</li> <li>• Asystole/pause <math>\geq</math> 6 seconds</li> </ul> <p><b>Tachycardia</b></p> <ul style="list-style-type: none"> <li>• 30 beats &gt; 231 bpm</li> </ul> <p><b>Arrhythmias</b></p> <ul style="list-style-type: none"> <li>• Atrial fibrillation &gt; 6 minutes in cryptogenic stroke patients</li> </ul>	<p><b>Bradycardia</b></p> <ul style="list-style-type: none"> <li>• <math>\leq</math> 30 bpm (without complete heart block)</li> <li>• Asystole/pause <math>\geq</math> 3 seconds</li> </ul> <p><b>Tachycardia</b></p> <ul style="list-style-type: none"> <li>• 16 beats &gt; 180 bpm</li> </ul> <p><b>Arrhythmias</b></p> <ul style="list-style-type: none"> <li>• Atrial fibrillation &gt; 6 min with indication other than cryptogenic stroke</li> </ul>

**Figure 7** Red and yellow alerts for pacemakers and implantable cardioverter-defibrillators. Red alerts are defined as critical alerts requiring urgent review. Yellow alerts are those that, with early review, may lead to an action that impacts patient outcomes. <sup>a</sup>Multiple shocks could demonstrate clinical deterioration or be ineffective. ATP = anti-tachycardia pacing; bpm = beats per minute; CRT = cardiac resynchronization therapy; LV = left ventricular; ICD = implantable cardioverter-defibrillator; ILR = implantable loop recorder; MRI = magnetic resonance imaging; NSVT = nonsustained ventricular tachycardia; PM = pacemaker; RA = right atrial; RV = right ventricular; VF = ventricular fibrillation.



**Figure 8** Remote monitoring alerts that should be considered “high-priority.” Red corresponds to red alerts, and yellow corresponds to yellow alerts. High/low impedance can be considered a red or yellow alert. ICD = implantable cardioverter-defibrillator.

yellow alerts. Shock therapies may indicate clinical deterioration requiring corrective action but may also indicate lead failure.<sup>39,48,154</sup> The capability to differentiate between effective and ineffective shocks is not currently available, and therefore multiple shocks delivered (>2) should be programmed as a red alert. Evidence for the high-priority character of ATP therapies delivered by the ICD is weaker than for shock therapies. Nevertheless, observational studies indicate that review of alerts related to ATP may be associated with reduced consequent adverse events such as shocks and emergency presentations.<sup>138,139</sup> Therefore, it is reasonable to consider such alerts high-priority alerts (Figure 8). Regarding ICD alerts, one set of alerts was tested in a randomized controlled trial and found to be safe during alert-based monitoring.<sup>155</sup>

## 8.2. Programming considerations to minimize inappropriate alerts

### Recommendations for programming considerations to minimize inappropriate alerts

COR	LOE	Recommendations	References
1	C-E0	1. In patients with CIEDs on RM from whom sufficient clinical data have been received, it is recommended that alert parameters be reprogrammed to avoid nonactionable alerts.	


### Synopsis

Unscheduled alert transmissions and the associated workload are an ongoing concern for RM clinics.<sup>3</sup> Alerts for arrhythmias that are already known, and where further alerts will not lead to any clinical action, can contribute to this workload.<sup>138</sup> In an observational study, two-thirds of transmissions were reported to have shown at least one abnormal event, with the majority requiring no clinical action.<sup>156</sup> Most nonactionable alerts occur for known arrhythmias. Individualizing RM alerts to suit patients’ individual clinical circumstances can improve clinic efficiency.<sup>24</sup> Ideally, optimized alert programming would occur at the time of implantation based on individual clinical circumstances.

### Recommendation-specific supportive text

1. Once sufficient information has been gathered regarding a particular alert and there is no further requirement to receive this information, it is recommended that RM set-

tings should be adjusted to receive only those alerts that will result in a clinical action and minimize further nonactionable alerts (Figure 9). The ongoing triage and review of unscheduled alerts has a significant impact on clinic workload and productivity. In one study, many unscheduled alert transmissions were not clinically relevant, as the information was already known and action had already been taken.<sup>157</sup> Alert transmissions occur more frequently in patients with known AF. Alert settings could be adjusted based on the patient’s clinical situation to minimize unnecessary alerts.<sup>111</sup> In addition, Morimoto et al. describe a high abnormal event rate (66.7%) in remotely monitored patients, but a low “critical event” rate (4.1%).<sup>156</sup> One method to reduce the volume of incoming transmissions is by reprogramming alert criteria from the CIED default settings to allow only critical events to be received.<sup>108</sup> This may include turning off alerts for a high burden of ventricular pacing in patients with known AV block or turning off AF alerts in patients known to have a high burden of chronic AF.



**Figure 9** Minimizing alerts for nonactionable events. Each cardiovascular implantable electrical device transmission alert is critically reviewed by a credentialed clinician. If the event is a known clinical event that has been previously addressed, the specific alert may be programmed OFF and it is no longer considered an actionable event. If this is not a known clinical event, more information is needed about the patient's status. Based on the review of additional information, the alert may be adjusted or programmed OFF. CIED = cardiovascular implantable electronic device.

### 8.3. Timeline recommendations for alert management

Recommendations for timeline recommendations for alert management			
COR	LOE	Recommendations	References
1	C-EO	1. For the care of patients with CIEDs on RM, it is recommended that patients and their caregivers be informed that automatic alerts transmitted by RM do not substitute for an emergency management system.	
2a	C-EO	2. For the care of patients with CIEDs on RM, it is reasonable for clinics to review and react to high-priority alerts within 1 business day.	

#### Synopsis

Management of alerts is a crucial part of the workflow in each remote device clinic. Reactions to critical alerts and noncritical alerts need to be tailored to the individual patient. Reactions to alerts transmitted during nonbusiness hours are frequently a particular concern for RM clinics. Concerns include potential liability for nonimmediate

response to incoming high-priority alerts. Nevertheless, there is no evidence for the need of an immediate response to alerts outside of the working hours. Most RM sites are not able to provide an immediate response. For this reason, it is crucial that patients and their care providers realize that RM should not be misinterpreted as a replacement for an emergency system.

### Recommendation-specific supportive text

1. For logistical and organizational reasons, the vast majority of RM sites operate during normal working hours<sup>158</sup> and are not able to provide review and response to these alerts outside of their normal business hours. The benefit of reactions to alerts outside of the normal business hours has not been investigated. It is important that patients and their caregivers have an emergency management plan for a device problem in addition to RM.
2. Timely review and appropriate reaction to high-priority alerts are considered crucial. The definition of the term “timely” regarding RM is unclear, as there are no direct comparisons of clinical outcomes based on differing reaction times to critical alerts. Prompt review of alerts is important. Indirect evidence shows that daily transmissions have better patient outcomes than less frequent transmissions.<sup>51</sup> Most device clinics are not designed for 7 days per week and/or 24-hour per day monitoring. Alerts should

be addressed within 1 business day, with red alerts prioritized. A workflow based on review of transmissions within 1 business day was highly effective for detection and management of clinical events without overwhelming staff and resources.<sup>29</sup> It should be emphasized to patients that RM is not an emergency management system.

### Section 9 Remote monitoring reporting

A report of the results of RM must offer detailed information on device functioning and clinical status of the patient. RM device transmissions include continuous or noncontinuous, alert-based, and patient-activated manual transmissions. Each transmission includes comprehensive data on device technical functioning and data related to arrhythmias and HF. All data should be stored in the medical record.

#### 9.1. Communication of the remote monitoring report to patients

##### Recommendations for communication of the RM report to patients

COR	LOE	Recommendations	References
2a	C-E0	1. For the care of patients with CIEDs on RM, it is reasonable for the results of all remote device transmissions to be shared with patients, based on patient preferences for content and mode of communication, and clinic workflows.	

#### Synopsis

Patient awareness of RM transmissions is critical to improve compliance and maximize clinical benefits. Sharing results of patient transmissions should take into account patient preference, considering culture and psychological and social status, as well as clinic workflow to avoid work overload. Modes of communication must be consistent with local regulations.

workflow, reports may be delivered by mail, secure e-mail, patient portal, or directly during in-person visits. Patient health information privacy should be emphasized. Incorporating device reports into the electronic health record (EHR) is crucial for data availability to all hospital services. This may include routinely to the primary care provider or urgently during emergency needs, to maintain optimal patient care.

### Recommendation-specific supportive text

1. Timing and mode of communication of transmission results to patients depend on clinical relevance and actionability of detected events. Actionable events should be promptly communicated, and clinical reaction performed with a timely plan. Routine transmission and nonactionable event reports, as well as billing, may be delivered periodically. According to patient preference and clinic

#### 9.2. Components of a comprehensive report

Similar to reports generated from in-clinic device visits, the content of an RM report will depend on clinical and technical factors as well as the type of CIED.<sup>1,16</sup> An additional consideration for RM is the context of remote transmission (ie, scheduled vs automatic/alert-driven). Suggestions for the components of a comprehensive remote follow-up/interrogation report are provided in [Figure 10](#).

Category	Data Element*	PM	ICD	CRT	ILR	Scheduled	Alert-Driven†
<b>General</b>							
Patient Information	Clinical indication	✓	✓	✓	✓	✓	✓
	Presenting rhythm	✓	✓	✓	✓	✓	✓
Battery	Voltage	✓	✓	✓	✓	✓	✓
	Estimated replacement time	✓	✓	✓	✓	✓	✓
	Battery impedance	✓	✓	✓		✓	
	Capacitor charge time		✓			✓	
Programming	Bradycardia settings	✓	✓	✓		✓	
	Tachycardia settings		✓			✓	
<b>Leads</b>							
Sensing	Sensing thresholds for all leads	✓	✓	✓		✓	
	Serial trend in sensing threshold(s)	✓	✓	✓		✓	
	Oversensing/undersensing	✓	✓	✓	✓	✓	✓
Pacing	Pacing thresholds for all leads	✓	✓	✓		✓	
	Serial trend in pacing threshold(s)	✓	✓	✓		✓	✓
Impedance	Lead impedance(s) for all leads	✓	✓	✓		✓	
	Serial trend in lead impedance(s)	✓	✓	✓		✓	✓
	Shock impedance		✓			✓	
	Shock impedance out of range		✓			✓	✓
	Polarity switch	✓	✓	✓		✓	✓
<b>Heart Rate, Rhythm, and Heart Failure</b>							
Heart Rate	% Atrial pacing	✓	✓	✓		✓	
	% Ventricular pacing	✓	✓	✓		✓	(✓)
	Characterize atrial and/or ventricular rate histograms (optional)	✓	✓	✓	✓	✓	
Arrhythmia(s)	AF/AT (% burden, maximum duration)	✓	✓	✓	✓	✓	(✓)
	Mode switches (optional)	✓	✓	✓		✓	✓
	Ventricular high-rate events episodes (number, duration, and EGMs)	✓	✓	✓	✓	✓	
	Therapies required for VT/VF termination (appropriate vs inappropriate)		✓			✓	✓
	Electrogram morphology template (for VT discrimination algorithm) (optional)		✓			✓	
	Pause (number and duration)				✓		✓
	Patient activated (symptom rhythm correlation)		✓	✓ (ICD)	✓		✓
Heart Failure	% Biventricular or LV pacing		✓	✓		✓	
	Thoracic impedances (optional)			✓		✓	
	Heart failure algorithms (optional)		✓	✓		✓	✓

**Figure 10** Suggested components of remote monitoring report

\*Additional manufacturer-specific features can be added if these data will influence patient care/management and be used by the local device clinic (eg, activity monitor, heart rate variability, heart failure algorithms). Listed data elements (✓) would be considered the mandatory minimal data set for a remote monitoring report, unless otherwise denoted. †Availability of alerts are manufacturer specific. These may include but are not limited to RV lead integrity alert, RV lead noise, lead impedance out of range, AT/AF daily burden (as per user set threshold), excessive charge time, and low battery voltage. Alert programming should balance patient safety and actionable clinical information with the burden of nonactionable alerts that device clinics may encounter with undiscerning programming. AF = atrial fibrillation; AT = atrial tachycardia; CIED = cardiovascular implantable electronic device; CRT = cardiac resynchronization therapy; EGM = electrogram; ICD = implantable cardioverter-

### 9.3. Techniques for incorporating reports into electronic health records

Recommendations for techniques for incorporating reports into EHRs			
COR	LOE	Recommendations	References
1	C-E0	1. For patients with CIEDs on RM, it is recommended that patient health information privacy be maintained when incorporating reports into EHRs.	
2a	C-E0	2. For the care of patients with CIEDs on RM, it can be beneficial to use universally accepted data element definitions and exchange formats when incorporating reports into EHRs.	
2b	C-LD	3. For the care of patients with CIEDs on RM, it may be beneficial to use patient management software to incorporate reports into EHRs.	28

## Synopsis

RM information must be private but also should be available in the patient's health record. The element definitions and report formats should be universally accepted, regardless of the manufacturer, to be compatible with management software that can be incorporated into EHRs. Manual or automatic capability for populating databases is essential both for the regular follow-up and for unscheduled transmission including site-based interrogations that can occur in emergency departments, intensive care units, or even long-distance service.

## Recommendation-specific supportive text

1. Solutions for data management continue to evolve. The goal is to be able to access data stored in CIEDs in a timely fashion, review the data for clinically valuable information, and present this information in a contextual and relevant format in the EHR system for the physician following the patient with a CIED. Device data downloads need to be accessible to, for example, operating rooms and emergency departments for interpretation by trained technical staff. With accessibility, however, comes challenges to maintaining the privacy of patient health information as well as potential issues related to liability when using RM-related services.<sup>159</sup>
2. Patient device data is regarded as a part of the patient file and should be stored in the hospital information system. The manufacturer's web-based platform provides data in a protected environment that are suitable for incorporation into the hospital information system. However, the diversity and incompatibility of sources for current device data is a barrier to high-quality patient care. Universally

accepted data element definitions and exchange formats facilitate accurate and efficient data transfer (regardless of manufacturer) from RM servers and programmers to EHRs and other data repositories, thereby increasing clinical and administrative efficiency, patient safety, regulatory post-marketing surveillance, product advisory recall management, and clinical research.<sup>1,25,160,161</sup>

3. For both remote transmission review and in-person clinic visits, time-saving protocols are driven by steps for documentation in EHRs. The staff time required per remote and in-person device check is less when a vendor-neutral CIED management software is used. A recent publication demonstrated that sites using management software reduced, on average, the total staff time to review a remote transmission by 2.1 minutes (11.5 vs 13.6 minutes) and an in-clinic visit by 2.2 minutes (50.4 vs 52.6 minutes). When extrapolated to an average clinic size of 5758 patients, the use of such software was associated with an estimated 10.1 cumulative staff hours saved during a clinic day (50.7 hours per week) based on 171 weekly clinic visits and 1335 weekly remote transmissions. Annually, this translates to 2639 hours of staff time saved, equivalent to 1.4 annual FTEs.<sup>28</sup>

## Section 10 Patient education for remote monitoring

Device implantation represents the beginning of a lifelong relationship between patients and their device clinic care providers. It requires communication and trust between patients and providers. Anticipating patients' concerns before and after device implantation as well as adapting to their changing needs over time increases the likelihood that patients understand and adhere to the quality-improving and




Figure 11 Patient as a team member in remote monitoring.

life-saving implications of RM.<sup>104,162,163</sup> Evidence to support specific algorithms for timing and methodologies of patient education is sparse. Available evidence is confounded by technology complexity, including different transmission platforms supported by the various device companies.<sup>162</sup> In-person instruction after device implantation is optimal, especially in the early follow-up period, to establish personal relationships with device clinic staff.<sup>164,165</sup> This is often not possible based on a patient's geographic distance from a device clinic. Also, patients may be overwhelmed by the experience of device implantation, so their retention of in-hospital

education may be suboptimal. There are different phases of patient education on RM (Figure 11); (1) *BEFORE* device implantation that promotes shared decision-making, (2) *SHORTLY AFTER* device implantation that increases patient satisfaction and adherence,<sup>92,164,165</sup> and (3) *ONGOING* education that adapts to the changing needs of the patient over time. The communication should be transparent, with clarity about the emergency action plan. An engaged patient is critical to the success of this partnership. Finally, the specific needs of the patient will vary with their technological skills, educational attainment, and facility with language.

### 10.1. Patient education for participation and compliance

#### Recommendations for patient education for participation and compliance

COR	LOE	Recommendations	References
1	C-LD	1. In patients with CIEDs on RM, patient education should be delivered in plain language, at a basic reading level, and be individualized to support patient communication preferences and educational needs throughout the continuum of care.	166,167
1	C-EO	2. In patients with CIEDs on RM, comprehensive patient education about RM is recommended for patients, families, and caregivers prior to device implantation to guide shared decision-making regarding device selection.	
1	C-EO	3. In patients with CIEDs on RM, it is recommended that patient education start before implant and include the importance of ensuring ongoing connectivity to improve post-implant patient compliance and monitoring effectiveness.	
2a	C-LD	4. In patients with CIEDs on RM, providing a hands-on education session with the RM device can be beneficial.	163

#### Synopsis

High-quality patient education is delivered when the patient's level of comprehension and dynamic communication preferences are considered. To promote maximal engagement of the patient in decision-making, family members should be included, and ideally the educational process should begin prior to device implantation. An initial in-person hands-on education session can promote trust and engagement.

#### Recommendation-specific supportive text

1. In a study that assessed the readability of patient education materials on ICDs from a variety of sources (including industry, hospital resources, and patient support organizations), it was determined that 95% of the materials exceeded the recommended 8<sup>th</sup> grade reading level. Accordingly, this may explain the acknowledged disparity that patients with a preference for RM tend to have higher educational attainment.<sup>167</sup> As part of identifying patients' individual needs for optimal comprehension, information should be adapted to address personal and cultural preferences that will optimize communication. Beyond patients'

reading skills, additional factors that may limit their comprehension should be considered when personalizing education including age, language barriers, learning preferences for written vs auditory information, sociodemographic factors, and physical limitations such as visual or auditory impairment. It is also relevant to acknowledge that an individual's educational preferences may change over time as individuals age.

2. Shared decision-making, especially for nonurgent procedures, ensures patient understanding and that their choices align with their goals and values.<sup>168</sup> Sensitivity to this topic is essential in acknowledging the impact this may have on a patient's decision to proceed with a CIED implantation. With a focus on patient-centered care, the Centers for Medicare and Medicaid Services (CMS) mandated documentation of an evidence-based patient decision aid for individuals receiving primary prevention ICDs for systolic HF.<sup>163</sup> The engagement of patients' family members and caregivers supports this process to promote the highest level of understanding possible. An additional factor regarding shared decision-making for a CIED implant can be the choice of manufacturer. What best aligns with an individual patient's preferences for



- RM interaction, such as app-based software, should be considered.
3. Formalized education on RM is an opportunity to enhance the understanding of practical device function and alert management.<sup>168</sup> For nonurgent device implants, patients may be overwhelmed by hospital events surrounding the device implantation procedure. It is recommended that these educational efforts begin prior to implantation, preferably during the discussion for indication of the device. As ongoing connectivity is paramount for appropriate monitoring, the importance of its maintenance should be included in standardized education.
  4. Survey-based studies have demonstrated that patients feel they receive less information and interact less with providers when they are remotely monitored than if they had in-person care.<sup>165,169</sup> Doing an in-person, hands-on demonstration of the manufacturer-specific transmitter or the software that the patient will use for RM can provide an opportunity to answer all questions about the system. While this is not feasible for all patients all of the time, it should be considered as part of the initial educational process to establish trust. Increased knowledge and understanding may improve patient adherence and connectivity to RM.

## 10.2. Patient education of clinic-specific policies

### Recommendations for patient education of clinic-specific policies

COR	LOE	Recommendations	References
2a	C-EO	1. In patients with CIEDs on RM, it is reasonable to communicate clinic-specific policies associated with RM to the patient.	

### Synopsis

The monitoring of patients with a CIED is a partnership between patients and their device clinic staff. When providing patient education, dialogue on clinic-specific policies sets clear expectations for patients who will be remotely monitored by that device clinic.

### Recommendation-specific supportive text

1. Clinic-specific policies should be established and presented to patients. In addition to verbal communication, this could also include an educational brochure or a patient/clinic agreement form. This information may include hours of clinic operation, remote scheduling, billing information, communication preference for device transmission report, use of third-party resources (see **Section 12**), and commitment to maintaining follow-up. The importance of updated and current contact information for the patient should be emphasized. It is critical to clarify that remote transmissions do not replace emergent care. Patients should develop an emergency plan in advance of a crisis situation. Instructions will be provided to the patient regarding who to contact for home monitoring troubleshooting including the manufacturers' technology service phone numbers.

## Section 11 Manufacturer responsibilities with remote monitoring

Manufacturers have a central role in the development of technology and in ensuring its safety and effectiveness. Responsibilities include (1) informing clinic staff and patients about any disruption in the RM service, (2) communication about recalls and advisories to CIED clinic providers and patients in a transparent and timely manner, and (3) refraining from direct patient care (either within the clinic or at home). Although manufacturer representatives can play an important role in training clinic staff, it is not their role to perform, collect, or triage data on behalf of the clinic staff or be used as a staffing resource in lieu of local qualified personnel. It is the responsibility of industry to ensure RM systems function across varying geographies. This includes a need to overcome problems related to the telephone network, communication evolution, and the impossibility of using the electromagnetic spectrum band of the CIED already assigned for other uses. As the data reside on servers owned and managed by the manufacturers, the onus lies with the manufacturers to maintain the servers in a secure and encrypted environment. Privacy is of paramount consideration. The minimal standard is to maintain privacy in accordance with local and national

laws. The data pooled from the servers are important to industry for quality assurance purposes (eg, tracking device performance and watching for early signs of device trouble) and for making improvements to the CIED technology. The data are also of value to individual CIED programs for improving the quality of their processes. Finally, these data are essential to investigators, independent of industry, and so it is important for manufacturers to have in place a procedure to process requests for an independent scientific review.

### 11.1. Manufacturers' role to optimize individual patient care

#### Recommendations for manufacturers' role to optimize individual patient care

COR	LOE	Recommendations	References
1	C-EO	1. For the care of patients with CIEDs on RM, manufacturers should provide clinic staff with adequate training, education, and technical support to optimize individual patient connectivity.	
1	C-EO	2. In patients with CIEDs on RM, the manufacturer should provide an RM system that is reliable, safe, accurate, and meets the needs of the patient.	
1	C-EO	3. For the care of patients with CIEDs on RM, manufacturers should include key stakeholders in the design and development of technologies for RM.	
1	C-EO	4. For the care of patients with CIEDs on RM, manufacturers should provide prompt notification of disconnection to the clinic, and to the patient to restore connectivity.	

#### Synopsis

Successful and ongoing connectivity of individual patients is associated with challenges for RM clinics.<sup>28</sup> Industry plays an important role in supporting clinics to provide and maintain this connectivity. This starts with the design and development of RM technology and continues through providing education to clinic staff and to patients directly. Patient care can benefit from the early notification of critical events, and this requires ongoing compliance with RM.

Including patient partners and clinic staff in the development and design of RM products will ensure that the technology will continue to evolve and meet stakeholder needs from the perspectives of ease of use, flexibility, and reliability.<sup>22,121</sup> Systems designed to clearly indicate, to both patients and the clinics, when connectivity has been interrupted will allow for the timely resumption of monitoring. Recent studies have highlighted the large workloads for RM clinics associated with maintaining connectivity.<sup>28</sup> Technology that empowers patients to independently troubleshoot their RM systems would be optimal.

#### Recommendation-specific supportive text

1. Ensuring optimal connectivity for remotely monitored CIED patients enhances patient safety and can aid in clinical decision-making. Manufacturer representatives are important partners in the training and education of RM clinic staff. This may take the form of onsite support (such as enrolling patients into an RM platform) or suggesting manufacturer-specific programming settings for alert parameters. This manufacturer support also extends to providing online, tele-

phone, or in-person (in the clinic) technical help when troubleshooting connectivity concerns of individual patients.

2. As new devices and RM platforms are developed and upgraded, it is important to remember that no single RM transmitter technology will be suitable for all patients. Fraiche et al. recently highlighted a lack of understanding by patients about how RM works.<sup>162</sup> Timmermans et al. found that patients with negative RM experiences will opt for in-clinic follow-up.<sup>170</sup> Manufacturer partners should consider having alternate systems available for

those patients who have limited mobile connectivity or digital literacy. As technology upgrades can place a financial burden on a patient, mobile device applications should allow compatibility with all smartphone manufacturers. Ideally, the RM transmitter will match the lifetime of the implanted device. Given the international mobility of patients, the RM systems should be designed to work in different jurisdictions. Security concerns, including cybersecurity, are important to ensure both patient safety and the safety of their personal health information.

3. There are workload implications for clinics when there are high volumes of alerts and calls with patients to troubleshoot connectivity.<sup>3,28</sup> The involvement of key stakeholders, including patients and clinic staff, in the development of RM technology will ensure that ongoing product designs will meet needs as technology rapidly evolves and changes. In addition, this collaborative approach with industry will lead to increased efficiency and satisfaction for stakeholders.

4. Studies have demonstrated that patient outcomes are directly correlated to RM adherence.<sup>22,97</sup> Clinics need to be notified about disconnected patients in a prompt manner. Manufacturer monitors, or mobile applications, should provide a clear indication to patients about transmission status and should provide easy-to-follow instructions to re-establish connection when connectivity is lost. Dechert et al. have found that when patients perceive a lack of device feedback (lack of recognition that the device is transmitting), patient-initiated

transmissions increase, resulting in more extraneous data for the RM teams to review.<sup>171</sup> If patients are able to troubleshoot and resolve connectivity issues

unassisted, patient will spend less time disconnected, clinic work load will decrease, and clinical care will improve.<sup>28</sup>

### 11.2. Manufacturers' role in the management of patient safety advisories via remote monitoring

As the implantation of CIEDs has become more commonplace, there have been more device hardware and software errors or failure, leading to manufacturer safety advisory or recalls. Data from as early as the 1990s and early 2000s found escalating numbers of recalls and advisories,<sup>172</sup> with a subsequent review of U.S. Food and Drug Administration (FDA) Enforcement Reports from 2000-2008 revealing a 26.4% recall alert of either device generator or leads.<sup>173</sup> Though there were no major complications attributed to these alerts, the patient burden related to extra visits or procedures did lead to an increased cost burden. Additional studies confirmed the high volume of patients affected, though there continued to be no evidence of associated increased mortality.<sup>174</sup> Acknowledging these challenges, in 2005 the HRS and the FDA convened a conference on PM and ICD performance. The resulting taskforce called for improved commu-

nication from manufacturers to physicians and patients regarding recalls and advisories, and generally more cooperation among industry, the FDA, and the physician community.<sup>17,175</sup> Industry was asked to use the Patient Device Advisory Notification letter format to communicate with physicians and use patient registration information found at the time of implant to communicate with patients. The HRS Task Force on Lead Performance Policies and Guidelines further recommended that manufacturers should develop and adapt RM technology to monitor longitudinal lead performance.<sup>176</sup> The increased number of advisories have had a significant impact on provider workflow, financial costs, patient anxiety, and patient safety. Patients can experience a range of emotions, including outrage, if such information is learned through media outlets and not from their clinical team.<sup>177</sup> The clinical team requires early access to recall and advisory information to preserve trust in the patient-provider relationship.

#### Recommendations for manufacturers' role in the management of patient safety advisories via RM

COR	LOE	Recommendations	References
1	C-EO	1. For the care of patients with CIEDs on RM, manufacturers should contact the managing clinics with details of a safety advisory and assist in identifying affected patients both immediately and on a regular basis.	
1	C-EO	2. For the care of patients with CIEDs with an advisory and on RM, manufacturers should provide guidance to clinics on optimal alert settings to manage the safety advisory.	

#### Synopsis

Manufacturers and industry representatives play a vital role in the management of patients affected by CIED safety advisories by providing timely patient reports to the clinical team when devices meet advisory conditions. To help navigate vendor-specific nuances, manufacturer guidance is critical for the clinical team to best manage the advisory through device reprogramming or reprogramming alert settings. Manufacturers provide ongoing support to the clinical team with updated patient lists and safety advisory details, and they should continue to do so.

#### Recommendation-specific supportive text

1. It is important that manufacturers directly contact the clinical team as soon as device safety advisories or recalls are issued. Providing the clinical team with a list of affected patients and specific system components involved in the

advisory could help enable a timely response. Industry representatives should continue to contact clinical providers using different modalities (email, certified mail, or in-person communication) until confirmation of communication is received. Updates to the safety advisories should be ongoing.

2. Many safety advisory and recall communications deal with issues that are particular to the system of the involved manufacturer. Therefore, it is important that manufacturers or industry representatives provide detailed guidance about how to manage the safety advisory through device reprogramming or alert settings. This may include changing the frequency of remote transmission or modifying details of critical alerts, or the development of novel advisory-specific alerts. Manufacturer representatives should also share planned or suggested long-term solutions to the safety advisory such as software updates or potential lead or device removal.

### 11.3. Support surrounding implantation from manufacturers

#### Recommendations for support surrounding implantation from manufacturers

COR	LOE	Recommendations	References
1	C-EO	1. For patients undergoing CIED implantation, it is recommended that manufacturers provide adequate resources, including personnel as appropriate, to ensure enrollment and connectivity to RM platforms before discharge or within 2 weeks of implantation.	
1	C-EO	2. For the care of patients undergoing CIED implantation, it is recommended that manufacturer representatives provide the clinic staff with adequate training to properly program remote alerts specific to the clinical indication to minimize inappropriate alerts and need for consequential reprogramming.	

#### Synopsis

RM platforms and device programming across manufacturers continue to have many distinct differences between manufacturers. Each manufacturer has a different RM interface that processes and reports alerts differently.<sup>3</sup> Manufacturers vary in what is considered a red vs yellow alert and in when these data get transmitted to the clinics.<sup>178</sup> For example, some devices provide continuous connectivity, while others provide only noncontinuous (or intermittent) connectivity. Some device RM systems are connected to a mobile transmitter, while others utilize a stationary transmitter. This impacts the speed and frequency with which information can be shared with the clinical team. Each manufacturer uses unique CIEDs algorithms and software (and sometimes multiple algorithms/systems within a manufacturer), which can make it challenging for an implanter to recall the nuances of each system and device. Guidance on optimal manufacturer-specific alert parameters relevant to a clinical scenario can minimize inappropriate alerts and need for immediate future reprogramming.

#### Recommendation-specific supportive text

1. Manufacturers should provide personnel as appropriate (in-person manufacturer representatives), adequate support of clinic staff through education, or “on-demand” off-site support to ensure that patients are properly enrolled into the manufacturer’s RM platform. This should ideally be accomplished prior to discharge, but no later than 2 weeks after discharge. This includes confirming that the chosen RM interface matches the patient’s technology literacy and ability. For example, connecting a patient living in a rural area with poor internet or cellular service to a cellular-based/wireless device may prevent successful remote transmissions and result in poor patient care.
2. CIED manufacturer-specific algorithms and software can pose challenges for implanters or clinic staff related to the nuances of each system and device. For example, criteria for a red (critical) alert can differ between manufacturers. Industry support during and immediately after implant can help ensure optimal device programming to meet the clinical indications. This

guidance on optimal manufacturer-specific alert parameters relevant to a clinical scenario can minimize inappropriate alerts. Industry support during and immediately after implant can help ensure timely and optimal device programming.

### Section 12 Third-party resources for remote monitoring

There is a high volume of data captured through RM systems. The amount of data can make it challenging to manage these data without adequate clinical staff and administrative support. To address this challenge, some hospitals and clinics have turned to third-party resources to aid in RM (Figure 12). Third-party resources refer to hiring an outside service to help with any of the tasks described later in this section. The use of third-party resources has potential clinical, financial, and workflow benefits but may also have drawbacks. The goal is to ease the workload on overwhelmed staff in order to improve timeliness of remote transmission review and enhance patient communication. Risks of using third-party resources include exposing private patient data to maleficence (hacking). Adoption of third-party resources into an RM program requires careful thought and consideration to ensure patient safety and optimize communication between the patient and medical team.

Third-party resources may be task specific (eg, only reviewing CIED alerts) or encompass the entire RM process. Third-party resources should not include professional decision-making. Some third-party providers act as “middleware services,” centralizing data from multiple manufacturers. Others offer comprehensive services that include facilitating patient enrollment on RM, assessing and addressing compliance to transmission, providing review of routine and acute CIED transmissions with accompanying report, notifying the medical team of actionable data, generating a service charge, and integrating report data with the electronic medical record to support patient communication. They can assist with troubleshooting, patient feedback, and billing.<sup>179</sup> These third parties may use either cloud-based or server-based services to store patient data.

## 12.1. Use of third-party resources in remote monitoring

### Recommendations for use of third-party resources in RM

COR	LOE	Recommendations	References
2a	C-EO	1. For the care of patients with CIEDs on RM, it is reasonable to use third-party resources to alleviate RM workload for staff.	
2a	C-EO	2. For the care of patients with CIEDs on RM, it is reasonable to inform patients about the use of third-party resources to facilitate patient care.	


### Synopsis

As stated above, there are many benefits associated with utilizing third-party resources with device clinics. In some cases, they can help to increase revenues and, in other cases, could assist programs with undersized staffing resources to meet the standards of care expected for an efficient RM program. The use of third-party resources poses many challenges, including cybersecurity risks, dependency on data processors to share clinical information, and potential financial burden. Third-party personnel should be well trained in device interrogation management and ideally have credentials that verify this training. Many third-party resources are cloud based and rely on cloud data storage. This can introduce a risk for data breach or loss, which may affect patient data privacy and safety. It is important for patients to be informed that the institution utilizes third-party services. Furthermore, institutions can become dependent upon the third-party resources to initially review and triage patient clinical information in an accurate and timely manner. Third-party resource workforce shortages or novice

employees may risk missing actionable event transmissions, thus affecting patient care and safety.<sup>179,180</sup> The costs of such third-party resources can become a financial burden in some cases.<sup>160</sup> One less technical concern is that the use of a third-party service may change the patient's perception of the patient-medical team relationship. The loss of a more personal connection with the clinic team may decrease patient compliance and satisfaction.

### Recommendation-specific supportive text

1. Third-party resources have created the infrastructure to manage high-volume data. Offloading administrative tasks from clinical personnel (nurses, advanced practitioners, and physicians) can improve staff efficiency with resulting financial benefits. Furthermore, redistribution of administrative tasks can help alleviate burnout associated with such burdensome tasks.<sup>181</sup> Quality of care and communication between providers and patients may improve when outsourcing to third parties if more data can be reviewed and results communicated in a timely manner.<sup>179,180</sup>



**Figure 12** Remote monitoring outsourcing to third-party resources. CIED = cardiovascular implantable electrical device.

2. RM is a communication process that transmits patient data between data controllers and data processors.<sup>182</sup> Institutions have traditionally been the data controllers, with manufacturers or third-party resources acting as data processors. Using third-party resources for their monitoring or reporting services adds an additional layer between the processor and controller (Figure 12). Each additional interface between the processor and controller introduces the opportunity for potential maleficence (hacking). Traditional data processors (device manufacturers) either use their own secure servers or engage the hosts' servers through a virtual private network connection. The legal and regulatory implications of outsourcing patient data must also be considered.<sup>182</sup> For example, the General Data Protection Regulation (GDPR) in the European Union was implemented in 2018 and provides a legal framework for participating countries. This requires patient consent for the transfer of data to a third party. Other countries across the globe are working to emulate this landmark regulation. CIED patients need to be aware of the use of third-party services in order to properly provide their informed consent for enrolling in an RM program.

### Section 13 Pediatric considerations with remote monitoring

As in the adult population, RM in pediatric patients (defined as those <18 years of age or followed by a pediatric provider) has significant benefit allowing the medical team to detect and intervene on CIED issues, such as battery depletion, lead or device malfunction, or arrhythmic issues.<sup>1,9,183-185</sup> RM can be useful to identify acute lead malfunction after new implants.<sup>184</sup> Younger age was associated with an increase in lead/device malfunction.<sup>184</sup> Although the overall likelihood of an actionable event in pediatric patients is low, RM is recommended for early detection and management of device or arrhythmia concerns, as the patient may be asymptomatic.<sup>183-185</sup> Tachyarrhythmia is the most common abnormality found on RM transmissions in younger patients.<sup>184</sup> A pediatric study showed the median time between RM interrogations was every 91 days and the median time between last follow-up and occurrence of actionable events was 46 days.<sup>185</sup> Pediatric studies support interrogations every 3 to 12 months RM for PM and every 3 to 6 months

for ICDs.<sup>183-185</sup> Frequency of RM noncontinuous device interrogations should be increased as the device reaches elective replacement, as device replacement is an actionable event and needs clinical attention.<sup>184</sup>

The recommendations outlined in this document for the adult population are applicable to the pediatric population. Recommendations detailing indications, management, and timing/frequency for pediatric patients with CIEDs on RM were outlined in the *2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients*.<sup>9</sup> Additional considerations for pediatric patients include the importance of engaging the patient early in their life to promote independence, and compliance as they reach adulthood. Transition, defined as the active process that focuses on the medical, psychosocial, and educational/vocational needs of adolescents as they move toward adulthood, to adult CIED care should be the eventual goal. The transition process is dynamic, and duration of transition can vary from patient to patient. Shared medical decision-making that promotes open dialogue and exchange of medical information between the child, parents, and provider can also help to support compliance, transition to adult care, and better outcomes. Implementation of focused patient education to adolescent patients has been shown to increase self-management and knowledge of their medical condition in a recent clinical trial. At each follow-up visit, pediatric CIED providers should evaluate transition readiness and provide targeted education on device care and the importance of RM beginning in the young adolescence period.

### Section 14 Geographic differences with remote monitoring practices

Despite near global availability of RM by a limited number of manufacturers, there is significant geographic variability in the uptake of RM, both within countries and between countries and regions.<sup>22,186</sup> Significant variability also exists as to how RM is conducted, including the frequency of scheduled transmissions, enrollment criteria for RM, and the technologies used for RM.<sup>187,188</sup> Disparity exists due to a multitude of barriers that include insufficient reimbursement for patients and care teams, a lack of personnel resources, and inadequate infrastructure for RM.<sup>3,86</sup>

#### 14.1. Availability of remote monitoring

Recommendations for availability of RM			
COR	LOE	Recommendations	References
1	C-E0	1. For the care of patients with CIEDs, health systems should identify local barriers, and develop strategies to optimize the successful use of RM globally.	

## Synopsis

RM has been developed to address limitations with in-office follow-up, such as late detection of clinical or technical actionable events, by providing need-based care and continuous surveillance of CIED devices. In 2013, an update on the use of RM in the Asia-Pacific region reported a global availability of RM, but the actual use of RM was highly variable.<sup>189</sup> Although the use of RM was very limited in South East Asia, India, and Hong Kong, up to 50% of patients with an ICD or CRT in Japan were provided with RM. Availability is a necessary prerequisite, but it does not necessarily lead to adequate use and patient compliance. Real-world data from 2014 on the RM of ICDs and CRT-Ds illustrated large geographical variability in the compliance of RM within the United States, with noncompliance rates ranging between 8.5% and 19.5%.<sup>190</sup>

## Recommendation-specific supportive text

1. There is very limited data available on geographical disparities in RM availability, use, and compliance. Future research should focus on identifying barriers to RM adoption and compliance as well as their respective solutions. Examples of these barriers include geographical and socioeconomic disparities. The optimal approach to this research would involve a collaboration between patients, health systems, and RM providers.

## Section 15 Knowledge gaps and future needs

The innovations in RM technologies over the last few decades have greatly contributed to the advancement in the “standard of care” for patients with CIEDs. The vast potential of these technologies is just starting to be harnessed. Advances are still needed on many fronts—technology development, policy leadership, payment reform, and patient-centered communications. Seven important challenges related to remote care of patients are enumerated below. If these can be adequately addressed in the coming years, there is great potential to improve the quality of care able to be delivered to patients.

### 15.1. Remote monitoring can “shorten” large geographic distances

While some countries are geographically small with a high population density, other countries are large with areas of very low population density. Examples of the latter in North America might be in parts of the central regions of the United States or in the Canadian North. Patients may need to travel great distances in order to receive CIED care. RM might be able to address this problem. It is likely not feasible to establish CIED clinics with trained staff in every rurality. However, site-based RM in smaller towns with transmission interpretation performed by off-site, trained CIED staff could be a solution. A network of site-based remote monitors could be deployed that could decrease the financial, time, and travel burden to patients as well as infrastructure and personnel

costs for local municipalities. If the CIED interrogation is reassuring, then no further action would be required.

### 15.2. Remote programming

One of the most notable benefits of RM is the ability to provide high-quality care to patients who are not near a CIED clinic (or a programmer). Currently, these benefits accrue primarily to those patients in whom the programmed settings are optimal. If the remote interrogation provides actionable information necessitating reprogramming, the patient needs to travel to a CIED clinic (or at least to a physical CIED programmer) for care. Fortunately, this applies only to a minority of interrogations.

Remote programming has recently become available for newer-generation ILRs. The next frontier will encompass not only RM of patients with CIEDs, but true “remote programming.”<sup>191</sup> In the future, care needs to be delivered to the patient where the patient lives—ideally in the patient’s home. More recently, remote programming has been reported in a case series from China,<sup>192</sup> in the context of reprogramming a CIED before and after an MRI scan,<sup>193</sup> and a small feasibility study from Bordeaux, France, with ongoing testing in a larger cohort.<sup>194</sup> Each of these have used a model of remote programming that requires a programmer near the patient, and remote control of that programmer to be performed by an off-site clinician. These small forays into remote programming need to be expanded to the point that they do not require the patient to be in a health care facility. The engineering challenges are likely easily surmountable. It is critical that this technology be deployed in a manner that instills confidence in both patients and providers about the safety and security of RM. Certain “high risk” features (eg, noninvasive programmed stimulation) should probably not be available to be programmed remotely. Conversely, the reprogramming of RM alert features should be easily accessible.

### 15.3. Inequitable access to cardiovascular implantable electronic device remote monitoring

RM was strongly recommended for most CIED patients in the 2015 HRS Expert Consensus Statement on RM. Across the world in 2022, most CIED patients did not have access to RM. There are significant disparities in the use of RM both between and within counties, with differing reasons for these disparities. In some cases, they relate to the cost burden on some national health systems. In other cases, the telecommunications infrastructure might not be able to provide a stable support for RM. In some smaller city-states, the value proposition has not been clear to the payers given the short distances between the citizens and the CIED clinics. Within the United States, patients are often required to make a recurring copayment for their RM. Without obvious benefits that are tangible to the patient, many patients decline further RM.

There are many different problems leading to this variability in access to RM, so there need to be many different solutions. In some cases, the solutions are changes to government policy; in other cases, technological solutions are needed; and in some cases, novel reimbursement models

are required. Efforts will be required on multiple fronts to decrease these disparities.

#### 15.4. Reimbursement reform for remote monitoring

There are currently many challenges with the reimbursement model for RM. First, there is a large variability in what the Medicare program pays for RM visits across the United States. This variability makes RM financially challenging in some parts of the United States. This makes little sense, especially since the background structural costs of RM are likely similar for central monitoring services.

Second, the co-payments required for RM (mentioned above) serve as a barrier to optimal patient care. In the United States, while co-payments are often required for diagnostic care and for treatments, co-payments can be waived for preventative care and screening tests. Most CIED RM could be considered a form of preventative care. The remote visits are to ascertain whether there is a problem that might be treated, even in the absence of symptoms, to prevent progression to more serious and potentially life-threatening problems.

Third, there is significant worldwide heterogeneity in the reimbursement for RM.<sup>86,189,195</sup> In Europe, many clinics receive no reimbursement for RM, and this has been identified as a major barrier to the use and expansion of RM.<sup>86,195</sup> Uptake of RM has slowed in parts of the Asia-Pacific region, with a lack of reimbursement identified as a barrier in many locales.<sup>189</sup>

Finally, a larger shift may be needed in how we think about RM of CIEDs. Currently, most remote visits are scheduled in advance at a prespecified interval. This is a relic from the CIED clinic visits that were used exclusively prior to RM. Most of these visits (both remote and in person) conclude that the CIED is working properly and that no further action is needed. One could argue that those visits are of “low value” to the patients, but they still require a significant effort from trained clinic staff (with the related costs). While clinic reimbursements are tied to these visits, this “low-value care” will continue. To shift efforts to an “alert-based” model of care that focuses on clinic visits for an actionable event will require a restructuring of CIED clinics and their reimbursement models. The reimbursement would need to shift from the current model of reimbursement on a per visit basis to a model of reimbursement for remote and in-person care over a window of time (eg, annually). We need a model where the system of reimbursement is designed to match the optimal care for the patient, instead of the care of the patient being designed to match the system of reimbursement. Such a change will require the involvement of a myriad of stakeholders, including patients, physicians, clinics/offices, and payers, to determine the optimal models and time windows.

#### 15.5. Better information, not more information

RM has generated a lot of information. CIED providers are already suffering from “information overload” with frequent transmissions, especially from ILRs. The increasing use of

wearable technologies with transmission capabilities will only make this problem worse.

The problem is that while some of these data are valuable, most of these data are not useful. It can be very labor intensive and costly to manually review all these data to find clinically actionable events or trends. Here, AI might prove to be particularly valuable. There have already been some early publications about AI models improving the classification accuracy of diagnoses by ILRs.<sup>196</sup> There are also studies assessing whether AI could be used to predict ventricular arrhythmia events and ICD therapies.<sup>197</sup> If these algorithms could be used to enrich the quality of the data that requires manual review by staff, this would enhance patient care.

A critical first step in this regard is standardizing the nomenclature used by the devices and RM systems across manufacturers and implementing new technical standards. This will make it easier for the transfer of information from the manufacturers’ proprietary systems to EHRs or middleware providers. This is a necessary step to accelerate the ability to use AI-based analytical approaches at scale. There is currently an HRS working group that is in the process of creating such standards.

#### 15.6. Direct patient access to device information

Some patients want to know about all their CIED parameters, while other patients just want to know that everything is okay. Both types of patients are entitled to information about the function of their CIED in their desired manner. This must be approached from the viewpoint that the patient owns their health information. Some jurisdictions have laws in place mandating this, such as the European Union regulation 2016/679 (General Data Protection Regulation) Article 20: Right to Data Portability<sup>198</sup> and the United States 21<sup>st</sup> Century Cures Act.<sup>199</sup> Whether or not it is the local law, taking a patient-centric perspective is the correct approach. The challenge is in presenting this information in a way that conveys information effectively and efficiently to the patient, in accordance with their preferences. Manufacturers need to provide clinics with better tools to aid in this communication. Further discussions among stakeholders are needed to determine if this communication to the patient is best kept via the clinics or whether there should be communication to the patient directly from the manufacturers. This is critical if our goal is to care for the patient and not just care for the device.

#### 15.7. Summary: Further research about remote monitoring

RM technologies are evolving quickly, and there has been a need to adapt, even without clear data on outcomes and best practices. Many of the recommendations in this document are based on expert opinion. This is a stopgap solution. Moving forward, research studies should ideally be performed to determine optimal models of RM clinics, including workflows, staffing, and management of alerts. Value can be defined in terms of patient satisfaction, costs, efficiencies, and improved patient outcomes. These benefits need to be



better studied and quantified. It will be important to assess whether RM can impact or improve important patient outcomes such as decreasing the rates of stroke or mortality.

### 15.8. Summary: Past, present, and future

RM has already enhanced the care of CIED patients, which is why the use of RM is a class I recommendation in the 2015 HRS Expert Consensus Statement on RM.<sup>1</sup> The early models of care with RM followed the same pattern as the prior clinic visits, with the sessions scheduled and planned. This is still the pattern with noncontinuous monitoring. Most of these visits confirm that the device is working appropriately and do not require any intervention from the clinic staff. The current schedule of RM visits is often driven by the reimbursement schedule for RM visits. For example, if reimbursement for RM is provided every 91 days, then clinics are incentivized to schedule these RM visits every 91 days.

Increasingly, we are seeing RM platforms with continuous connectivity of devices that can transmit to the clinic information about the lead function, device function, and the patient's clinical status (eg, development of AF) shortly after problems develop. This could allow for the transition to alert-based care. In this model, there would be fewer routinely scheduled "low-value visits" (and perhaps eventually none), with visits scheduled based on device alerts suggesting that device reprogramming or other intervention is needed for patient care ("high-value visits"). We can move to a model of care driven by optimizing care for the patient.

For this to happen, all stakeholders need to participate. Manufacturers need to transition more completely to RM platforms that offer reliable continuous connectivity. Health care facilities need to staff their clinics properly to address both the volume of RM transmissions and the unpredictable nature of alert-based RM. Payers need to develop novel payment schemes that provide payment to clinics for managing the patient with CIED for a duration of time (eg, annually), and not only for a visit.

This paradigm shift has the potential to reduce the requisite clinic resources, to decrease health care costs, to save time and money for patients, and to improve patient satisfaction.

## Appendix

### Supplementary data

Supplementary data (Appendix 3) associated with this article can be found in the online version at <https://doi.org/10.1016/j.hrthm.2023.03.1525>.

## References

- Slotwiner D, Varma N, Akar JG, et al. HRS expert consensus statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. *Heart Rhythm* 2015;12(7):e69–e100. <https://doi.org/10.1016/j.hrthm.2015.05.008>.
- Akinyele B, Marine JE, Love C, et al. Unregulated online sales of cardiac implantable electronic devices in the United States: A six-month assessment. *Heart Rhythm O2* 2020;1(4):235–238. <https://doi.org/10.1016/j.hroo.2020.06.007>.
- O'Shea CJ, Middeldorp ME, Hendriks JM, et al. Remote monitoring alert burden: An analysis of transmission in >26,000 patients. *JACC Clin Electrophysiol* 2021;7(2):226–234. <https://doi.org/10.1016/j.jacep.2020.08.029>.
- Indik JH, Patton KK, Beardsall M, et al. HRS clinical document development methodology manual and policies: Executive summary. *Heart Rhythm* 2017;14(10):e495–e500. <https://doi.org/10.1016/j.hrthm.2017.06.039>.
- Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. In: Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, eds. *Clinical Practice Guidelines We Can Trust*. National Academies Press; 2011.
- Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2016;67(13):1572–1574. <https://doi.org/10.1016/j.jacc.2015.09.001>.
- Varma N, Cygankiewicz I, Turakhia M, et al. 2021 ISHNE/ HRS/ EHRA/ APHRS collaborative statement on mHealth in arrhythmia management: Digital medical tools for heart rhythm professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society. *Ann Noninvasive Electrocardiol* 2021;26(2):e12795 <https://doi.org/10.1111/anec.12795>.
- Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. *Eur Heart J* 2021;42(35):3427–3520. <https://doi.org/10.1093/eurheartj/ehab364>.
- Shah MJ, Silka MJ, Silva JNA, et al. 2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients. *Heart Rhythm* 2021;18(11):1888–1924. <https://doi.org/10.1016/j.hrthm.2021.07.038>.
- Lakkireddy DR, Chung MK, Gopinathannair R, et al. Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. *Heart Rhythm* 2020;17(9):e233–e241. <https://doi.org/10.1016/j.hrthm.2020.03.028>.
- Varma N, Marrouche NF, Aguinaga L, et al. HRS/EHRA/APHRS/LAHRs/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. *Heart Rhythm* 2020;17(9):e255–e268. <https://doi.org/10.1016/j.hrthm.2020.06.010>.
- Nielsen JC, Lin YJ, de Oliveira Figueiredo MJ, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: Use the right tool for the right outcome, in the right population. *Heart Rhythm* 2020;17(9):e269–e316. <https://doi.org/10.1016/j.hrthm.2020.05.004>.
- Slotwiner DJ, Abraham RL, Al-Khatib SM, et al. HRS white paper on interoperability of data from cardiac implantable electronic devices (CIEDs). *Heart Rhythm* 2019;16(9):e107–e127. <https://doi.org/10.1016/j.hrthm.2019.05.002>.
- Slotwiner DJ, Tarakji KG, Al-Khatib SM, et al. Transparent sharing of digital health data: A call to action. *Heart Rhythm* 2019;16(9):e95–e106. <https://doi.org/10.1016/j.hrthm.2019.04.042>.
- Dubner S, Auricchio A, Steinberg JS, et al. ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). *Europace* 2012;14(2):278–293. <https://doi.org/10.1093/europace/eur303>.
- Wilkoff BL, Auricchio A, Brugada J, et al. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): Description of techniques, indications, personnel, frequency and ethical considerations. *Heart Rhythm* 2008;5(6):907–925. <https://doi.org/10.1016/j.hrthm.2008.04.013>.
- Carlson MD, Wilkoff BL, Maisel WH, et al. Recommendations from the Heart Rhythm Society Task Force on Device Performance Policies and Guidelines Endorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) and the International Coalition of Pacing and Electrophysiology Organizations (COPE). *Heart Rhythm* 2006;3(10):1250–1273. <https://doi.org/10.1016/j.hrthm.2006.08.029>.
- Chew DS, Li Z, Steinberg BA, et al. Arrhythmic burden and the risk of cardiovascular outcomes in patients with paroxysmal atrial fibrillation and cardiac implanted electronic devices. *Circ Arrhythm Electrophysiol* 2022;15(2):e010304 <https://doi.org/10.1161/circep.121.010304>.
- D'Onofrio A, Solimene F, Calò L, et al. Combining home monitoring temporal trends from implanted defibrillators and baseline patient risk profile to predict heart failure hospitalizations: Results from the SELENE HF study. *Europace* 2022;24(2):234–244. <https://doi.org/10.1093/europace/euab170>.
- Jang J-P, Lin H-T, Chen Y-J, Hsieh M-H, Huang Y-C. Role of remote monitoring in detection of atrial arrhythmia, stroke reduction, and use of anticoagulation therapy: A systematic review and meta-analysis. *Circ J* 2020;84(11):1922–1930. <https://doi.org/10.1253/circj.CJ-20-0633>.

21. Poole JE, Swerdlow CD, Tarakji KG, et al. Clinical performance of implantable cardioverter-defibrillator lead monitoring diagnostics. *Heart Rhythm* 2022; 19(3):363–371. <https://doi.org/10.1016/j.hrthm.2021.10.032>.
22. Varma N, Piccini JP, Snell J, Fischer A, Dalal N, Mittal S. The relationship between level of adherence to automatic wireless remote monitoring and survival in pacemaker and defibrillator patients. *J Am Coll Cardiol* 2015; 65(24):2601–2610. <https://doi.org/10.1016/j.jacc.2015.04.033>.
23. Wintrich J, Pavlicek V, Brachmann J, et al. Remote monitoring with appropriate reaction to alerts was associated with improved outcomes in chronic heart failure: Results from the OptiLink HF study. *Circ Arrhythm Electrophysiol* 2021; 14(1):e008693 <https://doi.org/10.1161/circep.120.008693>.
24. Maines M, Palmisano P, Del Greco M, et al. Impact of COVID-19 pandemic on remote monitoring of cardiac implantable electronic devices in Italy: Results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing). *J Clin Med* 2021;10(18):4086. <https://doi.org/10.3390/jcm10184086>.
25. Afzal MR, Nadkarni A, Niemet L, et al. Resource use and economic implications of remote monitoring with subcutaneous cardiac rhythm monitors. *JACC Clin Electrophysiol* 2021;7(6):745–754. <https://doi.org/10.1016/j.jacep.2020.10.014>.
26. Holtzman JN, Wadhwa RK, Choi E, et al. Trends in utilization and spending on remote monitoring of pacemakers and implantable cardioverter-defibrillators among Medicare beneficiaries. *Heart Rhythm* 2020;17(11):1917–1921. <https://doi.org/10.1016/j.hrthm.2020.05.044>.
27. O'Shea CJ, Middeldorp ME, Hendriks JM, et al. Remote monitoring of implantable loop recorders: False-positive alert episode burden. *Circ Arrhythm Electrophysiol* 2021;14(11):e009635 <https://doi.org/10.1161/CIRCEP.121.009635>.
28. Seiler A, Biundo E, Bacco MD, et al. Clinic time required for remote and in-person management of patients with cardiac devices: Time and motion workflow evaluation. *JMIR Cardio* 2021;5(2):e27720 <https://doi.org/10.2196/27720>.
29. Ricci RP, Morichelli L, D'Onofrio A, et al. Effectiveness of remote monitoring of CIEDs in detection and treatment of clinical and device-related cardiovascular events in daily practice: The HomeGuide Registry. *Europace* 2013; 15(7):970–977. <https://doi.org/10.1093/europace/eus440>.
30. Crossley GH, Chen J, Choucair W, et al. Clinical benefits of remote versus trans-telephonic monitoring of implanted pacemakers. *J Am Coll Cardiol* 2009; 54(22):2012–2019. <https://doi.org/10.1016/j.jacc.2009.10.001>.
31. Varma N, Epstein AE, Irimpen A, Schweikert R, Love C. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: The Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial. *Circulation* 2010;122(4):325–332. <https://doi.org/10.1161/circulationaha.110.937409>.
32. Varma N, Michalski J, Stambler B, Pavri BB. Superiority of automatic remote monitoring compared with in-person evaluation for scheduled ICD follow-up in the TRUST trial - testing execution of the recommendations. *Eur Heart J* 2014; 35(20):1345–1352. <https://doi.org/10.1093/eurheartj/ehu066>.
33. Hindricks G, Elsner C, Piorkowski C, et al. Quarterly vs yearly clinical follow-up of remotely monitored recipients of prophylactic implantable cardioverter-defibrillators: Results of the REFORM trial. *Eur Heart J* 2014;35(2):98–105. <https://doi.org/10.1093/eurheartj/eh207>.
34. Boriani G, Da Costa A, Ricci RP, et al. The MOnitoring Resynchronization dE-vices and CARdiac patiEnts (MORE-CARE) randomized controlled trial: Phase I results on dynamics of early intervention with remote monitoring. *J Med Internet Res* 2013;15(8):e167. <https://doi.org/10.2196/jmir.2608>.
35. Crossley GH, Boyle A, Vitense H, Chang Y, Mead RH. The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: The value of wireless remote monitoring with automatic clinician alerts. *J Am Coll Cardiol* 2011;57(10):1181–1189. <https://doi.org/10.1016/j.jacc.2010.12.012>.
36. Guédon-Moreau L, Lacroix D, Sadoul N, et al. A randomized study of remote follow-up of implantable cardioverter defibrillators: Safety and efficacy report of the ECOST trial. *Eur Heart J* 2013;34(8):605–614. <https://doi.org/10.1093/eurheartj/ehs425>.
37. Mabo P, Victor F, Bazin P, et al. A randomized trial of long-term remote monitoring of pacemaker recipients (the COMPAS trial). *Eur Heart J* 2012; 33(9):1105–1111. <https://doi.org/10.1093/eurheartj/ehr419>.
38. Landolina M, Perego GB, Lunati M, et al. Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: The evolution of management strategies of heart failure patients with implantable defibrillators (EVOLVO) study. *Circulation* 2012; 125(24):2985–2992. <https://doi.org/10.1161/circulationaha.111.088971>.
39. Varma N, Michalski J, Epstein AE, Schweikert R. Automatic remote monitoring of implantable cardioverter-defibrillator lead and generator performance: The Lumos-T Safely RedUces RouTine Office Device Follow-Up (TRUST) trial. *Circ Arrhythm Electrophysiol* 2010;3(5):428–436. <https://doi.org/10.1161/circep.110.951962>.
40. Varma N, Pavri BB, Stambler B, Michalski J. Same-day discovery of implantable cardioverter defibrillator dysfunction in the TRUST remote monitoring trial: Influence of contrasting messaging systems. *Europace* 2013;15(5):697–703. <https://doi.org/10.1093/europace/eus410>.
41. Ricci RP, Pignalberi C, Landolina M, et al. Ventricular rate monitoring as a tool to predict and prevent atrial fibrillation-related inappropriate shocks in heart failure patients treated with cardiac resynchronization therapy defibrillators. *Heart* 2014; 100(11):848–854. <https://doi.org/10.1136/heartjnl-2013-305259>.
42. Ricci RP, Morichelli L, Santini M. Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation. *Europace* 2009;11(1):54–61. <https://doi.org/10.1093/europace/eun303>.
43. Ricci RP, Vaccari D, Morichelli L, et al. Stroke incidence in patients with cardiac implantable electronic devices remotely controlled with automatic alerts of atrial fibrillation: A sub-analysis of the HomeGuide study. *Int J Cardiol* 2016; 219:251–256. <https://doi.org/10.1016/j.ijcard.2016.06.016>.
44. Ricci RP, Morichelli L, Gargaro A, Laudadio MT, Santini M. Home monitoring in patients with implantable cardiac devices: Is there a potential reduction of stroke risk? Results from a computer model tested through monte carlo simulations. *J Cardiovasc Electrophysiol* 2009;20(11):1244–1251. <https://doi.org/10.1111/j.1540-8167.2009.01543.x>.
45. Martin DT, Bersohn MM, Waldo AL, et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. *Eur Heart J* 2015;36(26):1660–1668. <https://doi.org/10.1093/eurheartj/ehv115>.
46. Chiu CSL, Timmermans I, Versteeg H, et al. Effect of remote monitoring on clinical outcomes in European heart failure patients with an implantable cardioverter-defibrillator: Secondary results of the REMOTE-CIED randomized trial. *Europace* 2022;24(2):256–267. <https://doi.org/10.1093/europace/euab221>.
47. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. *Lancet* 2011;377(9766):658–666. [https://doi.org/10.1016/s0140-6736\(11\)60101-3](https://doi.org/10.1016/s0140-6736(11)60101-3).
48. Hindricks G, Taborsky M, Glikson M, et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): A randomised controlled trial. *Lancet* 2014;384(9943):583–590. [https://doi.org/10.1016/s0140-6736\(14\)61176-4](https://doi.org/10.1016/s0140-6736(14)61176-4).
49. Kurek A, Tajstra M, Gadula-Gacek E, et al. Impact of remote monitoring on long-term prognosis in heart failure patients in a real-world cohort: Results from all-comers COMMIT-HF trial. *J Cardiovasc Electrophysiol* 2017;28(4):425–431. <https://doi.org/10.1111/jce.13174>.
50. Hindricks G, Varma N, Kacet S, et al. Daily remote monitoring of implantable cardioverter-defibrillators: Insights from the pooled patient-level data from three randomized controlled trials (IN-TIME, ECOST, TRUST). *Eur Heart J* 2017; 38(22):1749–1755. <https://doi.org/10.1093/eurheartj/ehx015>.
51. Parthiban N, Esterman A, Mahajan R, et al. Remote monitoring of implantable cardioverter-defibrillators: A systematic review and meta-analysis of clinical outcomes. *J Am Coll Cardiol* 2015;65(24):2591–2600. <https://doi.org/10.1016/j.jacc.2015.04.029>.
52. Geller JC, Lewalter T, Bruun NE, et al. Implant-based multi-parameter telemonitoring of patients with heart failure and a defibrillator with vs without cardiac resynchronization therapy option: A subanalysis of the IN-TIME trial. *Clin Res Cardiol* 2019;108(10):1117–1127. <https://doi.org/10.1007/s00392-019-01447-5>.
53. Husser D, Christoph Geller J, Taborsky M, et al. Remote monitoring and clinical outcomes: Details on information flow and workflow in the IN-TIME study. *Eur Heart J Qual Care Clin Outcomes* 2019;5(2):136–144. <https://doi.org/10.1093/ehjqcco/qcy031>.
54. Boehmer JP, Hariharan R, Devecchi FG, et al. A multisensor algorithm predicts heart failure events in patients with implanted devices: Results from the MultiSENSE study. *JACC Heart Fail* 2017;5(3):216–225. <https://doi.org/10.1016/j.jchf.2016.12.011>.
55. Burri H, da Costa A, Quesada A, et al. Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator. *Europace* 2018; 20(5):e69–e77. <https://doi.org/10.1093/europace/eux206>.
56. Saxon LA, Hayes DL, Gilliam FR, et al. Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: The ALTTITUDE survival study. *Circulation* 2010;122(23):2359–2367. <https://doi.org/10.1161/circulationaha.110.960633>.
57. Heidebuchel H, Hindricks G, Broadhurst P, et al. EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): A provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring. *Eur Heart J* 2015;36(3):158–169. <https://doi.org/10.1093/eurheartj/ehu339>.
58. Health Quality Ontario. Remote monitoring of implantable cardioverter-defibrillators, cardiac resynchronization therapy and permanent pacemakers: A health technology assessment. *Ont Health Technol Assess Ser* 2018;18(7):1–199.

59. Ricci RP, Vicentini A, D'Onofrio A, et al. Economic analysis of remote monitoring of cardiac implantable electronic devices: Results of the Health Economics Evaluation Registry for Remote Follow-up (TARIFF) study. *Heart Rhythm* 2017; 14(1):50–57. <https://doi.org/10.1016/j.hrthm.2016.09.008>.
60. Sequeira S, Jarvis CI, Benchouche A, Seymour J, Tadmouri A. Cost-effectiveness of remote monitoring of implantable cardioverter-defibrillators in France: A meta-analysis and an integrated economic model derived from randomized controlled trials. *Europace* 2020;22(7):1071–1082. <https://doi.org/10.1093/europace/euaa082>.
61. Ricci RP, Vicentini A, D'Onofrio A, et al. Impact of in-clinic follow-up visits in patients with implantable cardioverter-defibrillators: Demographic and socioeconomic analysis of the TARIFF study population. *J Interv Card Electrophysiol* 2013;38(2):101–106. <https://doi.org/10.1007/s10840-013-9823-5>.
62. Burri H, Sticherling C, Wright D, Makino K, Smala A, Tilden D. Cost-consequence analysis of daily continuous remote monitoring of implantable cardiac defibrillator and resynchronization devices in the UK. *Europace* 2013; 15(11):1601–1608. <https://doi.org/10.1093/europace/eut070>.
63. Petersen HH, Larsen MC, Nielsen OW, Kensing F, Svendsen JH. Patient satisfaction and suggestions for improvement of remote ICD monitoring. *J Interv Card Electrophysiol* 2012;34(3):317–324. <https://doi.org/10.1007/s10840-012-9675-4>.
64. Ricci RP, Morichelli L, Quarta L, et al. Long-term patient acceptance of and satisfaction with implanted device remote monitoring. *Europace* 2010;12(5):674–679. <https://doi.org/10.1093/europace/euq046>.
65. Zanaboni P, Landolina M, Marzegalli M, et al. Cost-utility analysis of the EVOLVO study on remote monitoring for heart failure patients with implantable defibrillators: Randomized controlled trial. *J Med Internet Res* 2013;15(5):e106 <https://doi.org/10.2196/jmir.2587>.
66. Guedon-Moreau L, Lacroix D, Sadoul N, et al. Costs of remote monitoring vs ambulatory follow-ups of implanted cardioverter defibrillators in the randomized ECOST study. *Europace* 2014;16(8):1181–1188. <https://doi.org/10.1093/europace/euu012>.
67. Leppert F, Siebermair J, Wesemann U, et al. The INFLUENCE of Remote monitoring on Anxiety/Depression, quality of life, and Device acceptance in ICD patients: A prospective, randomized, controlled, single-center trial. *Clin Res Cardiol* 2021;110(6):789–800. <https://doi.org/10.1007/s00392-020-01667-0>.
68. Versteeg H, Timmermans I, Widdershoven J, et al. Effect of remote monitoring on patient-reported outcomes in European heart failure patients with an implantable cardioverter-defibrillator: Primary results of the REMOTE-CIED randomized trial. *Europace* 2019;21(9):1360–1368. <https://doi.org/10.1093/europace/euz140>.
69. Neuzil P, Taborsky M, Holy F, Wallbrueck K. Early automatic remote detection of combined lead insulation defect and ICD damage. *Europace* 2008; 10(5):556–557. <https://doi.org/10.1093/europace/eun009>.
70. Spencker S, Coban N, Koch L, Schirdewan A, Müller D. Potential role of home monitoring to reduce inappropriate shocks in implantable cardioverter-defibrillator patients due to lead failure. *Europace* 2009;11(4):483–488. <https://doi.org/10.1093/europace/eun350>.
71. Varma N. Remote monitoring for advisories: Automatic early detection of silent lead failure. *Pacing Clin Electrophysiol* 2009;32(4):525–527. <https://doi.org/10.1111/j.1540-8159.2009.02314.x>.
72. Ricci RP, Morichelli L, Quarta L, et al. Effect of daily remote monitoring on pacemaker longevity: A retrospective analysis. *Heart Rhythm* 2015;12(2):330–337. <https://doi.org/10.1016/j.hrthm.2014.10.028>.
73. Varma N, Johnson MA. Prevalence of cancelled shock therapy and relationship to shock delivery in recipients of implantable cardioverter-defibrillators assessed by remote monitoring. *Pacing Clin Electrophysiol* 2009;32(Suppl. 1):S42–S46. <https://doi.org/10.1111/j.1540-8159.2008.02288.x>.
74. Varma N, Love CJ, Schweikert R, Moll P, Michalski J, Epstein AE. Automatic remote monitoring utilizing daily transmissions: Transmission reliability and implantable cardioverter defibrillator battery longevity in the TRUST trial. *Europace* 2018;20(4):622–628. <https://doi.org/10.1093/europace/eux059>.
75. Manyam H, Burri H, Casado-Arroyo R, et al. Smartphone-based CIED Remote Monitoring: Improved compliance and connectivity. *Eur Heart J Digit Health* 2022;4:43–52. <https://doi.org/10.1093/ehjdh/ztac071>.
76. Boston Scientific. MyLATITUDE™ Patient App. Available from: <https://www.bostonscientific.com/en-US/products/remote-patient-monitoring/mylatitude-patient-app.html>. Accessed October 25, 2022.
77. Tarakji KG, Zaidi AM, Zweibel SL, et al. Performance of first pacemaker to use smart device app for remote monitoring. *Heart Rhythm* 2021;2(5):463–471. <https://doi.org/10.1016/j.hroo.2021.07.008>.
78. Tilz RR, Shaik N, Piorkowski C, et al. Real-world adoption of smartphone-based remote monitoring using the Confirm Rx insertable cardiac monitor. *J Innov Card Rhythm Manag* 2021;12(8):4613–4620. <https://doi.org/10.19102/icrm.2021.120806>.
79. Bautista-Mesa RJ, Lopez-Villegas A, Peiro S, et al. Long-term cost-utility analysis of remote monitoring of older patients with pacemakers: The PONIENTE study. *BMC Geriatr* 2020;20(1):474. <https://doi.org/10.1186/s12877-020-01883-3>.
80. Buchta P, Tajstra M, Kurek A, et al. The impact of remote monitoring of implanted cardioverter-defibrillator (ICD) and cardiac resynchronization therapy device (CRT-D) patients on healthcare costs in the Silesian population: Three-year follow-up. *Kardiol Pol* 2017;75(6):573–580. <https://doi.org/10.5603/KP.a2017.0019>.
81. Calo L, Gargaro A, De Ruvo E, et al. Economic impact of remote monitoring on ordinary follow-up of implantable cardioverter defibrillators as compared with conventional in-hospital visits. A single-center prospective and randomized study. *J Interv Card Electrophysiol* 2013;37(1):69–78. <https://doi.org/10.1007/s10840-013-9783-9>.
82. Capucci A, De Simone A, Luzi M, et al. Economic impact of remote monitoring after implantable defibrillators implantation in heart failure patients: An analysis from the EFFECT study. *Europace* 2017;19(9):1493–1499. <https://doi.org/10.1093/europace/eux017>.
83. Chew DS, Zarrabi M, You I, et al. Clinical and economic outcomes associated with remote monitoring for cardiac implantable electronic devices: A population-based analysis. *Can J Cardiol* 2022;38:736–744. <https://doi.org/10.1016/j.cjca.2022.01.022>.
84. Hummel JP, Leopold RJ, Amorosi SL, et al. Outcomes and costs of remote patient monitoring among patients with implanted cardiac defibrillators: An economic model based on the PREDICT RM database. *J Cardiovasc Electrophysiol* 2019; 30(7):1066–1077. <https://doi.org/10.1111/jce.13934>.
85. Ladapo JA, Turakhia MP, Ryan MP, Mollenkopf SA, Reynolds MR. Health care utilization and expenditures associated with remote monitoring in patients with implantable cardiac devices. *Am J Cardiol* 2016;117(9):1455–1462. <https://doi.org/10.1016/j.amjcard.2016.02.015>.
86. Mairesse GH, Braunschweig F, Klersy K, Cowie MR, Leyva F. Implementation and reimbursement of remote monitoring for cardiac implantable electronic devices in Europe: A survey from the health economics committee of the European Heart Rhythm Association. *Europace* 2015;17(5):814–818. <https://doi.org/10.1093/europace/euu390>.
87. Piccini JP, Mittal S, Snell J, Prillinger JB, Dalal N, Varma N. Impact of remote monitoring on clinical events and associated health care utilization: A nationwide assessment. *Heart Rhythm* 2016;13(12):2279–2286. <https://doi.org/10.1016/j.hrthm.2016.08.024>.
88. Boriani G, Da Costa A, Quesada A, et al. Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: Results of the MORE-CARE multicentre randomized controlled trial. *Eur J Heart Fail* 2017;19(3):416–425. <https://doi.org/10.1002/ejhf.626>.
89. Chew DS, Piccini JP, Au F, Frazier-Mills CG, Michalski J, Varma N. Alert-driven vs scheduled remote monitoring of implantable cardiac defibrillators: A cost-consequence analysis from the TRUST trial. *Heart Rhythm* 2023; 20(3):440–447. <https://doi.org/10.1016/j.hrthm.2022.12.003>.
90. Dario C, Delise P, Gubian L, Saccavini C, Brandolino G, Mancin S. Large controlled observational study on remote monitoring of pacemakers and implantable cardiac defibrillators: A clinical, economic, and organizational evaluation. *Interact J Med Res* 2016;5(1):e4. <https://doi.org/10.2196/jmir.4270>.
91. Perl S, Stiegler P, Rotman B, et al. Socio-economic effects and cost saving potential of remote patient monitoring (SAVE-HM trial). *Int J Cardiol* 2013; 169(6):402–407. <https://doi.org/10.1016/j.ijcard.2013.10.019>.
92. Varma N, Love CJ, Michalski J, Epstein AE. Alert-based ICD follow-up: A model of digitally driven remote patient monitoring. *JACC Clin Electrophysiol* 2021; 7(8):976–987. <https://doi.org/10.1016/j.jacep.2021.01.008>.
93. Amara W, Montagnier C, Cheggour S, et al. Early detection and treatment of atrial arrhythmias alleviates the arrhythmic burden in paced patients: The SETAM study. *Pacing Clin Electrophysiol* 2017;40(5):527–536. <https://doi.org/10.1111-pace.13062>.
94. Lappegard KT, Moe F. Remote monitoring of CIEDs-for both safety, economy and convenience? *Int J Environ Res Public Health* 2021;19(1) <https://doi.org/10.3390/ijerph19010312>.
95. Kelly SE, Campbell D, Duhn LJ, et al. Remote monitoring of cardiovascular implantable electronic devices in Canada: Survey of patients and device health care professionals. *CJC Open* 2020;3(4):391–399. <https://doi.org/10.1016/j.cjco.2020.11.010>.
96. Muniyappa AN, Raitt MH, Judson GL, et al. Factors associated with remote monitoring adherence for cardiovascular implantable electronic devices. *Heart Rhythm* 2022;19(9):1499–1507. <https://doi.org/10.1016/j.hrthm.2022.04.025>.
97. Mittal S, Piccini JP, Snell J, Prillinger JB, Dalal N, Varma N. Improved survival in patients enrolled promptly into remote monitoring following cardiac implantable electronic device implantation. *J Interv Card Electrophysiol* 2016;46(2):129–136. <https://doi.org/10.1007/s10840-016-0112-y>.
98. Varma N, Epstein AE, Schweikert R, Michalski J, Love CJ. Role of automatic wireless remote monitoring immediately following ICD implant: The Lumos-T Reduces Routine Office Device Follow-Up Study (TRUST) trial. *J Cardiovasc Electrophysiol* 2016;27(3):321–326. <https://doi.org/10.1111/jce.12895>.

99. Akar JG, Bao H, Jones P, et al. Use of remote monitoring of newly implanted cardioverter-defibrillators: Insights from the patient related determinants of ICD remote monitoring (PREDICT RM) study. *Circulation* 2013;128(22):2372–2383. <https://doi.org/10.1161/CIRCULATIONAHA.113.002481>.
100. Ren X, Apostolakis C, Vo TH, et al. Remote monitoring of implantable pacemakers: In-office setup significantly improves successful data transmission. *Clin Cardiol* 2013;36(10):634–637. <https://doi.org/10.1002/clc.22207>.
101. Drak-Hernández Y, Toquero-Ramos J, Fernández JM, Pérez-Pereira E, Castro-Urda V, Fernández-Lozano I. Effectiveness and safety of remote monitoring of patients with an implantable loop recorder. *Rev Esp Cardiol (Engl Ed)* 2013;66(12):943–948. <https://doi.org/10.1016/j.rec.2013.06.009>.
102. Zanotto G, Melissano D, Baccillieri S, et al. Intrahospital organizational model of remote monitoring data sharing, for a global management of patients with cardiac implantable electronic devices: A document of the Italian Association of Arrhythmology and Cardiac Pacing. *J Cardiovasc Med (Hagerstown)* 2020;21(3):171–181. <https://doi.org/10.2459/jcm.0000000000000912>.
103. Maines M, Tomasi G, Moggio P, et al. Implementation of remote follow-up of cardiac implantable electronic devices in clinical practice: Organizational implications and resource consumption. *J Cardiovasc Med (Hagerstown)* 2020;21(9):648–653. <https://doi.org/10.2459/jcm.0000000000001011>.
104. Ryan P, McGrath C, Lawrie I, Fitzsimons C, O'Shea J, De Brún J. Enhancing efficiency in a cardiac investigations department by increasing remote patient monitoring. *Int J Qual Health Care* 2019;31(Suppl. 1):29–34. <https://doi.org/10.1093/intqhc/mzz065>.
105. Andersen TO, Nielsen KD, Moll J, Svendsen JH. Unpacking telemonitoring work: Workflow and telephone calls to patients in implanted cardiac device care. *Int J Med Inform* 2019;129:381–387. <https://doi.org/10.1016/j.ijmedinf.2019.06.021>.
106. Liljeroos M, Thylén I, Strömberg A. Patients' and nurses' experiences and perceptions of remote monitoring of implantable cardiac defibrillators in heart failure: Cross-sectional, descriptive, mixed methods study. *J Med Internet Res* 2020;22(9):e19550 <https://doi.org/10.2196/19550>.
107. Ricci RP, Morichelli L, D'Onofrio A, et al. Manpower and outpatient clinic workload for remote monitoring of patients with cardiac implantable electronic devices: Data from the HomeGuide Registry. *J Cardiovasc Electrophysiol* 2014;25(11):1216–1223. <https://doi.org/10.1111/jce.12482>.
108. Guédon-Moreau L, Finat L, Boulé S, et al. Validation of an organizational management model of remote implantable cardioverter-defibrillator monitoring alerts. *Circ Cardiovasc Qual Outcomes* 2015;8(4):403–412. <https://doi.org/10.1161/circoutcomes.114.001433>.
109. Ricci RP, Morichelli L, Porfili A, Quarta L, Sassi A. Diagnostic power and healthcare resource consumption of a dedicated workflow algorithm designed to manage thoracic impedance alerts in heart failure patients by remote monitoring. *J Cardiovasc Med (Hagerstown)* 2018;19(3):105–112. <https://doi.org/10.2459/jcm.0000000000000615>.
110. Papavasileiou LP, Forleo GB, Panattoni G, et al. Work burden with remote monitoring of implantable cardioverter defibrillator: Is it time for reimbursement policies? *J Cardiovasc Med (Hagerstown)* 2013;14(2):114–119. <https://doi.org/10.2459/JCM.0b013e328354e3e1>.
111. Maines M, Tomasi G, Moggio P, et al. Scheduled vs alert transmissions for remote follow-up of cardiac implantable electronic devices: Clinical relevance and resource consumption. *Int J Cardiol* 2021;334:49–54. <https://doi.org/10.1016/j.ijcard.202104.043>.
112. Cronin EM, Ching EA, Varma N, Martin DO, Wilkoff BL, Lindsay BD. Remote monitoring of cardiovascular devices: A time and activity analysis. *Heart Rhythm* 2012;9(12):1947–1951. <https://doi.org/10.1016/j.hrthm.2012.08.002>.
113. Han JK, Al-Khatib SM, Albert CM. Changes in the digital health landscape in cardiac electrophysiology: A pre-and peri-pandemic COVID-19 era survey. *Cardiovasc Digit Health J* 2021;2(1):55–62. <https://doi.org/10.1016/j.cvdhj.2020.12.001>.
114. Boriani G, Burri H, Mantovani LG, et al. Device therapy and hospital reimbursement practices across European countries: A heterogeneous scenario. *Europace* 2021;13(Suppl. 2):ii59–ii65. <https://doi.org/10.1093/europace/eur080>.
115. Grand View Research. Implantable Loop Recorders Market Size, Share & Trend Analysis Report By Application (Atrial Fibrillation, Cardiac Arrhythmia), By End-use (Hospitals, Cardiac Centers), By Region, And Segment Forecasts, 2020 – 2027. Accessed March 3, 2023. Available from: <https://www.grandviewresearch.com/industry-analysis/implantable-loop-recorders-market>.
116. Frankel DS, Dechert-Crooks BE, Campbell K, et al. 2021 HRS educational framework for clinical cardiac electrophysiology. *Heart Rhythm O2* 2022;3(2):120–132. <https://doi.org/10.1016/j.hroo.2022.02.013>.
117. Martin GR, Beekman RH, Ing FF, et al. The IMPACT registry: Improving Pediatric and Adult Congenital Treatments. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu* 2010;13(1):20–25. <https://doi.org/10.1053/j.pcsu.2010.02.004>.
118. Gaies M, Pasquali SK, Banerjee M, et al. Improvement in pediatric cardiac surgical outcomes through interhospital collaboration. *J Am Coll Cardiol* 2019;74(22):2786–2795. <https://doi.org/10.1016/j.jacc.2019.09.046>.
119. Intersocietal Accreditation Commission. Cardiac Electrophysiology Accreditation. Accessed March 3, 2023. Available from: <https://intersocietal.org/programs/cardiac-electrophysiology>.
120. Ahmed I, Patel AS, Balgaard TJ, Rosenfeld LE. Technician-supported remote interrogation of CIEDs: Initial use in US emergency departments and perioperative areas. *Pacing Clin Electrophysiol* 2016;39(3):275–281. <https://doi.org/10.1111/pace.12798>.
121. Mittal S, Younge K, King-Ellison K, Hammill E, Stein K. Performance of a remote interrogation system for the in-hospital evaluation of cardiac implantable electronic devices. *J Interv Card Electrophysiol* 2016;46(2):121–128. <https://doi.org/10.1007/s10840-015-0091-4>.
122. Burri H. Remote follow-up and continuous remote monitoring, distinguished. *Europace* 2013;15(Suppl. 1):i14–i16. <https://doi.org/10.1093/euro-pace/eut071>.
123. Varma N, Stambler B, Chun S. Detection of atrial fibrillation by implanted devices with wireless data transmission capability. *Pacing Clin Electrophysiol* 2005;28(Suppl. 1):S133–S136. <https://doi.org/10.1111/j.1540-8159.2005.00083.x>.
124. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med* 2014;370(26):2478–2486. <https://doi.org/10.1056/NEJMoa1313600>.
125. Watanabe E, Yamazaki F, Goto T, et al. Remote management of pacemaker patients with biennial in-clinic evaluation: Continuous home monitoring in the Japanese At-Home Study: A randomized clinical trial. *Circ Arrhythm Electrophysiol* 2020;13(5):e007734 <https://doi.org/10.1161/circep.119.007734>.
126. García-Fernández FJ, Osca Asensi J, Romero R, et al. Safety and efficiency of a common and simplified protocol for pacemaker and defibrillator surveillance based on remote monitoring only: A long-term randomized trial (RM-ALONE). *Eur Heart J* 2019;40(23):1837–1846. <https://doi.org/10.1093/eurheartj/ehz067>.
127. Zeitler EP, Patel D, Hasselblad V, Sanders GD, Al-Khatib SM. Complications from prophylactic replacement of cardiac implantable electronic device generators in response to United States Food and Drug Administration recall: A systematic review and meta-analysis. *Heart Rhythm* 2015;12(7):1558–1564. <https://doi.org/10.1016/j.hrthm.2015.04.003>.
128. Varma N. Automatic remote home monitoring of implantable cardioverter defibrillator lead and generator function: A system that tests itself everyday. *Europace* 2013;15(Suppl. 1):i26–i31. <https://doi.org/10.1093/europace/eut116>.
129. Ploux S, Varma N, Strik M, Lazarus A, Bordachar P. Optimizing implantable cardioverter-defibrillator remote monitoring: A practical guide. *JACC Clin Electrophysiol* 2017;3(4):315–328. <https://doi.org/10.1016/j.jacep.2017.02.007>.
130. Ploux S, Swerdlow CD, Strik M, et al. Towards eradication of inappropriate therapies for ICD lead failure by combining comprehensive remote monitoring and lead noise alerts. *J Cardiovasc Electrophysiol* 2018;29(8):1125–1134. <https://doi.org/10.1111/jce.13653>.
131. Ahmed FZ, Sammut-Powell C, Kwok CS, et al. Remote monitoring data from cardiac implantable electronic devices predicts all-cause mortality. *Europace* 2022;24(2):245–255. <https://doi.org/10.1093/europace/euab160>.
132. Wilkoff BL, Richards M, Sharma A, et al. A device histogram-based simple predictor of mortality risk in ICD and CRT-D patients: The heart rate score. *Pacing Clin Electrophysiol* 2017;40(4):333–343. <https://doi.org/10.1111/pace.13036>.
133. Böhm M, Drexler H, Oswald H, et al. Fluid status telemedicine alerts for heart failure: A randomized controlled trial. *Eur Heart J* 2016;37(41):3154–3163. <https://doi.org/10.1093/eurheartj/ehw099>.
134. Morgan JM, Kitt S, Gill J, et al. Remote management of heart failure using implantable electronic devices. *Eur Heart J* 2017;38(30):2352–2360. <https://doi.org/10.1093/eurheartj/ehx227>.
135. Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. *Heart Rhythm* 2011;8(9):1469–1475. <https://doi.org/10.1016/j.hrthm.2011.04.015>.
136. Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: Is a goal of 100% biventricular pacing necessary? *J Am Coll Cardiol* 2009;53(4):355–360. <https://doi.org/10.1016/j.jacc.2008.09.043>.
137. Guédon-Moreau L, Kouakam C, Klug D, et al. Decreased delivery of inappropriate shocks achieved by remote monitoring of ICD: A substudy of the ECOST trial. *J Cardiovasc Electrophysiol* 2014;25(7):763–770. <https://doi.org/10.1111/jce.12405>.
138. Boulé S, Ninni S, Finat L, et al. Potential role of antitachycardia pacing alerts for the reduction of emergency presentations following shocks in patients with implantable cardioverter-defibrillators: Implications for the implementation of remote monitoring. *Europace* 2016;18(12):1809–1817. <https://doi.org/10.1093/europace/euv392>.
139. Otsuki S, Izumi D, Sakaguchi Y, et al. Efficacy of antitachycardia pacing alert by remote monitoring of implantable cardioverter-defibrillators for out-of-hospital electrical storm. *Pacing Clin Electrophysiol* 2021;44(10):1675–1682. <https://doi.org/10.1111/pace.14334>.

140. Tse HF, Lau CP. Long-term effect of right ventricular pacing on myocardial perfusion and function. *J Am Coll Cardiol* 1997;29(4):744–749. [https://doi.org/10.1016/s0735-1097\(96\)00586-4](https://doi.org/10.1016/s0735-1097(96)00586-4).
141. Karpawich PP, Justice CD, Cavitt DL, Chang CH. Developmental sequelae of fixed-rate ventricular pacing in the immature canine heart: An electrophysiologic, hemodynamic, and histopathologic evaluation. *Am Heart J* 1990; 119(5):1077–1083. [https://doi.org/10.1016/s0002-8703\(05\)80237-6](https://doi.org/10.1016/s0002-8703(05)80237-6).
142. Dreger H, Maethner K, Bondke H, Baumann G, Melzer C. Pacing-induced cardiomyopathy in patients with right ventricular stimulation for >15 years. *Europace* 2012;14(2):238–242. <https://doi.org/10.1093/europace/eur258>.
143. Khurshid S, Epstein AE, Verdino RJ, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. *Heart Rhythm* 2014;11(9):1619–1625. <https://doi.org/10.1016/j.hrthm.2014.05.040>.
144. Kiehl EL, Makki T, Kumar R, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. *Heart Rhythm* 2016; 13(12):2272–2278. <https://doi.org/10.1016/j.hrthm.2016.09.027>.
145. Kim JH, Kang KW, Chin JY, Kim TS, Park JH, Choi YJ. Major determinant of the occurrence of pacing-induced cardiomyopathy in complete atrioventricular block: A multicentre, retrospective analysis over a 15-year period in South Korea. *BMJ Open* 2018;8(2):e019048 <https://doi.org/10.1136/bmjopen-2017-019048>.
146. Sharma AD, Rizo-Patron C, Hallstrom AP, et al. Percent right ventricular pacing predicts outcomes in the DAVID trial. *Heart Rhythm* 2005;2(8):830–834. <https://doi.org/10.1016/j.hrthm.2005.05.015>.
147. Perla HT, Chandra Srinath, Patloori S, Manickavasagam A, Chase D, Roshan J. Do the predictors of right ventricular pacing-induced cardiomyopathy add up? *Indian Heart J* 2021;73(5):582–587. <https://doi.org/10.1016/j.ihj.2021.07.011>.
148. Vijayaraman P, Zalavadia D, Haseeb A, et al. Clinical outcomes of conduction system pacing compared to biventricular pacing in patients requiring cardiac resynchronization therapy. *Heart Rhythm* 2022;19(8):1263–1271. <https://doi.org/10.1016/j.hrthm.2022.04.023>.
149. Afzal MR, Mease J, Koppert T, et al. Incidence of false-positive transmissions during remote rhythm monitoring with implantable loop recorders. *Heart Rhythm* 2020;17(1):75–80. <https://doi.org/10.1016/j.hrthm.2019.07.015>.
150. Sanders P, Pürerfellner H, Pokushalov E, et al. Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: Results from the Reveal LINQ Usability Study. *Heart Rhythm* 2016; 13(7):1425–1430. <https://doi.org/10.1016/j.hrthm.2016.03.005>.
151. Grigoriadis CJ, Dunn A, Parikh P, Wadhwa MK. Distribution of false arrhythmic alerts from implantable loop recorders in the Philips Geneva Health Solutions implantable device remote monitoring database (Abstract). *Cardiovasc Digit Health J* 2022;3(4 Suppl):S16. <https://doi.org/10.1016/j.cvdhj.2022.07.038>.
152. de Ruvo E, Sciarra L, Martino AM, et al. A prospective comparison of remote monitoring systems in implantable cardiac defibrillators: Potential effects of frequency of transmissions. *J Interv Card Electrophysiol* 2016;45(1):81–90.
153. Söth-Hansen M, Witt CT, Rasmussen M, Kristensen J, Gerdes C, Nielsen JC. Time until diagnosis of clinical events with different remote monitoring systems in implantable cardioverter-defibrillator patients. *Heart rhythm* 2018; 15(11):1648–1654. <https://doi.org/10.1016/j.hrthm.2018.05.025>.
154. Nishii N, Miyoshi A, Kubo M, et al. Analysis of arrhythmic events is useful to detect lead failure earlier in patients followed by remote monitoring. *J Cardiovasc Electrophysiol* 2018;29(3):463–470. <https://doi.org/10.1111/jce.13399>.
155. Varma N, Michalski J, Investigators TRUST. Alert notifications during automatic wireless remote monitoring of implantable cardioverter-defibrillators: Load, characteristics, and clinical utility. *Heart Rhythm* 2023;20:473–474. <https://doi.org/10.1016/j.hrthm.2022.11.019>.
156. Morimoto Y, Nishii N, Tsukuda S, et al. A low critical event rate despite a high abnormal event rate in patients with cardiac implantable electric devices followed up by remote monitoring. *Intern Med* 2019;58(16):2333–2340. <https://doi.org/10.2169/internalmedicine.1905-18>.
157. Maines M, Zorzi A, Tomasi G, et al. Clinical impact, safety, and accuracy of the remotely monitored implantable loop recorder Medtronic Reveal LINQTM. *Europace* 2018;20(6):1050–1057. <https://doi.org/10.1093/europace/eux187>.
158. Zanotto G, D'Onofrio A, Della Bella P, et al. Organizational model and reactions to alerts in remote monitoring of cardiac implantable electronic devices: A survey from the Home Monitoring Expert Alliance project. *Clin Cardiol* 2019; 42(1):76–83. <https://doi.org/10.1002/clc.23108>.
159. Varma N, Ricci RP. Impact of remote monitoring on clinical outcomes. *J Cardiovasc Electrophysiol* 2015;26(12):1388–1395. <https://doi.org/10.1111/jce.12829>.
160. Daley C, Toscos T, Allmandinger T, Ahmed R, Wagner S, Mirro M. Organizational models for cardiac implantable electronic device remote monitoring: Current and future directions. *Card Electrophysiol Clin* 2021;13(3):483–497. <https://doi.org/10.1016/j.ccep.2021.04.008>.
161. de Cock CC, Elders J, van Hemel NM, et al. Remote monitoring and follow-up of cardiovascular implantable electronic devices in the Netherlands: An expert consensus report of the Netherlands Society of Cardiology. *Neth Heart J* 2012;20(2):53–65. <https://doi.org/10.1007/s12471-011-0239-5>.
162. Fraiche AM, Matlock DD, Gabriel W, Rapley FA, Kramer DB. Patient and provider perspectives on remote monitoring of pacemakers and implantable cardioverter-defibrillators. *Am J Cardiol* 2021;149:42–46. <https://doi.org/10.1016/j.amjcard.2021.03.023>.
163. Laurent G, Amara W, Mansourati J, et al. Role of patient education in the perception and acceptance of home monitoring after recent implantation of cardioverter defibrillators: The EDUCAT study. *Arch Cardiovasc Dis* 2014; 107(10):508–518. <https://doi.org/10.1016/j.acvd.2014.06.009>.
164. Ricci RP, Morichelli L. Workflow, time and patient satisfaction from the perspectives of home monitoring. *Europace* 2013;15(Suppl. 1):i49–i53. <https://doi.org/10.1093/europace/eut113>.
165. Pedersen SS, Knudsen C, Dilling K, Sandgaard NCF, Johansen JB. Living with an implantable cardioverter defibrillator: Patients' preferences and needs for information provision and care options. *Europace* 2017;19(6):983–990. <https://doi.org/10.1093/europace/euw109>.
166. Strachan PH, de Laat S, Carroll SL, et al. Readability and content of patient education material related to implantable cardioverter defibrillators. *J Cardiovasc Nurs* 2012;27(6):495–504. <https://doi.org/10.1097/JCN.0b013e31822ad3dd>.
167. Timmermans I, Meine M, Zitron E, et al. The patient perspective on remote monitoring of patients with an implantable cardioverter defibrillator: Narrative review and future directions. *Pacing Clin Electrophysiol* 2017;40(7):826–833. <https://doi.org/10.1111/pace.13123>.
168. Barry MJ, Edgman-Levitan S. Shared decision making—pinnacle of patient-centered care. *N Engl J Med* 2012;366(9):780–781. <https://doi.org/10.1056/NEJMp1109283>.
169. Catalan-Matamoros D, Lopez-Villegas A, Tore-Lappegard K, Lopez-Liria R. Patients' experiences of remote communication after pacemaker implant: The NORDLAND study. *PLoS One* 2019;14(6):e0218521 <https://doi.org/10.1371/journal.pone.0218521>.
170. Timmermans I, Meine M, Szendey I, et al. Remote monitoring of implantable cardioverter defibrillators: Patient experiences and preferences for follow-up. *Pacing Clin Electrophysiol* 2019;42(2):120–129. <https://doi.org/10.1111/pace.13574>.
171. Dechert BE, Bradley DJ, Serwer GA, LaPage MJ. The impact of CIEDs with automatic “wireless” remote monitoring on efficiency. *Pacing Clin Electrophysiol* 2021;44(10):1671–1674.
172. Maisel WH, Sweeney MO, Stevenson WG, Ellison KE, Epstein LM. Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators. *JAMA* 2001;286(7):793–799. <https://doi.org/10.1001/jama.286.7.793>.
173. Schwartz J, Blangy H, Zinzus PY, Freysz L, Aliot E, Sadoul N. Recall alerts in implantable cardioverter-defibrillator recipients: Implications for patients and physicians. *Pacing Clin Electrophysiol* 2011;34(1):96–103. <https://doi.org/10.1111/j.1540-8159.2010.02918.x>.
174. Sengupta J, Kendig AC, Goormastic M, et al. Implantable cardioverter-defibrillator FDA safety advisories: Impact on patient mortality and morbidity. *Heart Rhythm* 2012;9(10):1619–1626. <https://doi.org/10.1016/j.hrthm.2012.07.002>.
175. Blake K. Postmarket surveillance of medical devices: Current capabilities and future opportunities. *J Interv Card Electrophysiol* 2013;36(2):119–127. <https://doi.org/10.1007/s10840-013-9778-6>.
176. Maisel WH, Hauser RG, Hammill SC, et al. Recommendations from the Heart Rhythm Society Task Force on Lead Performance Policies and Guidelines: Developed in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). *Heart Rhythm* 2009; 6(6):869–885. <https://doi.org/10.1016/j.hrthm.2009.04.024>.
177. Ottenberg AL, Mueller LA, Mueller PS. Perspectives of patients with cardiovascular implantable electronic devices who received advisory warnings. *Heart Lung* 2013;42(1):59–64. <https://doi.org/10.1016/j.hrtlng.2012.09.007>.
178. Zeidler EP, Piccini JP. Remote monitoring of cardiac implantable electronic devices (CIED). *Trends Cardiovasc Med* 2016;26(6):568–577. <https://doi.org/10.1016/j.tcm.2016.03.012>.
179. Giannola G, Torcivia R, Airò Farulla R, Cipolla T. Outsourcing the remote management of cardiac implantable electronic devices: Medical Care Quality Improvement Project. *JMIR Cardio* 2019;3(2):e9815 <https://doi.org/10.2196/cardio.9815>.
180. Giannola G, Torcivia R, Gardini A, Glisenti F. Outsourcing of remote management of cardiac implantable electronic devices through an external remote monitoring center: An efficacy and safety evaluation (Abstract). *Eur Heart J* 2017; 38(Suppl. 1):P4256. <https://doi.org/10.1093/eurheartj/ehx504.P4256>.
181. Nicolle E, Lanctin D, Rosemas S, De Melis M. Clinic time required to manage remote monitoring of cardiac implantable electronic devices: Impact of outsourcing initial data review and triage. *Europace* 2021;23(Suppl. 3) <https://doi.org/10.1093/europace/euab116.519>.

182. Nielsen JC, Kautzner J, Casado-Arroyo R, et al. Remote monitoring of cardiac implanted electronic devices: Legal requirements and ethical principles - ESC Regulatory Affairs Committee/EHRA joint task force report. *Europace* 2020; 22(11):1742–1758. <https://doi.org/10.1093/europace/eaab168>.
183. Dechert BE, Bradley DJ, Serwer GA, Dick M 2nd, LaPage MJ. Frequency of CIED remote monitoring: A quality improvement follow-up study. *Pacing Clin Electrophysiol* 2019;42(7):959–962. <https://doi.org/10.1111/pace.13707>.
184. Dechert BE, Serwer GA, Bradley DJ, Dick M 2nd, LaPage MJ. Cardiac implantable electronic device remote monitoring surveillance in pediatric and congenital heart disease: Utility relative to frequency. *Heart Rhythm* 2015;12(1):117–122. <https://doi.org/10.1016/j.hrthm.2014.10.009>.
185. Malloy LE, Gingerich J, Olson MD, Atkins DL. Remote monitoring of cardiovascular implantable devices in the pediatric population improves detection of adverse events. *Pediatr Cardiol* 2014;35(2):301–306. <https://doi.org/10.1007/s00246-013-0774-5>.
186. Varma N, Kondo Y, Park SJ, et al. Utilization of remote monitoring among patients receiving cardiac resynchronization therapy and comparison between Asia and the Americas. *Heart Rhythm* 2022;3(6Part B):868–870. <https://doi.org/10.1016/j.hroo.2022.06.013>.
187. Luzzi M, De Simone A, Leoni L, et al. Remote monitoring for implantable defibrillators: A nationwide survey in Italy. *Interact J Med Res* 2013;2(2):e27. <https://doi.org/10.2196/ijmr.2824>.
188. Palmisano P, Melissano D, Zanutto G, et al. Change in the use of remote monitoring of cardiac implantable electronic devices in Italian clinical practice over a 5-year period: Results of two surveys promoted by the AIAC (Italian Association of Arrhythmology and Cardiac Pacing). *J Cardiovasc Med (Hagerstown)* 2020;21(4):305–314. <https://doi.org/10.2459/jcm.0000000000000950>.
189. Lau CP, Zhang S. Remote monitoring of cardiac implantable devices in the Asia-Pacific. *Europace* 2013;15(Suppl. 1):i65–i68. <https://doi.org/10.1093/europace/eut081>.
190. Rosenfeld LE, Patel AS, Ajmani VB, Holbrook RW, Brand TA. Compliance with remote monitoring of ICDS/CRTDS in a real-world population. *Pacing Clin Electrophysiol* 2014;37(7):820–827. <https://doi.org/10.1111/pace.12358>.
191. Alexander B, Baranchuk A. Remote device reprogramming: Has its time come? *Circ Arrhythm Electrophysiol* 2020;13(10):e008949 <https://doi.org/10.1161/circep.120.008949>.
192. Tong L, Xiong S, Hou J, et al. Cloud follow-up in patients with cardiovascular implantable electronic devices: A single-region study in China. *Front Cardiovasc Med* 2022;9:864398 <https://doi.org/10.3389/fcvm.2022.864398>.
193. Siddamsetti S, Shinn A, Gautam S. Remote programming of cardiac implantable electronic devices: A novel approach to program cardiac devices for magnetic resonance imaging. *J Cardiovasc Electrophysiol* 2022;33(5):1005–1009. <https://doi.org/10.1111/jce.15434>.
194. Ploux S, Strik M, Demonière F, et al. Remote interrogation and reprogramming of cardiac implantable electronic devices using a custom multi-vendor solution. *Heart Rhythm* 2022; <https://doi.org/10.1016/j.hrthm.2022.12.015> [published ahead of print, December 13, 2022].
195. Boriani G, Burri H, Svennberg E, Imberti JF, Merino JL, Leclercq C. Current status of reimbursement practices for remote monitoring of cardiac implantable electrical devices across Europe. *Europace* 2022;24:1875–1880. <https://doi.org/10.1093/europace/eaac118>.
196. Mittal S, Oliveros S, Li J, Barroyer T, Henry C, Gardella C. AI filter improves positive predictive value of atrial fibrillation detection by an implantable loop recorder. *JACC Clin Electrophysiol* 2021;7(8):965–975. <https://doi.org/10.1016/j.jacep.2020.12.006>.
197. Brown G, Conway S, Ahmad M, et al. Role of artificial intelligence in defibrillators: A narrative review. *Open Heart* 2022;9(2):e001976 <https://doi.org/10.1136/openhrt-2022-001976>.
198. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). 2016. Accessed March 3, 2023. Available from, <https://eur-lex.europa.eu/eli/reg/2016/679/oj>.
199. 21st Century Cures Act, Pub L No. 114-255, (2016). March 23, 2023. <https://www.govinfo.gov/app/details/PLAW-114publ255/summary>.

## Appendix 1 Writing committee member disclosure of relationships with industry and other entities

Writing committee member	Employment	Honoraria/ speaking/ consulting	Speakers' bureau	Research*	Fellowship support*	Ownership/ partnership/ principal/ majority stockholder	Stock or stock options	Intellectual property/royalties	Other
Aileen M. Ferrick, PhD, ACNP, RN, FHRS (Co-Chair)	White Plains Hospital, White Plains, New York	None	None	None	None	None	None	None	None
Satish R. Raj, MD, MSCI, FHRS (Co-Chair)	University of Calgary, Calgary, Alberta, Canada	0: Arena Pharmaceuticals 1: Amneal Pharmaceuticals 1: Argenx 1: Elsevier 1: Regeneron 1: Servier 1: Spire Learning	None	0: Theravance 3: Stand Up To POTS 4: Heart & Stroke 5: CIHR 5: Dysautonomia International	None	None	None	None	0: AAS 0: CCS 0: Dysautonomia International
Thomas Deneke, MD, PhD, FHRS (EHRA Vice-Chair)	Heart Center Bad Neustadt, Bad Neustadt, Germany	1: Abbott 1: Biotronik 1: Farapulse 1: Galaxy Medical, Inc. 1: Imricor	None	None	None	None	None	None	1: Boston Scientific
Pipin Kojodjojo, MBBS, PhD, FHRS (APHRS Vice-Chair)	Asian Heart & Vascular Centre, Singapore	None	None	None	None	None	None	None	None
Nestor Lopez-Cabanillas, MD (LAHRS Vice-Chair)	Adventist Cardiovascular Institute, Buenos Aires, Argentina	None	None	None	None	None	None	None	None
Haruhiko Abe, MD, PhD	University of Occupational and Environmental Health Hospital, Kitakyushu, Japan	1: Abbott Japan	1: Boston Scientific Japan 1: Japan Medtronic, Inc.	None	None	None	None	None	None
Felix A. Ayala-Paredes, MD†	Universite de Sherbrooke Faculty Sherbrooke, Quebec, Canada	None	None	None	None	None	None	None	None

(Continued)

Appendix 1 (Continued)

Writing committee member	Employment	Honoraria/ speaking/ consulting	Speakers' bureau	Research*	Fellowship support*	Ownership/ partnership/ principal/ majority stockholder	Stock or stock options	Intellectual property/royalties	Other
Serge Boveda, MD, PhD, FEHRA, FESC	Clinique Pasteur, Toulouse, France	1: Boston Scientific 1: Microport CRM 1: Zoll Medical Corporation 2: Medtronic	None	None	None	None	None	None	None
Derek S. Chew, MD, MSc, FHRS	University of Calgary, Calgary, Alberta, Canada	1: UTI Limited Partnership (Innovate Calgary)	None	4: CIHR	None	None	None	None	None
Jong-Il Choi, MD, PhD, MHS	Korea University Medical Center, Seoul, Korea	0: Abbott 0: Medtronic 1: Boehringer Ingelheim 1: Chong Kun Dang Pharmaceutical Corp 1: Daewoong Pharm 1: Daiichi Sankyo 1: Johnson & Johnson 1: Menarini Group 1: Novartis 1: Sanofi 1: Samjin Pharmaceutical Co, Ltd	None	0: Sanofi 5: Chong Kun Dang Pharmaceutical Corp	None	None	None	None	None
Nikolaos Dargès, MD	Heart Center Leipzig at the University of Leipzig, Leipzig, Germany	None	None	None	None	None	None	None	0: EHRA
Aarti S. Dalal, DO, FACC, FHRS, CEPS-P	Vanderbilt University Medical Center, Nashville, Tennessee	1: Medtronic	None	None	None	None	None	None	None



Brynn E. Dechert, APN, FHRS, CCDS	C.S. Mott Children's Hospital, Ann Arbor, Michigan	None	None	None	None	None	None	None	None
Camille G. Frazier-Mills, MD, MHS, CCDS	Duke University Medical Center, Durham, North Carolina	1: Boston Scientific 1: Johnson & Johnson 2: Medtronic	None	None	None	None	None	None	None
Olivia Gilbert, MD, MSc, FACC	Wake Forest Baptist Medical Center, Winston-Salem, North Carolina	None	None	None	None	None	None	None	None
Janet K. Han, MD, FACC, FHRS	VA Greater Los Angeles Healthcare System, Los Angeles, California	1: Medtronic	None	None	None	None	None	None	None
Sheri Hewit, PharmD		None	None	None	None	None	None	None	None
Christine Kneeland, BSN	Mayo Clinic, Rochester, Minnesota	None	None	None	None	None	None	None	None
Starr DeEllen Mirza		None	None	None	None	None	None	None	None

(Continued)

Appendix 1 (Continued)

Writing committee member	Employment	Honoraria/ speaking/ consulting	Speakers' bureau	Research*	Fellowship support*	Ownership/ partnership/ principal/ majority stockholder	Stock or stock options	Intellectual property/royalties	Other
Suneet Mittal, MD, FHRS	The Valley Hospital, Ridgewood, New Jersey	1: Abbott 1: AltaThera Pharmaceuticals 1: ARCA Biopharma, Inc. 1: AtriCure, Inc. 1: Baylis Medical Company 1: Biosense Webster, Inc. 1: BMS / Pfizer Alliance 1: CathVision 1: CVRx Inc. 1: Haemonetics 1: Implicity 1: Impulse Dynamics USA 1: Octagos 2: Catawba 2: Philips 3: Boston Scientific 4: Medtronic	None	None	None	None	None	None	None
Renato Pietro Ricci, MD	Cardio Arrhythmology Center, Rome, Italy	0: Abbott 1: Dompé Farmaceutici S.p.A.	None	None	None	None	None	None	None
Mary Runte, PhD	University of Lethbridge, Lethbridge, Alberta, Canada	None	None	None	None	None	None	None	None
Susan Sinclair, NZCS, PGDHSc	Auckland City Hospital, Auckland, New Zealand	None	None	None	None	None	None	None	None

Ricardo Alkmim-Teixeira, MD, PhD	Hospital Renascentista, Pouso Alegre, Minas Gerais, Brazil	1: Abbott 1: Bayer Healthcare Pharmaceuticals 1: Daiichi Sankyo 1: Spectranetics Corporation 1: Wyeth	None	None	None	None	None	None	None
Bert Vandenberk, MD, PhD	University of Calgary, Calgary, Alberta, Canada Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium	None	None	None	4: Frans Van de Werf Fund for Clinical Cardiovascular Research	None	None	None	None
Niraj Varma, MA, MD, PhD	Cleveland Clinic, Cleveland, Ohio	0: Biotronik 0: Boston Scientific 0: Pacemate 1: EP Solutions 1: Implicity 1: Medtronic 2: Abbott 3: Impulse Dynamics USA	None	None	None	None	None	None	None

AAS = American Autonomic Society; CCS = Canadian Cardiovascular Society; CIHR = Canadian Institute of Health Research; EHRA = European Heart Rhythm Society.

Number value: 0 = \$0; 1 = ≤ \$10,000; 2 = > \$10,000 to ≤ \$25,000; 3 = > \$25,000 to ≤ \$50,000; 4 = > \$50,000 to ≤ \$100,000; 5 = > \$100,000.

This table is a comprehensive list of the relationships with industry and other entities (RWI)—regardless of relevance to the document topic—disclosed by each writing committee member for the 12 months prior to the initial meeting of the writing committee and up through the completion of the document. The table does not necessarily reflect the RWI of the writing committee members at the time of publication. Please refer to the [HRS Code of Ethics and Professionalism](#) for definitions of disclosure categories or additional information about the HRS policy on the disclosure of relationships with industry and other entities. To mitigate potential bias and conflict of interest, the recommendations and supportive text were written by writing committee members who were free of relevant RWI.

\*Research and fellowship support are classed as programmatic support. Sources of programmatic support are disclosed but are not regarded as a relevant relationship with industry for writing group members or reviewers.

<sup>†</sup>Dr. Ayala-Paredes stepped down from the writing committee in July 2022 when he developed a new role in industry, which precluded him from participation in the development of the document. Dr. Ayala-Paredes was one of the authors for Section 9, Remote Monitoring Reporting. He left the writing committee before recommendations were developed in this section. After his departure, this section was re-reviewed by the section lead/authors and the document chairs, and the evidence for this section was re-reviewed by the document methodologists.



Markus Stühlinger, MD, FACC, FEHRA	Medical University of Innsbruck, Innsbruck, Austria	1: Biotronik 1: Daiichi Sankyo 1: Medtronic	None	None	None	None	None	None	None
Paul D. Varosy, MD	VA Eastern Colorado Health Care System, Aurora, Colorado	None	None	4: NIH	None	None	2: HRCRS/ 3PH Alliance	None	0: ACC 0: NCDR

Number value: **0** = \$0; **1** = ≤ \$10,000; **2** = > \$10,000 to ≤ \$25,000; **3** = > \$25,000 to ≤ \$50,000; **4** = > \$50,000 to ≤ \$100,000; **5** = > \$100,000.

This table is a comprehensive list of the relationships with industry and other entities (RWI)—regardless of relevance to the document topic—disclosed by the reviewers at the time the document was under review. The table does not necessarily reflect the RWI of the reviewers at the time of publication. Please refer to the [HRS Code of Ethics and Professionalism](#) for definitions of disclosure categories or additional information about the HRS policy on the disclosure of relationships with industry and other entities.

ACC = American College of Cardiology; HRCRS = Heart Rhythm Clinical Research Solutions; NCDR = National Cardiovascular Data Registry; NIH = National Institutes of Health.

\*Research and fellowship support are classed as programmatic support. Sources of programmatic support are disclosed but are not regarded as a relevant relationship with industry for writing group members or reviewers.